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Abstract
The human macula is essential for precise vision. It contains many more cone photore­
ceptors than the peripheral retina, especially in the fovea. Cones are known to express 
specific opsins and other proteins that form part of the phototransduction cascade.
However, relatively little is known about retinal macular gene expression compared 
with the rod-rich peripheral retina. I obtained human donor eyes and used foveo-macular 
and macular punches and sections of peripheral retina to study differential gene expres­
sion. I combined multiple microarray experiments with quantitative PCR, statistical, and 
bioinformatic analyses.
I identified several known and previously unidentified retinal genes that are more 
abundant in the macula. I went on to characterize proteins encoded by histone deacetylase 
9 and the morpheus gene family. Both were expressed in the human macula, especially 
in the photoreceptors. Several other genes also provided insight into the mechanisms 
of precise vision and its maintenance. Genes identified by this approach are excellent 
candidates for macular disease.
1
Contents
1 Introduction 16
1.1 R e t in a .................................................................................................................... 18
1.1.1 Retinal pigment epithelium ................................................................... 21
1.1.2 Neural r e t i n a .......................................................................................... 22
1.1.3 P ho to recep to rs ....................................................................................... 23
1.1.4 Photoreceptor co n n ec tio n s ................................................................... 26
1.1.5 Bipolar cells .......................................................................................... 27
1.1.6 Ganglion cells ......................................................................................  28
1.1.7 Horizontal c e l l s ......................................................................................  30
1.1.8 Amacrine c e l l s ......................................................................................  31
1.2 Phototransduction................................................................................................ 32
1.2.1 Cones versus rods ................................................................................  33
1.2.2 Photoreceptor tu rn o v e r.........................................................................  35
1.3 Macular gene e x p re ss io n ....................................................................................  35
1.3.1 Serial analysis o f gene ex p re ss io n ......................................................  36
1.3.2 Macular d isease....................................................................................... 38
1.3.3 Age-related macular degenera tion ...................................................... 46
1.3.4 Functional g e n o m ic s ............................................................................. 50
1.4 O bjectives.............................................................................................................  52
1.5 R esults...................................................................................................................  53
1.6 Discussion.............................................................................................................  56
2
CONTENTS  3
1.7 C onclusions........................................................................................................ 58
2 Methods 59
2.1 Tissue p rocurem ent..........................................................................................  59
2.2 D issection ...........................................................................................................  60
2.3 RNA e x tra c tio n .................................................................................................  60
2.3.1 Handling R N A ....................................................................................  60
2.3.2 Isolation of RNA from Small Quantities o f T issue.........................  61
2.3.3 RNA gel electrophoresis.................................................................... 64
2.4 Analysis of foveal and peripheral retinal m R N A .......................................... 66
2.5 Construction o f cDNA library .......................................................................  67
2.6 Library sc ree n in g ..............................................................................................  67
2.7 Microarray ........................................................................................................  68
2.8 Quantitative P C R ..............................................................................................  73
2.9 Tissue and antibody resources .......................................................................  76
2.10 Tissue c u l tu re ..................................................................................................... 77
2.11 Enzyme linked immuno-sorbent assay (E L IS A ).......................................... 79
2.11.1 C o a tin g .................................................................................................  79
2.11.2 B lo c k in g ..............................................................................................  79
2.11.3 S a m p le .................................................................................................. 79
2.11.4 W a s h .....................................................................................................  80
2.11.5 C onjugate..............................................................................................  80
2.11.6 W a s h .....................................................................................................  80
2.11.7 S u b s tra te ..............................................................................................  81
2.11.8 S to p ........................................................................................................  81
2.12 Western b lo tting .................................................................................................. 81
2.13 Im m unofluorescence........................................................................................  83
2.13.1 Cell c u ltu re ...........................................................................................  83
2.13.2 Retinal sec tio n s ....................................................................................  84
CONTENTS  4
2.13.3 Im ag in g ................................................................................................... 85
2.14 Antisera p roduction ............................................................................................  86
2.15 C lo n in g ................................................................................................................  88
2.16 Prokaryotic protein ex p re ss io n ........................................................................  92
3 Microarray analysis 93
3.1 Introduction......................................................................................................... 93
3.2 O bjectives............................................................................................................  99
3.3 R esults................................................................................................................... 99
3.3.1 R esources................................................................................................  99
3.3.2 Experiments .............................................................................................100
3.3.3 O p tim isa tio n .............................................................................................101
3.3.4 Data a n a ly s is .............................................................................................105
3.3.5 Data m in ing ................................................................................................ 108
3.4 D iscussion............................................................................................................... 109
3.5 C onclusions............................................................................................................116
4 Quantitative PCR 117
4.1 Introduction............................................................................................................ 117
4.2 O bjectives............................................................................................................... 122
4.3 R esults...................................................................................................................... 122
4.4 D iscussion............................................................................................................... 123
4.4.1 Differentially expressed g e n e s ............................................................... 127
4.4.2 P ro te in s .......................................................................................................130
4.5 C onclusions............................................................................................................ 130
5 Histone deacetylase 9 131
5.1 Introduction ............................................................................................................ 131
5.2 O bjectives................................................................................................................133
5.3 R esults...................................................................................................................... 133
CONTENTS  5
5.4 D iscussion...............................................................................................................135
5.5 C onclusions........................................................................................................... 137
6 Morpheus 138
6.1 O bjectives...............................................................................................................142
6.2 R esults..................................................................................................................... 142
6.3 D iscussion...............................................................................................................148
6.4 C onclusions............................................................................................................152
6.5 Overall conclusions.............................................................................................. 153
6.6 Future w o r k ............................................................................................................153
6.6.1 Gene e x p re s s io n .....................................................................................153
6.6.2 Mutation screen in g ................................................................................. 154
6.6.3 Functional m o d e l s ................................................................................. 155
Appendices 158
A Scripts 158
A.l Microarray data ca lib ra tion ................................................................................. 158
A.2 Microarray data m in in g ........................................................................................161
A.2.1 Final table d e s ig n .....................................................................................161
A.2.2 Example queries for robust over- and under-expression................... 162
A.2.3 Importing data into a spreadsheet ......................................................... 163
A.3 Graph to simulate ideal and real P C R .................................................................164
B Supplementary data 166
List of Figures
1.1 Transverse section o f the left eye......................................................................  17
1.2 Schematic diagram of the vertebrate retina.....................................................  19
1.3 Light micrograph showing a vertical section o f human retina......................  19
1.4 Fundus photograph of a normal human retina................................................. 20
1.5 Schematic drawing o f rod and cone photoreceptor cells...............................  24
1.6 Phototransduction cascade.................................................................................  32
1.7 Phototoreceptor outer segment proteins linked to retinal disease................. 34
1.8 Serial analysis of gene expression....................................................................  37
1.9 Stargardt disease..................................................................................................  40
1.10 Best disease..........................................................................................................  41
1.11 Dominant drusen.................................................................................................. 43
1.12 Sorsby fundus dystrophy....................................................................................  44
1.13 X-linked retinoschisis.........................................................................................  46
1.14 Drusen in AMD.................................................................................................... 47
1.15 Geographic atrophy.............................................................................................  47
1.16 Choroidal neovascularization............................................................................  48
1.17 Two formamide agarose gels of retinal RNA..................................................  53
1.18 Total RNA extracted from ten individual peripheral retinal sections. . . .  54
1.19 Amplification of non-homologous cone and rhodopsin cDNA from 4mm 
foveal and peripheral retinal cDNA...................................................................  54
1.20 Analysis of cone and rhodopsin mRNA by Northern hybridization  55
6
LIST OF FIGURES 1
1.21 Several inserts from the foveal library...............................................................  55
2.1 Phase separation....................................................................................................  63
2.2 Schematic diagram to show the cloning strategy adopted............................... 89
3.1 Low resolution merged two-channel image of microarray slide 6.................... 102
3.2 Diagnostic microarray plots.................................................................................... 103
3.3 Relative v.v. rank mean expression ratios in six microarray experiments. . 107
4.1 Graph to show qPCR data and an exponential model of amplification. . . 119
4.2 Amplification plot with log-transformed fluorescence values............................119
4.3 Agarose gel to show amplification of part of rhodopsin..................................... 123
4.4 Graph to show quantitative PCR data comparing gene expression in pooled
foveo-macular with pooled peripheral retinal RNA............................................125
5.1 Schematic diagram of HDAC9............................................................................... 132
5.2 Western blot showing expression of full-length HDAC9 in mammalian
cell lines.....................................................................................................................133
5.3 Confocal microscope images of cultured human neuroblastoma cells trans­
fected with HDAC9................................................................................................. 134
5.4 Full-length HDAC9 expression in human fovea.................................................. 135
6.1 Western blot to show NPIP in human retina.........................................................144
6.2 Confocal microscope images of cultured human neuroblastoma cells trans­
fected with NPIP. ...................................................................................................145
6.3 Confocal microscope images of cultured human neuroblastoma cells trans­
fected with two different NPIP GFP constructs...................................................146
6.4 Confocal microscopy showing NPIP and PNA staining in human fovea. . 147
B.l Direct sequencing of npip-brain 1 cDNA (forward strand)................................. 168
B.2 Direct sequencing of npip-brain 1 cDNA (reverse strand)...................................169
B.3 DART-PCR for red/green cone o p s in .................................................................. 170
LIST OF FIGURES 8
B.4 DART-PCR for red/green cone o p s in ................................................................ 171
B.5 Multiple alignment of NPIP protein.........................................................173
B.6 Multiple alignment of NPIP reference cDNA......................................................176
B.7 Multiple alignment of NPIP reference protein.....................................................176
List of Tables
1.1 Table of amplified foveal library inserts that were bi-directionally se­
quenced and identified by using BLAST against dbEST  56
2.1 PCR primer pairs....................................................................................................  75
2.2 Immunisation/bleeding timetable........................................................................  87
2.3 PCR primers used in cloning of full-length NPIP cDNA................................. 88
3.1 Diagnostic microarray data......................................................................................104
3.2 Background-corrected fluorescence and variance stabilized microarray data
for rod and red/green cone opsin........................................................................... 110
3.3 Background-corrected fluorescence and variance stabilized microarray data
for S-antigen and nuclear pore complex interacting protein (NPIP) I l l
3.4 Summary of microarray data................................................................................... 112
4.1 Summary of qPCR data.........................................................................................124
B.l Retina-related genes in the microarray................................................................... 167
9
List of abbreviations
aa amino acids
ABI Applied Biosystems International
ACTB beta actin
ad autosomal dominant
AEBSF 4-(2-Aminoethyl)benzenesulphonyl fluoride
AMD age-related macular degeneration
apoE apolipoprotein
ar autosomal recessive
AREDS age related eye disease study
ARM age related maculopathy
ARP acidic ribosomal phosphoprotein
b base
BBS Bardet-Biedl syndrome
BLAST Basic Local Alignment Search Tool
BMP bitmap
bp base pairs
BSA bovine serum albumin
10
11
CCD charge coupled device
cDNA complimentary DNA
cGMP cyclic guanosine monophosphate
CNV choroidal neovascularization
Crx cone rod homeobox
Cy3 cyanine 3
Da Dalton
DAPI 4’,6-Diamidino-2-phenylindole
DART-PCR Data Analysis for Real-Time PCR
dbEST EST database at NCBI
dCTP deoxyribose cytosine triphosphate
DIC differential interference contrast
DMEM Dulbecco’s Modified Eagle Medium
DNA deoxyribose nucleic acid
dpi dots per inch
dUTP deoxyuracil triphosphate
ECACC European Collection of Cell Cultures
ECL enhanced chemiluminescence
EGF epidermal growth factor
EIF eukaryotic translation initiation factor 2 alpha kinase 4
ELISA enzyme-linked immunosorbent assay
EMBOSS European Molecular Biology Open Software Suite
EOG electro-oculogram
12
ERG electro-retinogram
EST expressed sequence tag
EtBr ethidium bromide
FBS fetal bovine serum
FCH FER/CIP4 homology
FISH fluorescence in situ hybridization
GA geographic atrophy
GABA gama-amino butyric acid
GAP GTPase-activating protein
GCL ganglion cell layer
GEO Gene Expression Omnibus
GFAP glial fibrillary acid protein
GFP green fluorescent protein
GST glutathione S-transferase
GTP guanosine triphosphate
H histone
HDAC histone deacetylase
HPLC high performance liquid chromatography
HRP horesradish peroxidase
IACUC Institutional Animal Care and Use Committee
ILM inner limiting membrane
INL inner nuclear layer
IPL inner plexiform layer
13
IPTG Isopropyl beta-D-thiogalactopyranoside
IRBP interphotoreceptor binding protein
JPEG Joint Photographic Experts Group
ICLH keyhole limpet hemacyanin
LB Luria-Bertani
LCR low-copy repeat
LGN lateral geniculate nucleus
MBP maltose binding protein
MBS m-Maleimidobenzoyl-N-hydroxysuccinimide ester
MEGAP mental disorder-associated GAP protein
MeOH methanol
mRNA messenger RNA
NCBI National Center for Biotechnology Information
NDS normal donkey serum
NFL nerve fibre layer
NPIP nuclear pore complex interacting protein
OMIM Online Mendelian Inheritance in Man
ONL outer nuclear layer
OPL outer plexiform layer
PBS phosphate buffered saline
PCR polymerase chain reaction
PDE phosphodiesterase
PDF portable document forma
14
PMT photomultiplier tube
PNA peanut agglutinin
qPCR quantitative PCR
RDS retinal degeneration, slow
RHOGAP Rho GTPase activating protein
RNA ribonucleic acid
ROM rod outer segment membrane protein
RP retinitis pigmentosa
RPE retinal pigment epithelium
RPM revolutions per minute
rRNA ribosomal RNA
RS retinoschisin
RT-PCR reverse transcriptase PCR
SAG s-antigen
SAGE serial analysis of gene expression
SDS sodium dodecyl sulphate
SFD Sorsby fundus dystrophy
SMA statistics for microarray analysis
SQL structured query language
SRGAP SLIT-ROBO Rho GTPase activating protein
SRNVM sub-retinal neovascular membrane
SSC sodium chloride - sodium citrate
Taq Thermus aquaticus
15
TB transfer buffer
TGF transforming growth factor
TIFF tagged image file format
TIMP tissue inhibitor of metalloproteinase
tRNA transfer RNA
UBC ubiquitin C
VEGF vascular endothelial growth factor 
VMD vitelliform macular dystrophy 
X-Gal 5-bromo-4-chloro-3-indolyl-beta-D-galactoside 
XLRS X-linked retinoschisis
Chapter 1
Introduction
The human eye (Figure 1.1) is a highly specialized organ of vision. It subserves the pro­
cess by which light energy from the environment produces changes in specialized nerve 
cells in the retina -  the rod and cone photoreceptors. These changes result in nerve im­
pulses that are subsequently relayed via the optic nerve to the brain where the information 
is consciously appreciated as vision. All the other structures in the eye are secondary to 
this process. Some structures are part of the system necessary for focusing and transmit­
ting the light onto the retina -  for example the cornea, iris, ciliary body and lens. Other 
structures are necessary for nourishing and supporting the tissues of the eye -  for example 
the lacrimal (tear) apparatus, choroid and aqueous outflow system.
The human eye is approximately spherical, with a diameter of 2.5cm and a volume of 
6.5ml. More accurately, it is part of two spheres: a smaller one anteriorly, the cornea, that 
has a greater curvature than the sclera, which constitutes the larger sphere. The cornea 
constitutes one sixth of the circumference of the eye and has a diameter 15.5mm. The 
remaining five-sixths is formed by the sclera, which has a diameter of 23mm.
The human eye is situated in the anterior part of the orbit, closer to the lateral than the 
medial wall and nearer the roof than the floor. The eye is made up of three basic layers 
or coats, often known as tunics. These are the fibrous (comeo-scleral) coat, the uvea or 
uveal tract (composed of choroid, ciliary body, and iris), and the neural layer (retina). 
The coats surround the contents -  the lens and the transparent media (aqueous humour
16
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and vitreous jelly). The cornea and sclera together form a tough envelope that protects 
the ocular tissues. This fibrous coat also provides important structural support for the 
intra-ocular contents and for attachment of extra-ocular muscles.
1.1 Retina
The human retina is the innermost layer of the eye. It is the plane in which the image falls 
after it is focused by the eye's optical system. The retina is responsible for converting 
information from the image of the external environment into neural impulses that travel to 
the brain. It is the light-sensitive intima of the eye, from which the optic nerve emanates.
The vertebrate retina consists of two main layers: an inner neurosensory retina and 
an outer epithelium -  the retinal pigment epithelium (RPE). These two layers can be 
traced embryologically to the inner and outer layers of the optic cup. In the adult they are 
continuous anteriorly with the epithelial layers over the ciliary processes and the posterior 
surface of the iris. Between the neural retina and the RPE is a potential space, the sub- 
retinal space, across which the two layers adhere. The neural retina is only firmly attached 
at its anterior termination, the ora serrata, and at the optic nerve head border. Adhesion 
between the neural retina and RPE is normally maintained by electrostatic forces, negative 
pressure and proteoglycans.
The retina is bound by Bruch’s membrane externally and the vitreous internally. It is 
continuous with the optic nerve posteriorly, the site of exit of ganglion cell axons from 
the eye.
The central retina is a 5 to 6mm diameter circular zone situated between the superior 
and inferior temporal retinal arteries. It is distinct from the peripheral retina in the pre­
domination of cone rather than rod photoreceptors. Also, the inner retina (INL, IPL, GCL, 
NFL) is thicker due to the increased density of cone-synapsing second order neurones and 
is characterized by the presence of more than a single layer of ganglion cells. In the pit 
of the fovea, a small depression at the centre of the retina, the densely packed hexagonal 
mosaic of cone photoreceptors displaces all other layers laterally.
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Figure 1.2: Schematic diagram of the vertebrate retina. NFL = nerve fibre layer. GCL = ganglion 
cell layer. AC = amacrine cell. BC  = bipolar cell. HC = horizontal cell. RPE = retinal pigment 
epithelium. Adapted from www. a m e r i c a n s c i e n t i s t . o rg .
C H
R P E  
O S  
IS
O N L
O P L
IN L
I P L
G C L
n f l  ^
IL M
Figure 1.3: Light micrograph showing a vertical section of human retina. ILM  = inner limiting 
membrane. NFL = nerve fibre layer. GCL = ganglion cell layer. IPL = inner plexiform layer. INL 
= inner nuclear layer. OPL = outer plexiform layer. ONL = outer nuclear layer. IS = photoreceptor 
inner segment. OS = photoreceptor outer segment. RPE = retinal pigment epithelium. CH = 
choroid. Bruch’s membrane is highlighted in red. Adapted from m edocs . u c d a v i s  . edu .
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Figure 1.4: Fundus photograph of a normal human retina. The macula (circled) appears as a darker 
area of pigmentation 11.8° temporal to the optic disc.
The human macula is a yellow spot (macula luted) surrounding the fovea, defined 
as 3mm of intense pigmentation, surrounded by a 1mm wide zone of less pigmentation 
[Polyak, 1941]. The macula is located 3.4mm temporal to the optic disc margin. One 
degree of visual angle is equal to 288^m on the retina, without correction for shrinkage 
[Drasdo and Fowler, 1974], The macula is yellow partly as a result of yellow screening 
xanthophyll carotenoid pigments (xeaxanthin and lutein) in the cone axons. This may 
serve to act as a short wavelength filter protecting against UV irradiation. Through an 
ophthalmoscope, the macular pigmentation appears as a darker area compared with the 
peripheral retina (see Figure 1.4).
The fovea is defined as the central 1.5mm of the macula and the foveola is the central 
0.35-mm wide zone, consisting of a depression surrounded by slightly thickened margins. 
The foveola is where cone photoreceptors are concentrated at maximum density to the 
exclusion of rods. The inner retinal layers in the margins of the pit (clivus) are displaced 
laterally and the outer retina consists purely of cones. The foveal retina is avascular and 
relies on the choriocapillaris for nutritional support.
The optic disk lies 3mm medial to the centre of the macula. There are no normal 
retinal layers in this zone, hence the blind spot. At the optic disk, the ganglion cell axons
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from the retina pierce the sclera to enter the optic nerve. This pale pink/whitish area is 
1.8mm in diameter with a slightly raised rim. The central retinal vessels emerge at the 
centre of the optic disk, pass over the rim, and radiate out to supply the retina.
The peripheral retina is the remainder of the retina outside the central retina. The 
distance from the optic disk to the ora serrata is 23-24mm on the temporal aspect and 
approximately 18.5mm on the nasal aspect. The peripheral retina is 110-140//m in thick­
ness, rich in rods, and possesses only one layer of ganglion cell bodies.
The ora serrata is the dentate anterior margin of the sensory retina. At this transition 
zone, the neuroretina is continuous with the columnar non-pigmented epithelial cells in 
the pars plana of the ciliary body. The ora serrata is around 1mm closer to the corneo­
scleral limbus on the nasal than on the temporal side.
The retina is divided, for descriptive purposes, into nasal and temporal halves by a 
vertical line through the fovea. The optic nerve head is often used as central point to 
describe the retina as having supero- and infero-nasal and supero- and infero-temporal 
quadrants. The area of the retina is approximately 1250mm2 and varies in thickness from 
100/ym in the periphery to 230//m near the optic nerve head.
1.1.1 Retinal pigment epithelium
The Retinal pigment epithelium (RPE) is a continuous monolayer of cuboidal or colum­
nar epithelial cells that extends from the margin of the optic nerve head to the ora serrata, 
where it is continuous with the pigment epithelium of the ciliary body. This cell layer 
has many physical, metabolic, biochemical, optical and transport functions, which play 
a critical role in the normal visual process. These include: maintaining adhesion of the 
neurosensory retina, providing a selectively permeable barrier between the choroid and 
neurosensory retina, phagocytosis of rod and (to a lesser extent) cone outer segments, 
synthesis of interphotoreceptor matrix, absorption of light and reduction of scatter (thus 
improving image resolution), and transport as well as storage of metabolities and vitamins 
(especially vitamin A). The complex morphology of this neuroectoderm-derived epithe-
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Hum reflects these multiple functions.
The RPE cells vary in size and shape depending on age and location, being more 
columnar in the central retina and more flattened in the peripheral retina. The basal aspect 
of the cells lies on Bruch’s membrane and their apical surface is intimately associated with 
the photoreceptor outer segments. When examined ‘en face’ they form a highly organized 
hexagonal pattern of homogeneously sized cells.
The RPE has low regenerative capacity in the normal eye. Therefore, cell loss is ac­
commodated by hyperplasia of adjacent cells. Therefore, in older eyes the regular hexag­
onal array is lost and a heterogeneous mixture of sizes and shapes is more evident. The 
number of RPE cells per eye varies from 4-6 million.
1.1.2 Neural retina
The neural retina is a thin transparent layer of neural tissue, which in life has a red/purple 
tinge due to the presence of visual pigments. Post mortem and in fixed specimens the 
neural retina is opaque white and often detached from the underlying RPE.
Light stimuli are converted into neural impulses in the neural retina. Some degree 
of processing then occurs locally before transmission of information to the brain via the 
ganglion cell axons in the optic nerve. The neural retina consists of several cell types. As 
well as neurones, other cell types include glial cells, vascular endothelium and microglia. 
The three principal neurone cell types that relay impulses generated by light are photore­
ceptors, bipolar cells, and ganglion cells -  their activity is modulated by horizontal cells, 
amacrine cells, and possibly by non-neuronal elements such as the neuroglia. It is the 
culmination of this neural processing concerning the visual image that is eventually trans­
mitted to the brain along the optic nerve. Retinal cells are arranged in a highly organized 
manner, and in histological sections appear as distinct layers that include three layers of 
nerve cell bodies and two layers of synapses (Figure 1.3).
The neural retina acts both as a transducer and a comparator. Photoreceptors convert 
light energy from absorbed photons into electrical energy in the form of neural impulses.
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The circuitry between the photoreceptors and the retinal ganglion cells serves to compare 
the level of neural activity in different photoreceptors -  this ability to detect contrast is a 
fundamental part of vision.
1.1.3 Photoreceptors
There are two types of photoreceptor in the human eye: rods and cones. They are situated 
on the outer aspect of the retina. There are approximately 120 million rods and 6 million 
cones in the human eye. Rods are responsible for sensing contrast, brightness, and motion, 
while cones subserve fine spatial resolution and colour vision. The density of rods and 
cones varies in different regions of the retina. The central 0.5mm of the fovea, which is 
1.5mm in total diameter, contains only cone photoreceptors. Away from the centre the 
spatial density of cones falls rapidly from a maximum of ^  150,000/mm2 to ^ 7 ,000/mm2 
at 3mm retinal eccentricity. The spatial density of rods is zero in the centre of the retina, 
but rises quickly to reach a peak of ^  150,000/mm2 at an eccentricity of 5-7mm, beyond 
which it steadily declines [Rodieck, 1998].
Each photoreceptor consists o f a long narrow cell with an inner and outer segment 
joined by a connecting stalk consisting of a modified cilium (Figure 1.5). These inner and 
outer segments are separated from the cell body by an outer limiting membrane formed 
by Muller cells. The nucleus is situated in the outer nuclear layer of the retina and axons 
pass into the outer plexiform layer where they form synaptic terminals with bipolar cells 
and horizontal cells. The outer segments of rods and cones are shaped as their names 
imply. They contain the visual pigments that are responsible for absorption of light and 
initiation of phototransduction impulse.
Rods
Rods are long (100pm) slender cells whose outer segment contains the visual pigment 
rhodopsin, which has a maximal spectral sensitivity of 500nm. Rhodopsin is contained 
within membrane-bound disks. There are up to 1000 disks per cell, each of which is
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Figure 1.5: Schematic drawing of rod and cone photoreceptor cells. The primary events of photo­
transduction take place in the outer segment of the cell, shown in brown.
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10-15nm thick. The disks are enclosed by a single membrane. Each outer segment is 1- 
1.5//m in width and 25//m long. The disks are produced at the base of the outer segment 
and over the course of 10 days travel to the rod tips, which are enclosed by the apical 
microvilli of the RPE. Here they are phagocytosed by the RPE cells in a circadian manner 
-  rod disks are thought to be predominantly shed in the early morning in humans [Young, 
1967], shortly after the onset of light in all species examined [Bernstein et al., 1984],
The rods are separated by a modified extracellular ground substance containing inter­
photoreceptor binding protein (IRBP) within a sialic acid and proteoglycan matrix. The 
inner half of the inner segment is known as the myoid, the outer half the ellipsoid (3//m 
in length).
The ellipsoid is connected to the outer segment by a modified cilium consisting of nine 
doublet microtubules without a central pair. The connecting cilium represents the embry- 
ological vestige of the ciliated neuroepithelial cells that line the primitive optic ventricle. 
The cilium acts as a conduit for metabolites and lipids between the inner and outer seg­
ments. The remainder of the ellipsoid contains numerous mitochondria, indicative of the 
high metabolic activity of these cells.
The myoid region contains numerous organelles, including Golgi apparatus, smooth 
endoplasmic reticulum, microtubules, and glycogen -  evidence of a metabolically and 
synthetically active cell.
Metabolic disturbances in the photoreceptors may lead to disturbances in visual pig­
ment or photoreceptor membrane synthesis and therefore specific abnormalities in vision. 
In addition dehydration of the interphotoreceptor matrix can lead to retinal detachment 
due to loss of adhesive forces between the outer segments and the RPE.
Cones
Daylight vision relies exclusively on cones, which generate precise vision due to their 
density in the foveal region [Hendrickson, 1994]. In most diurnal animals, two spectrally 
distinct cone types exist -  one maximally sensitive to short wavelengths and one to long
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wavelengths. However, in Old World primates, apes and humans, a third cone type exists. 
The three types are generally referred to as red, green, and blue (or long, medium, and 
short wavelength) cones. Cone outer segments are generally shorter than rods and gener­
ally conical (6^m at the base, 1.5/im at the tip) -  hence the term cones. However, in the 
fovea cones are long, slender, and tightly packed. The cone disks are not surrounded by 
a plasma membrane in the same manner as rods but are in free communication with the 
interphotoreceptor matrix. Cone disks have a greater lifespan than rods and are thought 
to be shed shortly after the cessation of light [Bernstein et al., 1984].
Cones are surrounded by the long villous melanin-containing apical processes of the 
RPE and are about 60-75//m in length. The outer segment is connected to the mitochondria- 
rich ellipsoid region (containing around 600 mitochondria per cell) of the inner segment 
by a cilium similar to that described in rods. The cell body of the cone can be identified 
histologically in the outer nuclear layer because of its large, pale-staining nucleus and 
perinuclear cytoplasm.
1.1.4 Photoreceptor connections
The cell bodies o f rods and cones are connected by an inner fibre to specialized expanded 
synaptic terminals, known as spherules and pedicles respectively. These synapse with 
bipolar and horizontal cells and contain many highly specialized presynaptic vesicles.
Rod spherules are further out (towards the sclera) than the cone pedicles and are 
deeply indented by bipolar and horizontal cell processes (telodendria). A specialized re­
gion known as a synaptic ribbon is present between two adjacent nerve fibres. Horizontal 
cell telodendria penetrate deeply into the rod spherule, whereas the bipolar cell dendrites 
have a shallower penetration. Up to five processes may be embedded in one spherule. 
There is no apparent contact between rod spherules; cone pedicles may be connected by 
gap junctions.
Cone pedicles are broader than rod spherules and have a pyramidal shape. In the cone 
pedicle there are up to 12 indentations, each of which contains three neuronal terminals.
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The central process in each triad is a midget bipolar cell dendrite. The lateral processes in 
the triad are horizontal cell (telodendria) that may be involved in several triads on a cone 
pedicle. Therefore, there may be up to 25 synaptic ribbons in each pedicle. Each cone 
is usually contacted by all the horizontal cells (four to six) in the immediate field. Each 
pedicle also has numerous shallow indentations or synapses with flat diffuse bipolar cells.
1.1.5 Bipolar cells
The retina contains approximately 35 million bipolar cells, which comprise several func­
tional and morphologic subtypes. They are the neurones primarily responsible for trans­
mitting signals from photoreceptors to ganglion cells. Their cell bodies lie in the inner 
nuclear layer and are oriented radially, parallel to the photoreceptors. Single or multiple 
bipolar cell dendrites pass outwards to synapse, principally with photoreceptors but also 
with horizontal cells, while their single axon passes inwards to synapse with ganglion and 
amacrine cells.
In the foveal region, the ratio of cones:bipolar cells:ganglion cells is 1:1:1, whereas 
in the peripheral retina one bipolar cell receives stimuli from up to one hundred rods. In 
intervening regions, the ratio corresponds to the decreasing visual acuity present in the 
mid-peripheral retina. Summation of stimuli is a crucial factor in the sensitivity of the rod 
system to low levels of illumination.
Human bipolar cells can be subdivided into nine morphological subtypes: one type of 
rod bipolar and eight types of cone bipolars. The cone bipolars can in turn be subdivided 
into five types of diffuse cone bipolars and three types of midget bipolars.
Rod bipolars
Rod bipolar cells have a receptive field or dendritic tree that is small in the central retina 
(15//m wide, 10-20 rods) and larger in the peripheral retina (30//m, 30-50 rods). These 
represent 20% of all bipolar cells and are most dense around the fovea. In the periphery, 
rod bipolars contact up to 50 rods and synapse with All amacrine cells; only rarely do
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Diffuse cone bipolars
Diffuse cone bipolar cells are concerned with converging information from many cones. 
Their dendrites fan out up to 100//m to end in clusters of between five and twenty cone 
pedicles. The overlap of adjacent cells of this type is extensive in the peri-foveal region.
Midget bipolars
Invaginating midget bipolar cells are the smallest of the bipolars. Their dendrites penetrate 
the base of a single cone pedicle to form the central element in a triads. The near 1:1 ratio 
of midget bipolar cells:cones decreases peripherally. Midget bipolar dendrites synapse 
with amacrine cells and midget ganglion cells.
Flat midget bipolar cells are similar to invaginating midget bipolar cells except their 
dendrites do not invaginate deeply into the cone pedicle. Potentially, most cones can be 
in contact both types of midget bipolar cells as well as the diffuse type.
Blue cone-specific bipolar cells have been described in primates and humans [Kolb 
et al., 1992] and appear to make invaginating contact with only the blue cones in their 
territory.
1.1.6 Ganglion cells
The cell bodies of most ganglion cells are located in the innermost nucleated layer of 
the retina -- the ganglion cell layer situated between the nerve fibre layer and the inner 
plexiform layer (Figure 1.2). Ganglion cells are the last link in the retinal component of 
the visual pathway. Their axons form the nerve fibre layer on the innermost surface of the 
retina and synapse with cells in the lateral geniculate nucleus (LGN) of the thalamus.
Ganglion cell axons form bundles that are both separated and ensheathed by glial 
cells. These bundles leave the eye to form the optic nerve. On exiting through the lamina 
cribrosa, the axons become myelinated by oligodendrocytes.
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Up to seven layers of ganglion cell bodies are present in the central retina, where the 
ganglion cell layer is 6O-80^m thick. There is as few as one layer of cells in the peripheral 
retina (10-20//m). There are approximately a million ganglion cells in the retina so there 
are about 100 rods and four to six cones per ganglion cell.
While they are functionally diverse, ganglion cells are all characterized morphologi­
cally by a large cell body, abundant Nissl substance (arrays of rough endoplasmic reticu­
lum), and large Golgi apparatus. Ganglion cells are classified into different types on the 
basis of cell body size, dendritic tree spread, branching pattern, and branching level in the 
inner plexiform layer. Some ganglion cells in the macula may contain yellow (xantho- 
phyll carotenoid) pigment in the cytoplasm.
Ganglion cell impulses are received primarily from bipolar cells and amacrine cells 
via axo-dendritic and axo-somatic synapses, the former occurring predominantly in the 
inner plexiform layer where their dendrites repeatedly branch to form the ‘dendritic tree’. 
Thee form and size of the ganglion cell dendritic tree varies considerably and is correlated 
with location in the retina and therefore function (receptive field size).
Due to their morphological diversity, ganglion cells (up to 25 types in mammalian 
and 18 types in human retinas) can be classified into categories a  , j3 and 7 , or X, Y, 
and W types, predominantly based on research in the cat. In the cat, functional correlates 
(contrast, spatial resolution) are better understood than in primates, which have been less 
well investigated (Rowe, 1991; Kolb et al, 1992).
Midget ganglion cells
Midget ganglion cells synapse with one or more amacrine cells and a single midget bipolar 
cell and therefore usually one cone. The dendritic tree is about 5-10//m in diameter in the 
central retina; however, this increases 10-fold at 2mm eccentricity and attains a maximum 
of over 100//m in the periphery. Neighbouring midget ganglion cell dendritic trees do not 
overlap but form mosaics. In humans, midget ganglion cells are also known as P-cells 
because they project to the parvocellular layer of the lateral geniculate nucleus (LGN).
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Diffuse (parasol) ganglion cells
Diffuse ganglion cells include a large synaptic field from all types of bipolars except 
midget bipolar cells. They occur in the central retina and their cell bodies are 8-16/^m in 
diameter with 30-70//m dendritic fields, these being smaller nearer the fovea than in the 
periphery. Diffuse ganglion cells are also known as M-cells because they project to the 
magnocellular layer of the LGN. The finding that midget ganglion cells synapse exclu­
sively with the midget bipolar cells (and that both are common near the fovea) provides 
the anatomical basis for the observation of small receptive fields and high visual acuity in 
this region.
1.1.7 Horizontal cells
Horizontal cells derive their name from the extensive horizontal extensions of their cell 
processes. There are two distinct morphological varieties in the retina of most species, of 
which the cat is the most extensively studied. Type A horizontal cells are large axonless 
cells with stout dendrites that contact only cones. Type B horizontal cells have smaller 
bushier dendritic trees that contact cones exclusively, but in addition have axons of up to 
300/im in length that end in an extensive arborization that is postsynaptic only to rods. 
Type A cells have much larger receptive fields than type B. In primates it appears that the 
two types of horizontal cell, HI (approximates to type B) and HII (approximates to type 
A), both possess axons. More recently a third type (HIII) has been described in the human 
retina by Kolb et al. [1994].
Each rod has connections with at least two horizontal cells and each cone with three 
or four horizontal cells of each type. In primates, the stout dendrites of each HI cell 
body contact around seven cones near the fovea (the dendritic tree covering 15/xm ). This 
number increases to as many as 18 further from the fovea (the dendritic tree covering 80- 
100//m ). The axon from each HI cell passes laterally and terminates up to 1 mm away in 
a thickened axon terminal in (up to 100) rod spherules.
HII dendritic trees are more spidery and contact about twice as many cones. Their
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axons are generally shorter (100-200^m ) and contact cone pedicles by small wispy ter­
minals. HII cell bodies are located primarily in the outer part of the inner nuclear layer and 
have few distinctive cytoplasmic organelles except the crystalloids -  a series of densely 
stacked tubules with associated ribosomes. HII processes ramify in the outer plexiform 
layer close to the cone pedicles.
The overlap between horizontal cells is considerable and any one area of retina may 
be served by up to 20 horizontal cells. Horizontal cells have an integrative role in reti­
nal processing and release inhibitory neurotransmitters, mainly gama-amino butyric acid 
(GABA). Recent evidence suggests that there is some colour-specific wiring for the three 
types of horizontal cells in the human retina [Ahnelt and Kolb, 1994].
1.1.8 Amacrine cells
Amacrine cells are association neurones that were originally thought to lack axons. How­
ever, recent studies have shown that some do indeed possess an axon [Mariani, 1990]. 
They are located in the inner aspect of the inner nuclear layer and are distinguishable 
from bipolar cells in this layer as a result of their larger size (12/im ) and oval shape. 
Amacrine cells display a remarkable degree of morphological (and pharmacological) di­
versity. There are at least 25 different types in the monkey and human retina. Their cell 
body is usually flask shaped and the numerous dendritic processes o f these cells ramify 
and terminate predominantly in the synaptic complexes formed by bipolar and ganglion 
cell processes, namely the inner plexiform layer.
The shape of amacrine cell dendritic fields is highly variable. They can be divided 
into subtypes on several criteria such as the stratification of their dendrites in the in­
ner plexiform layer or their shape for example diffuse, starburst, and stratified. Diffuse 
types can cover narrow fields (approximately 25/xm wide), their fibres being cone shaped. 
Other types may spread their axon-like processes several millimeters. Amacrine cells may 
also be classified on the basis of their neurotransmitters. They may be GABAergic and 
dopaminergic or can release acetylcholine -  indicating, together with their morphology,
CHAPTER 1. INTRODUCTION 32
chs* membrane cytoplasm
GCAP
Rhodopsin
photon T ransducin
cGMP
Figure 1.6: Phototransduction cascade.
that these cells play a role in (inhibitory) modulation of signals reaching ganglion cells.
1.2 Phototransduction
The visual pigment of the rod photoreceptors, rhodopsin (R), consists of the transmembrane- 
spanning protein opsin linked to the chromophore 11-cis-retinal at Lys 296. Rhodopsin 
is specifically localised to photoreceptor outer segments in the disc (but also plasma) 
membrane. Photon absorption by the chromophore leads to its isomerization to the all- 
trans configuration along with accompanying comformational changes. This form of 
rhodopsin, R*, is catalytically active and binds the G-protein transducin (T). Activated 
transducin (T*) in turn activates a membrane-associated phosphodiesterase (PDE).
In the photoreceptor outer segment, cation channels are directly gated by cGMP and 
control the influx of ions across the plasma membrane. The hydrolysis of cGMP by PDE 
results in a change in cGMP-gated channel conformation resulting in channel closure. 
This decreases the conductance of the plasma membrane to cations and causes hyperpo-
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larization and therefore a decrease in glutamate neurotransmitter release, which results in 
signaling of the light stimulus to adjacent neurones.
Calcium ions play a key role in the recovery of the dark state of photoreceptors through 
the regulation of guanylate cyclase (GC), the enzyme that catalyzes the conversion of 
GTP to cGMP. Calcium ion concentration is high in the dark (^500nM ) and GC activity 
is low. After photoactivation, closure of the plasma membrane channels reduces the influx 
of cations, including calcium. However, the sodium/calcium/potassium exchanger contin­
ues to efflux calcium ions and as a result their concentration decreases, activating GC to 
produce cGMP via the calcium-inactivated guanylate cyclase activating protein (GCAP).
Mutations in many proteins related to the phototransduction cascade are associated 
with retinal degenerative diseases. These are summarised in Figure 1.7 and those with 
specific relevance to the macula are discussed in sec:macdisease.
1.2.1 Cones versus rods
In cones, the molecules of the biochemical cascade are similar to rods. However, they 
occur for the most part, on infoldings of the plasma membrane rather than on discrete discs 
(see Figure 1.5). Cone opsin molecules and other membrane proteins are able to diffuse 
from infolding to infolding, expanding the number of transducin molecules an activated 
opsin can encounter and the number of PDE molecules activated transducin can encounter. 
The most notable difference between cone and rod response is that the cone response is 
biphasic, consisting of a hyperpolarization phase (similar to that in rods) followed by 
an undershoot (instead of a slow re-polarization) before returning to the baseline. Rods 
saturate in bright light whereas cones do not.[Rodieck, 1998]
Topological differences between rods and cones represents a major anatomical dis­
parity between the two types of cell, yet we do not yet fully understand its functional 
significance. One interesting possibility is that the enormous increase in stability of the 
rhodopsin molecule is aided in some way by the sealing-off of the discs. Perhaps it is 
advantageous to expose the amino-terminal region of rhodopsin not to the extracellular
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Figure 1.7: Phototoreceptor outer segment proteins linked to retinal disease. ADRP = autoso­
mal dominant retinitis pigmentosa. ARRP = autosomal recessive retinitis pigmentosa. XLRP = 
x-linked retinitis pigmentosa. CSNB = congenital stationary night blindness. CD = cone dystro­
phy. CRD = cone-rod dystrophy. LCA = Leber’s congenital amaurosis. MD = pattern macular 
dystrophy. Stgdt MD = Stargardt macular dystrophy. XLRS = X-linked retinoschisis.
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solution, but instead to the intra-discal medium. For cones, the greatly increased surface- 
to-volume ratio that is possible with patent sacs may be important, as this speeds the rate 
of change of intracellular ion concentrations mediated by plasma membrane fluxes. This 
is likely to be especially important for calcium ions because of the negative feedback to 
the cascade.
1.2.2 Photoreceptor turnover
The lipids and proteins that comprise the discs and sacs of photoreceptor outer segments 
eventually deteriorate. The photoreceptor needs to perform continual maintenance during 
its life span. Rods periodically shed old discs from the distal tip of the outer segment, 
and continually generate new foldings at the base of the outer segment, that in due course 
pinch off to form discs. Thus, rod outer segments are not of uniform age, but rather the 
newer components ‘move up’ as they achieve seniority. A similar process of renewal and 
shedding occurs in cones. However, because the entire membrane is continuous, protein 
components of different ages are distributed along the length of the cone outer segment.
The existence of quantitative as well as qualitative differences between rods and cones 
implies that there must be differences in gene expression between them. Furthermore, be­
cause of both the increased cone concentration in the macula and the fact that the macula 
is specialized for precise vision, it follows that there are differences in gene expression 
between the macula and the peripheral retina. These differences in gene expression can 
provide molecular clues to understanding both the physiology and pathology of the mac­
ula.
1.3 Macular gene expression
Relatively little is known about gene expression in the human macula. This is partly 
due to the difficulty in obtaining fresh human tissue. A number of expressed sequence 
tags (ESTs) have been identified from enriched and non-enriched central retinal cDNA
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libraries (n c b i  . n lm . n i h . gov). These ESTs have contributed to the number of genes 
known to be expressed in the macula, although many of these are likely not to be dif­
ferentially expressed compared with the peripheral retina. Northern analysis has been 
used to compare gene expression between central and peripheral retina. For example, 
ten randomly sequenced clones from a non-normalized foveal cDNA library were used to 
probe RNA from central and peripheral retina. This confirmed that there are significant 
differences in gene expression [Bernstein et al., 1996]. More recently, techniques such as 
serial analysis of gene expression (SAGE) and using subtracted libraries have been used 
to study macular gene expression.
1.3.1 Serial analysis of gene expression
Serial analysis of gene expression (SAGE) is a relatively new technique that determines 
the frequency of expression of a large number of genes in a given tissue or cells [Vel- 
culescu et al., 1995]. The method is based on two principles.
Firstly, a short (9-20 base) nucleotide sequence that is sufficiently specific to dis­
criminate different transcripts from each other. For example, a 9-base pair sequence can 
distinguish approximately 250,000 transcripts. Given that the estimated number of hu­
man genes is lower than 100,000, unique 9-base pair sequences can theoretically provide 
expression information on all human genes.
Secondly, concatenation of short sequence tags allows efficient analysis of transcripts 
by sequencing them within a clone, followed by sequence comparison with the nucleotide 
database to identify the expressed sequences. The number of times that a sequence of a 
given gene is found within the isolated clones represents the frequency of the transcript.
In SAGE, double stranded cDNA is synthesized from mRNA of the tissue or cells by 
using a biotinylated oligo(dT) primer. The cDNAs are cleaved with a restriction endonu­
clease that recognizes a specific sequence of four or more bases in the cDNA molecule. 
The most 3’ part of the cleaved biotinylated cDNA is bound to strepavidin beads. This 
assures that the site binding to the strepavidin is closest to the poly(A) tail. The cleaved
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Figure 1.8: Serial analysis o f gene expression (SAGE) library construction. (A) An RNA pop­
ulation is reverse transcribed to cDNAs using oligo-T primers attached to magnetic beads. (B) 
cDNAs are collected and digested with the restriction endonuclease NlalH. (C) Linkers containing 
sequence recognized by BsmFI are ligated to the digested cDNAs. Sequence tags are released 
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and then digested with NIa III to remove the linkers. (F) Ditags are ligated together to form a 
concatemer which is then clones into a plasmid vector to generate a SAGE library. The identity 
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cDNAs are split into two aliquots and ligated, via the ‘sticky end’ left by enzymatic cleav­
age, to one of two linkers that contain a type IIS restriction site (tagging enzyme).
Type IIS restriction endonucleases cleave at a defined distance, up to 20bp away from 
their asymmetric recognition sites. The linkers are designed so that cleavage of the lig­
ation products with the tagging enzyme leads to the release of the linker along with a 
short fragment of cDNA. The two pools of released tags are ligated to each other by the 
created blunt ends. This is followed by PCR, which serves to amplify the tag sequences 
and provides orientation and punctuation of the tag sequences. The amplified product 
contains the two tags (ditags), which are linked tail to tail and are flanked by sites for the 
anchoring enzyme. This results in 4bp punctuation per ditag. Then, the ditags are released 
from the PCR products by cleavage with an anchoring enzyme. Finally, released ditags 
are concatenated by ligation, cloned and sequenced.
Recently, SAGE was used to compare the peri-macular region (6mm) with peripheral 
retina [Sharon et al., 2002]. This provided additional evidence for significant quantitative 
differences in gene expression between central and peripheral retina. Sharon et al. [2002] 
constructed SAGE libraries using two eyes and sequenced the gene tags. 24 tags were re­
ported to be significantly over-represented in ‘macula’ (HMAC2-SAGE) compared with 
peripheral retina (HPR2-SAGE). However, 36 gene tags were also reported to be signif­
icantly differentially expressed between the two peripheral retinas (HPR1/2-SAGE) used 
in the study.
1.3.2 Macular disease
As well as eliciting important mechanisms in precise vision, studying differential ex­
pression in the macula may be important to understanding degenerative disease. There 
are a number of Mendelian retinal degenerations (cone dystrophies, cone-rod dystro­
phies and macular dystrophies) for which no causative mutation has yet been found 
(www. s p h . u t h . tm c . e d u /R e tn e t ) .  Monogenic dystrophies are excellent starting 
places for determining gene function in the retina. Molecular genetic differences between
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the peripheral retina and the macula are also likely to be of importance to the much more 
common multifactorial disease age-related macular degeneration (AMD).
The inherited macular dystrophies are a heterogeneous group of disorders that are 
characterised by loss of central vision and atrophy of the macula and underlying RPE. 
Monogenic macular dystrophies are a useful source of insight into the molecular pathol­
ogy of the macula.
Stargardt disease, ABCA4
Stargardt macular dystrophy is the most common inherited macular dystrophy with a 
prevalence of 1 in 10,000 and an autosomal recessive mode of inheritance. It shows a very 
variable phenotype with respect to age of onset and severity. Most cases present with cen­
tral visual loss in the early teens and there is typically macular atrophy with white flecks 
at the level of the RPE (see Figure 1.9. Fluorescein angiography classically reveals a dark 
or masked choroid. This is believed to be secondary to excess lipofuscin accumulation in 
the RPE [Fish et al., 1981]. It has been demonstrated histologically that the number of 
photoreceptor cells is reduced in the presence of increased quantities of lipofuscin in the 
RPE, leading to the proposal that autofluorescent material may accumulate prior to cell 
death [Dorey et al., 1989].
The causative gene of Stargardt disease has been identified as ABCA4 [Allikmets 
et al., 1997]. Subsequently, mutations in ABCA4 have also been implicated in other dis­
orders, including retinitis pigmentosa (RP)[Martinez-Mir et al., 1998] and cone-rod dys­
trophy (CORD) [Maugeri et al., 2000]. ABCA4 encodes a transmembrane rim protein lo­
cated in the discs of rod and foveal cone outer segments, that is involved in ATP-dependent 
transport of retinoids from photoreceptors to the RPE [Weng et al., 1999; Molday et al.,
2000]. Failure of this transport results in deposition of the major lipofuscin fluorophore, 
N-retinylidene-N-retinylethanolamine, in the RPE [Weng et al., 1999]. It is proposed that 
this accumulation may be deleterious to the RPE, with consequent secondary photorecep­
tor degeneration.
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Figure 1.9: Stargardt disease. Fundus photograph showing white flecks at the level of the RPE at 
the posterior pole. There is early macular atrophy.
Best disease, VMD2
Best disease is a dominantly inherited macular dystrophy that is characterised by a round 
or oval yellow sub-retinal macular deposit (see Figure 1.10). The yellow material is grad­
ually resorbed over time, leaving an area of RPE atrophy and often sub-retinal fibrosis. 
The electro-retinogram (ERG) is normal but the electro-oculogram (EOG) shows a very 
reduced or absent light rise, indicating that there is widespread dysfunction of the RPE 
[Deutman, 1969]. In common with Stargardt disease, histopathology shows accumulation 
of lipofuscin throughout the RPE [Weingeist et al., 1982]. Although the ophthalmoscopic 
abnormality is usually confined to the macular region, this evidence of more widespread 
retinal involvement is in common with the majority of inherited macular dystrophies de­
scribed to date.
Best disease shows very variable expressivity and the visual prognosis is surprisingly 
good, with most patients retaining reading vision into the fifth decade of life or beyond. 
Most individuals carrying mutations in the vitelliform macular dystrophy 2 (VMD2) gene 
on chromosome 11 q 13 [Petrukhin et al., 1998] have an abnormal EOG, but the macular 
appearance may be normal in some [Mohler and Fine, 1981]. The protein product of
CHAPTER 1. INTRODUCTION  41
Figure 1.10: Best disease. Fundus photograph of showing a partially resorbed yellow subretinal 
macular deposit.
VMD2, bestrophin, has been localised to the basolateral plasma membrane of the RPE, 
where it forms a component of a chloride channel [Marmorstein et al., 2000]. This reg­
ulates fluid transport across the RPE, and it has been suggested (following optical coher­
ence tomography) that impaired fluid transport in the RPE secondary to abnormal chloride 
conductance may lead to accumulation of fluid and/or debris between the RPE and pho­
toreceptors, and between the RPE and Bruch’s membrane, in turn leading to detachment 
and secondary photoreceptor degeneration [Pianta et al., 2003].
Pattern dystrophy, peripherin2
The pattern dystrophies are a group of inherited disorders of the RPE, which are char­
acterised by bilateral symmetrical yellow-orange deposits at the macula in various distri­
butions, including butterfly or reticular patterns. These dystrophies are often associated 
with a relatively good visual prognosis, although in some cases a slowly progressive loss 
of central vision can occur. There is usually psychophysical or electrophysiological evi­
dence of widespread photoreceptor dysfunction [Kemp et al., 1994]. Electrophysiological 
findings usually reveal an abnormal pattern ERG, a normal full-field ERG, but an abnor­
mal EOG.
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Mutations in the peripherin2 gene on chromosome 6p have been identified in patients 
with pattern dystrophies [Nichols et al., 1993]. Peripherin was originally identified in a 
strain of mice with a photoreceptor degeneration known as ‘retinal degeneration, slow’ 
(RDS). The RDS mouse, which is homozygous for a null mutation in peripherin, is char­
acterised by complete failure to develop photoreceptor outer segments, downregulation 
of rhodopsin expression, and photoreceptor apoptosis. Subsequently, the orthologous hu­
man peripherin gene was shown to cause autosomal dominant retinitis pigmentosa (adRP) 
[Kajiwara et al., 1991]. A mutation in codon 172 of peripherin has also been implicated 
in autosomal dominant macular dystrophy [Downes et al., 1999].
Peripherin is a membrane associated glycoprotein restricted to photoreceptor outer 
segment discs in a complex with the orthologous rod outer segment membrane protein 1 
(ROM1). Peripherin functions as an adhesion molecule involved in the compact arrange­
ment of outer segment discs [Travis et al., 1991]. Peripherin has also been shown to inter­
act with the glutamic acid and proline rich region of the beta-subunit of rod cGMP-gated 
channels in a complex including the sodium/calcium/potassium exchanger [Poetsch et al.,
2001]. This interaction may have a role in anchoring the channel-exchanger complex in 
the rod outer segment plasma membrane.
Dominant drusen, EFEMP1
Dominant drusen (Doyne honeycomb dystrophy) is characterised by round yellow-white 
deposits -  drusen -  under the RPE, distributed at the macula and around the optic disc, 
that begin to appear in early adult life. Visual acuity is maintained through the fifth decade 
but patients usually become legally blind by the seventh decade.
Drusen are comprised of photoreceptor outer segment products and other materials 
that are deposited in Bruch’s membrane because they cannot be digested by the RPE 
cells. If enough drusen accumulate in the membrane, exchange of nutrients between the 
RPE cells and the adjacent choroidal blood vessels is compromised. As a result, RPE 
cells die, which in turn leads to photoreceptor cell. Thus in Doyne’s, visual loss is usually
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Figure 1.11: Dominant drusen. Fundus photograph showing multiple drusen-like deposits at the 
macula and around the optic disc. Small drusen-like deposits can also be seen to radiate from 
the periphery of the main drusen mass. The established complication of subretinal neovascular 
membrane is present centrally.
due to macular atrophy, but less commonly may follow formation of a subretinal neovas­
cular membrane (SRNVM). The presence of drusen-like deposits makes this dystrophy 
potentially very relevant to age-related macular degeneration (AMD).
A single mutation (R345W) in the gene that codes for epidermal growth factor (EGF)- 
containing fibulin-like extracellular matrix protein (EFEMP1) on chromosome 2p has 
been identified in the majority of patients with dominant drusen [Stone et al., 1999]. 
EFEMP1 is a widely expressed gene of unknown function. Based on its sequence homol­
ogy to the fibulin and fibrillin gene families, EFEMP1 is predicted to be an extracellular 
matrix glycoprotein. It has recently been proposed that mis-folding and aberrant accu­
mulation of EFEMP1 within RPE cells (and between the RPE and Bruch’s) may underlie 
drusen formation in both Doyne honeycomb dystrophy and AMD, although EFEMP1 
does not appear to be a major component of the drusen [Marmorstein et al., 2002].
CHAPTER 1. INTRODUCTION 44
Figure 1.12: Sorsby fundus dystrophy. Fundus photography showing subretinal haemorrhage as a 
complication of choroidal neovascularisation.
Sorsby fundus dystrophy, TIMP3
Sorsby fundus dystrophy (SFD) is a rare autosomal dominant macular dystrophy with 
onset of night blindness in the third decade and loss of central vision from macular atro­
phy or sub-retinal neovascular membrane (SRNVM) formation by the fifth decade (see 
Figure 1.12).
The tissue inhibitor of metalloproteinase-3 (TIMP3) gene on chromosome 22q has 
been implicated in SFD [Weber et al., 1994], Most of the known mutations in TIMP3 -  
including Serl81Cys, Serl56Cys, and Tyrl72Cys -  introduce unpaired cysteines to the 
C-terminus of TIMP3. This results in inappropriate disulphide bond formation and thus 
an abnormal tertiary structure that alters TIMP3-mediated extracellular matrix turnover. 
This in turn leads to thickening of Bruch’s membrane and widespread accumulation of 
abnormal material beneath the RPE [Chong et al., 2000].
Interestingly, treatment with high doses of vitamin A reverses night blindness due to 
SFD [Jacobson et al., 1995]. This suggests that the retinal dysfunction may be due to 
reduction in the permeability of Bruch’s membrane (by accumulated extracellular debris) 
resulting in the hindrance of transport of vitamin A from the choriocapillaris to the pho-
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toreceptors. Mutant TIMP3 has also been used to induce apoptosis of RPE cells [Majid 
et al., 2002]. suggesting that apoptosis may be the final common pathway for cell death 
in SFD. TIMP3 has also been shown to be a potent inhibitor of angiogenesis via its ef­
fect on vascular endothelial growth factor (VEGF), which may account for the recognised 
complication of SRNVM formation seen in SFD [Qi et al., 2003].
X-linked retinoschisis, RSI
X-linked retinoschisis (XLRS) is a vitreo-retinal degeneration that commonly presents 
in childhood with mild loss of central vision [George et al., 1995a]. The characteristic 
fundus abnormality is a cystic spokewheel-like maculopathy (foveal schisis) in virtually 
all affected males (see Figure 1.13). Peripheral retinal abnormalities -  including bilateral 
schisis cavities, vascular closure, inner retinal sheen, and pigmentary retinopathy -  are 
also seen in approximately 50% of cases [George et al., 1995b]. Full-field ERG typically 
reveals a negative waveform, in that the a-wave is larger in amplitude than the b-wave. 
Prognosis is good in most affected males in whom retinal detachment or vitreous haem­
orrhage does not occur. The histopathological findings in XLRS include splitting within 
the superficial layers of the retina, photoreceptor degeneration, thinning of the ganglion 
cell layer, and a focally absent or proliferative RPE [Manschot, 1972],
XLRS has been linked to mutations in the gene RSI on Xp22.2 [Sauer et al., 1997]. 
Juvenile retinoschisis shows wide phenotypic variability both between and within families 
with different genotypes [Eksandh et al., 2000]. RSI encodes a 224 amino acid protein 
that contains a highly conserved discoidin domain that is involved in cell-cell adhesion 
and cell-matrix interactions. These functions correlate well with the observed retinal 
schisis in XLRS.
RS1 is assembled in both photoreceptors and bipolar cells as a disulfide-linked oligomeric 
protein complex [Molday et al., 2001]. The secreted RSI complex associates with the 
surface of these cells, where it may function as a cell adhesion protein in maintaining the 
integrity of the central and peripheral retina.
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Figure 1.13: Fundus photograph showing a characteristic spoke-wheel lesion in the fovea of X- 
linked retinoschisis.
Knockout mice have been generated that are deficient in Rsl h -  the murine orthologue 
of the human RSI gene [Weber et al., 2002]. The hemizygous Rslh-/Y male mouse was 
shown to share several diagnostic features with human XLRS, including the typical ERG 
response and the development of cystic structures within the inner retina, followed by 
dramatic photoreceptor cell loss. The presence of atypical ribbons at the photoreceptor 
terminals suggested a role for RS1 in photoreceptor-bipolar synapse formation. Failure 
of synaptic connections could very well lead to photoreceptor cell death.
1.3.3 Age-related macular degeneration
Age-related macular degeneration (AMD) is the most common cause of blindness in the 
developed world. It is now responsible for over 50% of blind and partial sighted registra­
tions in the UK [O’Shea, 1998]. Approximately 10% of people over the age of sixty-five, 
and 30% over seventy-five suffer from it. Moreover, the prevalence of AMD is increasing 
[Evans and Wormald, 1996]. AMD causes loss of central vision.
While early AMD presents as drusen (see Figure 1.14) and related pigmentary changes,
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Figure 1.14: Drusen in AMD.
Figure 1.15: Geographic atrophy resulting in visualization of choroidal vessels underlying the 
retina.
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Figure 1.16: Macular haemorrhage seen in a patient with ‘wet’ AMD as a result of choroidal 
neovascular membrane formation.
late AMD can take two forms: geographic atrophy (GA, see Figure 1.14) and choroidal 
neovascularization (CNV, see Figure 1.16).
The pathogenesis of AMD is poorly understood and this has hampered the develop­
ment of rational therapies. Options for the treatment of AMD are limited. There is some 
evidence that high dose vitamin C and E, beta carotene, and zinc supplementation (the 
AREDS supplements) leads to a lower probability of progressing from early to advanced 
AMD. [Group, 2001 ] However, the confidence interval on the odds ratio is fairly wide 
and barely excludes unity (0.72; 99% confidence interval, 0.52-0.98). The AREDS sup­
plement is contraindicated in smoking -  the largest known risk factor for AMD apart 
from age -  so getting people to give up smoking may be more useful in preventing AMD 
than the AREDS supplement. For the treatment of GA, low vision aids and training can 
be offered. For CNV, the mainstay of therapy is laser photocoagulation, though only a 
small number of patients are suitable for treatment and recurrence is common [Yates and 
Moore, 2000].
Both genetic and environmental risk factors contribute to AMD. Twin and sibling
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studies suggest that the genetic component of AMD is at least one quarter [Heiba et al., 
1994; Meyers et al., 1995; Klaver et al., 1998; Gottfredsdottir et al., 1999], It is likely that 
genetic susceptibility to AMD is attributable to 3 or more genes of moderate effect. That 
is, genes which confer approximately twice the population risk to the sibling (or other 
1--degree relative) of an affected individual (Xs ^  2). A feasible genetic model involves 
three subtypes of risk gene: one subtype contributes towards the overall predisposition 
(lifetime risk) to AMD, a second subtype influences the age of onset of AMD, and a third 
subtype hones the disease’s characteristics (AMD phenotype, eg. GA or CNV). AMD 
may well be caused by environmental factors triggering disease in susceptible individuals 
[Yates and Moore, 2000]. It is also possible that AMD represents a final common pathway 
of degeneration in the macula.
Of all the genes studied in relation to AMD, the alleles of the apolipoprotein E (apoE) 
gene have been the most consistently associated with disease. However, not all apoE 
studies have found an association, and among these the associations differ. On balance, 
the epsilon4 allele appears to be protective, or at least delays the onset o f the disease, 
whereas the epsilon2 allele appears to speed the onset of AMD. [Baird et al., 2004]
One approach to find genes, and thus proteins, important in the pathogenesis o f AMD 
has been to study inherited retinal dystrophies with phenotypic similarities to AMD. Can­
didates for AMD have been chosen from genes in which mutations are known to cause 
macular disease. However, mutational analyses have failed to yield statistically signifi­
cant association of sequence variants with AMD [Allikmets, 1999]. Although the ABCA4 
gene has previously been linked to AMD, the story is much more complicated than first 
imagined as there are so many sequence variants. Allikmets [2000] gave a tally of all 
ABCA4 alleles as 350 to 400, making the heterogeneity of ABCA4 comparable to that of 
another member of the ABC superfamily -  the cystic fibrosis transmembrane conductance 
regulator.
A second method for yielding candidate genes for AMD has been to study linkage and 
association of polymorphic genetic markers in families, populations, and siblings with
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AMD. Unfortunately, these studies have also not revealed any significant susceptibility 
genes despite candidates from monogenic retinal dystrophies [Yates and Moore, 2000].
More recently, whole genome scans have been undertaken to search for genetic sus­
ceptibility to AMD [Weeks et al., 2000,2001,2004; Schick et al., 2003] that have yielded 
candidate genes from a number of loci. There is evidence -  from a large AMD fam­
ily and 11 unrelated individuals -  that mutations in the fibulin6 gene at one of these loci 
(ARMD1) segregate with AMD [Schultz et al., 2003]. Very recently, mutations have been 
found in two genes that confer an increased susceptibility to AMD: fibulin5 [Stone et al., 
2004] and clotting factor H [Edwards et al., 2005; Haines et al., 2005; Klein et al., 2005]. 
Clotting factor H mutations were estimated to account for about half o f AMD.
Fibulin5 and fibulin6 are both similar to EFEMP1 gene, which causes dominant drusen. 
Fibulin6, is an adhesion molecule that contains 6 calcium-binding EGF-like domains and 
an Arginyl-glycyl-aspartic (RGD) cell adhesion motif. Fibulin5 is prominently expressed 
in developing arteries. Fibulin5 promotes adhesion of endothelial cells through interac­
tion of integrins and the RGD motif and may play a role in vascular development and 
remodelling. Clotting factor H is a serum glycoprotein that controls the function of the 
alternative complement pathway and acts as a cofactor with factor I as a complement 3b 
inactivator. Factor H regulates the activity of the C3 convertases, such as C4b2a.
1.3.4 Functional genomics
An alternative approach to investigate the molecular genetics of macular degeneration is 
to study gene expression in the macula itself. As well as containing a higher density 
of cones than rods, foveal cones are known to be somewhat different from peripheral 
cones (at least with respect to gene expression) for example in the expression of calbindin 
[Haley et al., 1995]. Bernstein and Wong [1998] suggested that analyzing the regional 
expression of specific candidate genes could provide important clues for dissecting the 
pathophysiological basis for retinal disease.
Very high-titer cDNA libraries containing more than a million independent clones can
CHAPTER I. INTRODUCTION 51
be constructed in lambda vectors, for example ATriplEx, because of the high efficiency 
packaging and transduction of recombinant phage into E. coli [Sambrook et al., 1989]. 
In ATriplEx phagemid vectors (Clontech) the cloning sites are within a plasmid that is 
itself embedded in a lambda phage and flanked by loxP recombination sites. Transducing 
ATriplEx into an appropriate E. coli strain promotes Cre recombinase-mediated release 
and circularization of the smaller /?/as/wc/pTriplEx at the loxP sites [Elledge et al., 1991].
Den Hollander et al. [1999b] isolated thirty-three cDNAs expressed specifically, or 
at highest levels, in the retina or RPE/choroid compared with other tissues. This was 
achieved by constructing a cDNA library using a polymerase chain reaction (PCR) based 
suppression subtractive hybridization technique that normalizes sequence abundance and 
achieves high enrichment for differentially expressed genes [Diatchenko et al., 1996]. A 
mutation in one of the genes found using this approach turned out to be the cause of 
retinitis pigmentosa 12 [den Hollander et al., 1999a].
As AMD susceptibility is due to both environmental and hereditary factors, it is logical 
to look at gene expression in order to try and understand the disease process. Indeed, our 
molecular genetic understanding of both the macula and AMD are likely interlinked. The 
macula is responsible for gathering information necessary for fine visual acuity. It is 
precisely this acuity -  allowing us to read, write, and distinguish faces -  that is lost in 
macular degeneration.
Functional genomics is a relatively new term that describes tissue-specific evaluation 
of changes in gene expression in relation to underlying differences in biology. New tech­
nologies such as DNA microarrays (see chapter 3) offer opportunities to investigate gene 
expression in the macula from both a functional and pathological point of view. Rather 
than relying on linkage o f one or more genomic regions with macular disease, this ap­
proach focuses on patterns o f transcript expression in retinal tissue. This may be useful to 
determine important candidate genes for macular degeneration. On a larger scale, func­
tional genomics may help elicit the whole cacophony of molecular events involved in 
precise vision and its maintenance in the retina.
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In combination with other molecular and genetic approaches, functional genomic 
techniques offer an invaluable tool for understanding the interactions of the many cel­
lular processes that maintain the human macula and contribute to macular disease [Gorin 
et al., 1999].
1.4 Objectives
My overall objectives in studying human macular gene expression were:
1. To look for genes that are differentially expressed in macula compared with periph­
eral retina.
2. To characterize one or more of the proteins encoded by these genes in relation to 
the macula.
I aimed to characterize robust differential expression in genes not previously implicated 
in macular function or dysfunction.
In the course o f the thesis, I will cover the specific objectives of how the human macu­
lar resource was obtained and verified, microarray analysis to find differentially expressed 
genes, confirmation by quantitative PCR, and characterization of histone deacetylase 9 
and the morpheus gene family.
The first stage, towards reaching the overall objectives in studying human macular 
gene expression, was to obtain a source of human retinal RNA. Once access to enough 
fresh tissue was obtained, techniques for dissection of the macula from human donor eyes 
and RNA extraction using small quantities of neural retina needed to be refined. The next 
logical step was then to test samples of the RNA obtained for enrichment in genes that 
are known to be differentially expressed in the macula, such as red or green cone opsin. 
Finally, a cDNA library was constructed as a long-term resource.
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Figure 1.17: Two formamide agarose gels of retinal RNA. The left panel shows total RNA ex­
tracted from ten 2mm foveo-macular punches. RNA size markers are labelled in kilobases (kb). 
The right panel shows RNA from twelve pooled 2mm foveo-macular punches (left) and two 4mm 
macular punches (right).
1.5 Results
I procured and dissected over 60 human donor eyes and extracted RNA from over 50, 
using multiple sections from many eyes. For each donor eye and specimen patient details 
including: age, sex, times of death, morgue admission, enucleation and dissection, cause 
of death, medical and ocular history, and any visible ocular pathology were recorded on 
the consent form. This form was retained in the laboratory, which sadly suffered a fire 
recently.
A ten percent aliquot (3/i/ of 30/i/) of RNA extracted using the modified TRIzol 
method (2.3.2) from ten 2mm foveal punches was analysed by gel electrophoresis (Fig­
ure 1.17, left panel). Approximately 40 micrograms of total RNA was obtained (« 1 .3/ig//il 
). Five microlitres of l/ig//il RNA ladder (0.24-9.49kb) was loaded in all RNA gels to help 
assess the quality and quantity o f the extracted RNA. Smaller aliquots (1/d of 30/d ) of 
RNA obtained from column-based extraction of RNA from twelve 2mm punches and two 
4mm punches were also run on a gel (Figure 1.17, right panel). Approximately 30 mi­
crograms of total RNA was obtained («0.5/ig//d ). In both gels, ribosomal 18S and 28S 
RNA, and several mRNA bands in between can clearly be identified.
Aliquots of RNA extracted separately from ten sections of peripheral retina from dif­
ferent eyes were also analysed on a gel (Figure 1.18). Thirty microlitres of total RNA 
was obtained from each extraction with concentrations ranging from «0.25/ig//d to over 
5/ig//d .
CHAPTER 1. INTRODUCTION 54
Figure 1.18: Total RNA extracted from ten individual peripheral retinal sections. RNA size mark­
ers are labelled in kb.
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Figure 1.19: Amplification of non-homologous cone and rhodopsin cDNA from 4mm foveal and 
peripheral retinal cDNA respectively. The major bands were cut out before use as probes for 
Northern hybridization.
The PCR primer pairs for cone and rhodopsin yielded predominantly 345 and 424 
base pair products, as predicted, with 1- strand cDNA from 4mm foveal and peripheral 
retinal RNA respectively (Figure 1.19). Faint auxiliary bands in the amplified cone opsin 
cDNA were likely due to the small difference in size between red and green cone opsin.
Northern analyses using the purified, 32P-dCTP labelled rod and cone and opsin cDNA 
probes showed higher expression of cone opsin mRNA at the expected molecular weight 
of 1.4kb in the 4mm foveal punches compared with the peripheral retina (Figure 1.20). 
Conversely, higher expression of rhodopsin was seen in the peripheral retina with a band 
at the expected weight o f 1.75kb and two additional bands. There was some difficulty 
loading exactly the same amount of RNA in each lane, due to the imprecise nature of 
quantification by gel analysis. However, cone and rhodopsin levels were higher in fovea 
(4mm) and peripheral retina respectively, despite less total RNA being loaded into these 
lanes.
Initial library analysis carried out by Clontech counted approximately 3.4 million 
independent clones in the unamplified foveo-macular library. PCR analysis of 20 ran-
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Figure 1.20: Analysis of cone and rhodopsin mRNA in fovea 4mm (F) and peripheral retina (P) 
by Northern hybridization.
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Figure 1.21: Several inserts from the foveal library. Size markers (first lane) are labelled in base 
pairs. Note that the upper bands represent linearized pTriplex at 3570 base pairs and that the lower 
bands represent the inserts. There was no apparent insert in two of the plasmids run on this gel.
domly selected clones yielded 20 unique inserts ranging between 0.5 and 7kb in length 
(mean 2.6kb). My initial hybridization screening revealed at least five clones in the am­
plified foveo-macular library (0.025%) using the cone opsin probe, compared with none 
in the amplified total retinal library from Jeremy Nathans’ laboratory. About ten clones in 
each of the total retinal (2%) and foveal (0.05%) libraries lit up with a rhodopsin probe. 
Bi-directional sequencing and subsequent BLAST analysis of plasmid inserts (see Fig­
ure 1.21) obtained by converting the amplified library into plasmid revealed 11/16 non- 
repetitive sequences with several corresponding to genes that are known to be expressed 
in retina (see Table 1.1).
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NADH dehydrogenase.
Repetitive DNA. Chromosome 3.
Similar to Alu.
Likely Ribosomal protein.
Human EST various tissues.
Human eukaryotic translation initiation factor 4 gamma (eIF4G).
Similar to Alu.
Similar to Alu.
Human protein, various tissues.
Human lens epithelium derived growth factor p52. Retinal EST.
Human EST various tissues including retina.
Identical to sections of known protein. Human EST. Contains repetitive DNA.
Human protein. Neural origin.
Mitochondrial ATP-dependent (Ion) protease.
Similar to Alu.
Human protein, various tissues.
Table 1.1: Table of amplified foveal library inserts that were bi-directionally sequenced and iden­
tified by using BLAST against dbEST.
1.6 Discussion
The quality and yield of the RNA extracted from donor eyes varied from excellent to poor. 
Long delays between enucleation and dissection adversely affected the RNA but this did 
not seem like such a big factor when either the cadaver was placed quickly in the morgue 
or the enucleated eye was quickly refrigerated. A time between death and dissection of 
less than 12 hours was desirable, although not an absolute requirement to obtain good 
quality RNA. The quality and yield of RNA was also improved by careful attention to 
detail in the planning process although a speedy extraction procedure was important.
I obtained more than enough high-quality RNA, with my modifications to the T R Iz o l  
extraction method, to construct a library using SMART cDNA synthesis. A non-normalized, 
un-subtracted library was chosen because this is the closest representation of the original 
source material. Normalization of the library would help if a sequencing project were 
undertaken to identify a large number of foveal genes as it would reduce the number of 
times the same common transcript was re-sequenced. A subtracted library, for example 
made using suppression subtractive hybridization [Diatchenko et al., 1996] and periph­
eral retinal material as the ‘driver’ that is subtracted, could be a useful fovea-specific gene
CHAPTER 1. INTRODUCTION  57
discovery tool. However, both subtraction and normalization, like any manipulation of a 
library including amplification, tend to diminish the abundance of rarer transcripts.
The T R Iz o l  extraction technique, even with my modifications, proved somewhat sus­
ceptible to carry-through of RNase, as evidenced by some of my gels that inferred in­
creased RNA degradation after a single ffeeze-thaw cycle (data not shown). The two 
largest factors in improving RNA quality were use of the column-based RNaqueous- 
4-PCR kit, in which the extraction procedure is speedy, and immersing the globes in 
RNAlater as soon as possible after enucleation.
The nucleotide sequence for green (medium-wave) cone opsin is 96% identical to 
that of red (long-wave) cone-opsin and so it is very difficult to design PCR primers that 
will differentially amplify only one of these two cone pigment transcripts. It is almost 
impossible to distinguish red and green opsins by hybridization. Both red and green 
cone opsins are known to be expressed in the fovea, whereas blue (short-wave) cone 
opsin is mostly expressed in the far-periphery. The PCR for cone opsin was sub-optimal. 
However, as the major band from each reaction was cut and purified from the gel, it is 
likely that the presence o f faint auxiliary bands would not have affected the cone opsin 
hybridization probe.
The Northern analyses show that a 4mm macular punch is relatively enriched for 
cone-specific genes. A single transcript was seen corresponding to red/green cone opsin 
as expected. Three distinct bands were seen for rhodopsin, similar to that reported by 
other investigators. [Bernstein et al., 1996; al Ubaidi et al., 1990] Variation in opsin 
mRNA size is due to the presence of cryptic polyadenylation sites in the untranslated re­
gion in the primate opsin gene. Loading exactly the same quantity of RNA sample in 
each lane requires a large amount for running multiple gels, especially as assessment of 
RNA quantity is imprecise by gel electrophoresis. Standard laboratory spectrophotome­
ters are also imprecise in determining RNA concentration. However, because there was 
more RNA in the lanes that showed less expression, this was not important to achieve a 
good semi-quantitative result. Foveo-macular 2mm punches are likely to be even more
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enriched for cone-specific, and hence other macula-specific or enriched genes. Northern 
blotting is an insensitive [Bustin, 2000] technique that requires a lot of RNA. It is possi­
ble to detect macula-enriched genes of lower abundance than cone opsin by using more 
sensitive techniques for studying differential expression such as microarrays (chapter 3) 
and quantitative PCR (chapter 4).
The initial screening suggested the unamplified foveo-macular library was of rela­
tively high quality as there were a large number of independent clones. The inserts were 
also large and the vast majority differed in length. Hybridization screening using the am­
plified library demonstrated at least some enrichment for cone opsin in comparison to 
a widely used total retinal amplified library. It is likely that other macula-related genes 
are also enriched in this library. Direct sequencing of colonies from the amplified foveal 
library showed that the great majority o f inserts contained non-repetitive DNA that cor­
responded to known genes or ESTs, including those represented in other retinal libraries 
according to dbEST. It is likely that the library amplification process resulted in the loss of 
lower abundance transcripts so there will be a richer transcript profile in the unamplified 
stock. Also, it is difficult to completely eliminate genomic DNA in the original library 
construction process, although this could have been reduced by treating the RNA with 
DNase. I did not treat the RNA with DNase at the time as it involved taking the RNA 
off ice and I was very concerned about RNA degradation due to carry-through of RNase 
during T R Izol extraction.
1.7 Conclusions
I procured a resource o f human macular tissue that was of high enough quality for gene 
expression studies. I showed that my dissection technique was accurate and that, together 
with RNAlater and diligent extraction, it could yield high-quality RNA that was enriched 
in macula-related genes. The cDNA library should also prove to be a useful long-term 
resource.
Chapter 2
Methods
2.1 Tissue procurem ent
It is not easy to procure human tissue for research purposes. This has become increasingly 
difficult in the UK since the Alder Hey case. In fact, it is still almost impossible to obtain 
human eyes for research that are in a good enough condition to obtain RNA for gene 
expression studies at the Institute o f Ophthalmology.
I collected a human macular resource in Vancouver, British Columbia, Canada. I 
was based in Bob Molday’s laboratory at the University of British Columbia (www. 
b io c h e m .u b c  . c a /F a c u l t y /M o ld a y  .h tm l). I formed a collaboration with the 
Eye Bank of British Columbia to gain access to human donor eyes. I produced an outline 
of my research aims and potential benefits to health-care and presented this both orally 
and in writing. I subsequently arranged for the Eye Bank to put donor eyes in RNAlater 
(Ambion), after removing the cornea for transplantation, in order to obviate RNA degra­
dation. Informed consent to use the eyes for the purpose of my research was obtained 
from the relatives o f each donor in accordance with Canadian regulations.
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2.2 Dissection
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I developed a technique to obtain foveo-macular punches (8mm, 4mm, 2mm) from the 
retinas of post-mortem donor eyes (see Figure 1.4). This involved dissecting the eyes on 
ice to remove the cornea (if present), iris, and lens. I placed the eye on a square of pink 
dental wax and used an 8mm biopsy punch to excise the macula and underlying RPE, 
choroid, and sclera. I carefully detached the neural retina from the RPE/choroid part of 
the punch so that the macula lutea could be visualised. I then made a second, internal 
punch of either 4mm or 2mm with the appropriate biopsy tool. This smaller punch was 
placed in a 1.5ml microcentrifuge tube. If the eye had been immersed in RNAlater, I 
filled the microcentrifuge with at least 5 punch-volumes o f fresh RNAlater, or a minimum 
of 200/il for 2mm punches. Otherwise, punches were flash-frozen in liquid nitrogen. I 
subsequently dissected the remaining peripheral retina on ice, and preserved it in a similar 
manner. Flash-frozen samples were stored in a -80°C freezer. Samples in RNAlater were 
stored at 4°C over-night or at -80°C for longer periods.
2.3 RNA extraction
I tried three different RNA extraction techniques. Firstly, I used the TRIzol®  reagent 
(Gibco BRL) according to the manufacturer’s protocol. I then made several modifications 
to this technique (see 2.3.2) and started using GlycoBlue (Gibco BRL) for pellet visu­
alisation. However, GlycoBlue is not suitable for use with microarrays. Finally, I used 
Ambion’s RNaqueous-4-PCR according to their protocol. It is a rapid, column-based 
kit and includes DNase treatment. The yield of RNA and its degradation by RNase is a 
critical factor when using such small amounts of scarcely available tissue.
2.3.1 Handling RNA
It is necessary to take careful precautions to avoid contaminating experiments with RNase, 
which is present on the surface of the skin as well as in some molecular biology reagents:
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1. Use nanopure or DEPC-treated water (RNase free).
2. Wear gloves at all times. Change regularly.
3. Clean workbench and shelves.
4. Place fresh lab paper or aluminium foil on workbench.
5. Use disposable plastic-ware from unopened packages e.g. micro-centrifuge tubes, 
pipette tips.
6. Treat all glass, metal, and non-disposable plastic equipment with DEPC to make 
RNase free:
(a) Incubate equipment in 0.1% diethyl pyrocarbonate (DEPC) at 37°C  1 hour- 
overnight.
(b) Autoclave suitable equipment for 45 minutes on liquid cycle, otherwise rinse 
at least twice in RNase free water. (DEPC can methylate nucleic acids)
(c) Dispose of DEPC appropriately (suspected carcinogen).
7. Do not ffeeze-thaw RNA samples unless absolutely necessary - aliquot.
2.3.2 Isolation of RNA from Small Quantities of Tissue 
Preparation
1. Prepare RNase-free materials:
• 1.5ml microcentrifuge tubes
• metal test tube rack
•  glass mortar and pestle
•  glass homogenizer
• 26-gauge needle and 1ml syringe
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•  forceps
2. Place metal test tube rack in — 80°C freezer for at least 2 hours.
3. Place isopropanol in — 20° C freezer.
4. Fill an ice bucket.
5. Label a 1.5ml microcentrifuge tube for each sample and place on ice.
6. Prepare a dish containing liquid nitrogen.
Tissue Lysis
1. Transfer microcentrifuge tubes containing tissue samples from —80°C freezer to 
frozen test tube rack.
2. Cool glass mortar and pestle in liquid nitrogen.
3. Place mortar and pestle in frozen rack.
4. Transfer tissue samples to glass mortar with forceps.
5. Grind samples to powder with glass pestle.
6. Place mortar on ice and immediately add TRIzoL®(Gibco BRL) to begin RNA
isolation.
RNA isolation
1. Keep sample on ice at all times, except where explicitly stated.
2. Add 1ml TRIzoL® (Gibco BRL) to the sample.
3. Transfer sample to 1.5ml microcentrifuge tube.
4. Vortex at high speed for 10 seconds.
5. Transfer sample to glass homogenizer.
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6. Homogenize (on ice) until sample is fully dissolved in TRIzoL®(Gibco BRL).
7. Shear the genomic DNA by passing twice through a 26-gauge needle connected to 
a 1ml syringe.
8. Transfer the sample to a fresh 1.5ml microcentrifuge tube.
9. Add 160fil of chloroform to sample and vortex for to 30 seconds.
10. Spin at maximum speed in the microcentrifuge at 4°C  for 5 minutes to separate the 
phases.
11. Transfer the top 80% of the upper (aqueous) phase to a fresh microcentrifuge tube.1
80% aqueous phase (RNA) 
interphase 
organic phase
Figure 2.1: Phase separation.
12. Add 400/z/ ice-cold isopropanol.
13. Add 5/zg GlycoBlue.
14. Allow the sample to precipitate at —20°C 1 hour-overnight.
15. Pellet the RNA by centrifugation at maximum speed in the microcentrifuge for 15 
minutes at 4°C. Repeat this step until pellet is formed (blue).
16. Carefully pipette off supernatant so as not to disturb pellet.
17. Wash the pellet in 200/i/ of 70% ethanol and spin for 10 minutes maximum speed 
at 4°C.
1 The bottom 20% of the aqueous phase may contain protein from the interphase, including RNase.
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18. Carefully pipette off supernatant, removing as much as possible without disturbing 
the pellet.
19. Dry briefly in a stream of nitrogen gas.
20. Dissolve the pellet in RNAse-free water. Use as much water to make a roughly 
1 —  2pg/pl  solution (use between 5 and 30/i/ water).
21. Vortex until pellet is fully dissolved.
22. Store at —80°^.
The glycogen remains in the aqueous phase and is co-precipitated with the RNA. It 
does not inhibit first-strand synthesis at concentrations up to 4 mg/ml and does not inhibit 
PCR.
I have obtained up to 3 micrograms o f total RNA from a single 4mm foveal punch, and 
nanograms o f total RNA from a single 2mm foveal punch, suitable for first strand cDNA 
synthesis and detection o f both rod and cone opsin by PCR.
2.3.3 RNA gel electrophoresis 
Materials
1. Prepare RNase-free materials:
•  electrophoresis apparatus
• 500pi microcentrifuge tubes
• 50m/ measuring cylinder
• conical flask
• 1 Ox MOPS solution (RNA running buffer)
•  agarose
• RNase-free water
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2. Prepare fresh RNA loading buffer (or use frozen aliquot):
•  0.72m/ deionized formamide
•  0.16m/ 1 OX MOPS
• 0.26m/ 37% formaldehyde
•  0.2ml RNase-free water
•  0.08m/ 100% glycerol
•  0.08m/ bromophenol blue (saturated solution)
3. Prepare fresh dilution of 1:10 ethidium bromide with RNase free water from 1 Omg/ml 
stock solution.
Methods
1. Melt 0.5<? agarose in 42.3m/ RNase-free water (microwave on high for 2 minutes) 
in conical flask.
2. Add 5m/ 1 OX MOPS.
3. When cool (~  10 minutes) add 2.1ml formaldehyde (in fume hood).
4. Pour gel into taped gel dish under fume hood. Apply appropriate gel comb.
5. For each sample, mix 1/i/ o f RNA loading buffer per /// of RNA in a 500/iZ micro­
centrifuge tube.
6. Denature RNA by heating to 95°C  for 2 minutes.2 Immediately cool on ice.
7. Add 1/i/ of 1:10 ethidium bromide to each sample. Mix.
8. Remove gel comb from set gel. Apply samples to lanes. Run at up to 12017.
2Do not microwave.
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2.4 Analysis o f  foveal and peripheral retinal mRNA
I compared the level o f rod and cone opsin expression in the 4mm foveal punches to that 
in the peripheral retina (ex. fovea) by Northern analysis. Initially, I synthesised 1- strand 
cDNA from total RNA extracted from a 4mm foveal punch, using reverse transcriptase 
(Superscript II, Gibco BRL) and an oligo-dT primer. I then designed primer pairs for rod 
and red/green cone opsin in order to synthesise cDNA probes for Northern analysis. The 
primers and probes were designed by hand and checked for specificity using the Basic Lo­
cal Alignment Search Tool (BLAST) at n c b i  . n lm . n i h . gov . I then amplified rod and 
red/green cone opsin cDNA by using the polymerase chain reaction (PCR). This, and all 
subsequent PCRs were optimised by making up a standard master-mix of buffer (includ­
ing magnesium), dNTP, primers, template and polymerase. In this case I used Thermus 
aquaticus (Taq) polymerase and varied the annealing temperature and magnesium con­
centration until a single strong band was seen by agarose electrophoresis. Thirty seconds 
extension time was allowed per kilobase (kb) of template for Taq.
I ran the products of the optimised PCR reactions for rod and red/green cone opsin 
on a gel by electrophoresis. All DNA gels were made up as ^  1 % agarose in TAE buffer 
(40mM Tris, 20mM acetic acid, ImM EDTA).[Sambrook et al., 1989] I purified the bands 
using the QiaQuick (Qiagen) Gel Extraction Kit according to the instructions. I then 
radio-labelled each PCR product separately with 32P-dCTP by random priming (Prime- 
a-Gene Labelling System, Promega) before use as non-homologous cDNA probes for 
Northern hybridization.
I performed multiple Northern analyses for rod and red/green cone opsin mRNA levels 
to compare the 4mm foveal punches with peripheral retina. Firstly, I ran equal quantities 
of total RNA from each sample on a formamide-agarose gel (see 2.3.2 for protocol) as 
assessed by gel imaging. I then transferred the RNA from the gel onto a nylon mem­
brane (Hybond N+, Amersham) by capillary transfer (see Sambrook et al. [1989]). I 
pre-hybridized, hybridized the membrane with the probe, and washed the membrane, us­
ing the UltraHyb™ kit (Ambion) according to the protocol. I imaged the membranes by
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exposing a phosphor screen for 2-4 hours and then scanned the screen using a phosphor 
imaging system (Fujifilm).
2.5 Construction o f cDNA library
I procured 2mm foveo-macular punches from many eyes for construction of a cDNA li­
brary. I extracted total RNA from ten of these punches. An aliquot of this RNA was anal­
ysed by gel electrophoresis. I sent off the remaining RNA for construction of a ATriplEx2 
cDNA expression library. Because o f the small amount of tissue available, the mRNA was 
first amplified using SMART™-PCR (Clontech). Whilst I did not produce the SMART 
cDNA for library construction, I did later perform the SMART technique myself with the 
Clontech kit using both foveal and peripheral retinal RNA.
2.6 Library screening
I performed a round of hybridization screening to compare the foveal library with a total 
retinal cDNA library, obtained from Jeremy Nathans’ laboratory (www. b s  . j hmi . e d u /  
m b g /d e p t /n a th a n s  . htm), for enrichment o f cone-specific transcripts. I followed the 
instructions in the Clontech ATriplEx cDNA library construction protocol that came with 
the cDNA library.
I first grew a primary streak plate -  LB-tetracycline(5/i/ml) -  o f XL 1-Blue host cells 
(Clontech) according to the manufacturer’s protocol: a single colony from this plate was 
used to grow a working stock plate -  LB-MgSO4(20mM)-tetracycline(5^/ml) -  of host 
cells. From the working stock plate, I grew a single colony overnight in LB-MgSO4(20mM)- 
maltose(20%) broth to a relative (to the growth medium) optical density (OD60o) of 2.0.
I incubated the cells (resuspended in 20mM M gS04) with the diluted ( «  20,000 plaque 
forming units) library phage at 37°C for 15 minutes and plated them out in melted LB- 
M gS04 soft-top agarose onto an LB-MgS04-tetracycline agar(0.7%) plate. I grew the 
plate at 37°C overnight. I then took duplicate lifts of the plates and treated the nylon
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membranes (denatured 5 minutes, neutralized 5 minutes, rinsed 30 seconds, UV light 4 
minutes) to bind the DNA from the transformed bacterial colonies. Finally, I used the Ul- 
traHyb kit with 32P-dCTP labelled rod and separate red/green cone opsin probes as with 
the Northern analyses. I imaged the membranes using the phosphor imaging system.
I also sequenced several colonies to check that they contained meaningful inserts. I 
first converted the library from phage to plasmid according to the ATriplEx library con­
version protocol (Clontech). I transformed 200/il of BM25.8 cells (pre-incubated at an 
O D 60o of 1.2 with lOmM MgCl2) with 2 million plaque forming units of library lysate. 
I plated out the cells onto standard LB-ampicillin agar (0.7% agar, 50/x/ml ampicillin) 
grew them overnight and picked colonies to be grown in 5ml of standard LB-ampicillin 
(50/x/ml ampicillin) for a further night. [Sambrook et al., 1989] I then extracted the plas­
mid DNA using the QiaQuick plasmid miniprep kit (Qiagen). I performed a restriction 
digest using the enzyme Sfil to check for an insert and used ATriplEx2 specific primers 
to obtain bi-directional sequence. I checked to see what each insert contained using the 
BLAST with the EST database (dbEST) and the human genome database at the National 
Center for Biotechnology Information (n c b i . n lm . n i h . gov).
2.7 M icroarray
The microarray slides I used were designed at the Gene Array Centre, University of 
British Columbia (w w w .p r o s t a t e la b .o r g /a r r a y c e n t r e ). A set of 13,899 70- 
mers were obtained from the Operon (Qiagen) Human Genome Oligo Set version 1.1 
(om ad. q i a g e n . com/human). All probes were designed from the UniGene Database 
Build Hs. 147 and the Human Reference Sequence (RefSeq) Database, both developed 
and maintained at the National Center of Biotechnology Information (n c b i . n lm . n i h . 
gov). Before choosing the array I checked that there were a substantial number of known 
retinal genes included on the array as controls specific to my source material.
Each microarray slide contained 28,704 spots composed of a 12x4 meta-grid of 
23x26 spot grids including GFP markers at each comer and a number of control and
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empty spots. Clean preparations of each 70-mer probe were spotted robotically onto the 
glass slides so that duplicates o f each probe were in adjacent spots. The slide manufacture 
process was subject to strict quality-control.
I prepared the RNA targets and hybridized them to the arrays according to the Ar­
ray Centre’s protocols. I prepared targets with 7.5/zg total RNA using either Cy3- or 
Cy5-dUTP and Superscript II (Invitrogen) reverse transcriptase. I cleaned up the reac­
tions using the QiaQuick PCR purification kit (Qiagen) in light-shielded conditions and 
precipitated the labelled cDNA overnight at -20°C with ethanol and sodium acetate.
I resuspended each target in 50/d of hybridization solution containing: 25/il of for- 
mamide, 12.5//I o f 20x  SSC (3.0 M NaCl, 300 mM NaCitrate, pH 7.0), 0.5/d o f 10% 
SDS, 5/zl of 2gl-1 BSA, 5/d o f 5gl—1 yeast tRNA and 2/d of 10gl-1 salmon testes DNA. 
The probe was denatured by immersing the slides in water at 95°C for two minutes just 
before use. The Cy3 and Cy5 target were mixed together and hybridized to the slide under 
a cover-slip in a moisture-rich environment at 42°C overnight.
The next day, I removed the cover-slip by floating the slide in 0.2 x SSC. The slide 
was then washed 3 times for 5 minutes with 0.1 x SSC, 0.1% SDS and 3 times for 5 
minutes in 0.1 x SSC. Finally, I span the slide in a falcon tube at 2000rpm for 5 minutes 
to dry before imaging on a Virtek ChipReader.
I overlaid grids onto images o f each slide using ImageGene software (BioDiscovery), 
which was also used to quantify each spot in the two channels corresponding to Cy3 and 
Cy5 fluorescence. I parsed the raw intensity data by adapting Array Centre in-house algo­
rithms written in the R statistical computing language ( r - p r o j e c t . o rg ) to associate 
each spot with its corresponding probe identity from the Operon set.
I adjusted the individual spot intensities with an Array Centre in-house background 
correction algorithm (see Appendix A). The algorithm is based on the observation that 
(due to variations in transcript levels and probe efficiencies) less than half of the probes 
will light up for a given target. The algorithm is used to calculate the mean of the low­
est 10% of intensity values for each sub-grid as the background for that sub-grid. This
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Protocol #S001: Processing Printed Arrav-It Slides 
STEP 1 -  Preparation of Arrav-lt slides:
(a) Wash slides twice in 0.1% SDS for 5 minutes with shaking.
(b) Wash slides in water five times for one minute each, with shaking on a vortex at low 
speed.
STEP 2 - Probe Labeling and Preparation:
(a) Refer to one of the following protocols:
(1) Protocol #S004: Direct Labeling: MIRUS
(2) Protocol #S003: Indirect Labeling: Reverse Transcription - Cyanine Dyes
(3) Protocol #S002: Indirect Labeling: Reverse Transcription -  Amino-allyl dUTP
STEP 3 - Denaturing slides:
(a ) Denature slides for 3 minutes in 95°C water bath just before use. Air dry.
STEP 4 - Hybridization of Labeled Probe to Microarrav:
(a) Denature probe (prepared in STEP 2) for 3 minutes at 95°C and then keep at 65°C until 
use.
(b) Add probe to the denatured Array-It slide and put on cover slip.
(c) Place slide in hybridization chamber and allow probe to hybridize overnight at 42°C.
STEP 5 - Washing Hybridized Slides:
(a) Disassemble the hybridization chamber.
(b) Remove cover slip by floating the slide on 0.2X SSC.
(c) Wash the slide 3 times for 5 minutes each in Wash Solution I (0.1X SSC, 0.1% SDS) and 
3 times for 5 minutes in Wash Solution II (0.1X SSC).
(d) Place slides in a falcon tube and spin at 2000 rpm for 5 minutes until dry.
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Protocol #S003: Reverse Transcriptase Reaction with Cyanine dve-labeled dUTP
STEP 1 -  Reverse Transcriptase Reaction:
(a) In the reaction, use 15-20 pg of total RNA. Set up the reaction on ice as follows:
8.0 pl 5X First Strand Buffer
1.5 pl 100 pM Anchor T primer
3.0 pl 20 mM dNTPs -dTTP (6.7 mM each)
1.0 pl 2 mM dTTP
1.0 pl 1 mM Cy dUTP
4.0 pl 0.1 MDTT
15-20 pg RNA
to 40 pl DEPC Water
Control RNA can also be used in the reaction (ie. Arabidopsis).
(b) Incubate the reaction at 65°C for 5 minutes, then 42°C for 5 minutes.
(c) Add 2 pi Superscript II and 1 pl RNasin.
(d) Incubate at 42°C for 2-3 hours.
(e) Add 8 pl 1 M NaOH and incubate at 65°C for 15 minutes.
(f) Add 8 pl 1 M HC1 and 4 pl 1 M Tris-Cl, pH 7.5 to neutralize.
STEP 2 -  Probe Purification and Denaturation:
(a) Clean up probe with Qiagen PCR purification kit or other type of spin column.
Elute in the elution buffer that comes with the Qiagen kit.
(b) Now is a good time to combine Cy3 and Cy5 reactions if necessary and add 1-2 pl 
labeled GFP (see Protocol #S005 for GFP preparation).
(c) Optional : add 1 pl glycogen (20 pg/pl).
(d) Add 1/10 volume of 3M sodium acetate. Add 2.5 volumes of 95% ethanol. Precipitate 
at -20°C for at least 1 hour.
(e) Spin at top speed for 10 minutes. Wash pellet with 70% ethanol.
(f) Allow pellet to dry. Resuspend in 50 pl Hybridization solution (for one slide).
(g) For 50 pl Hybridization solution add the following:
For Oligo Slides: For cDNA Slides:
25 pl Formamide 25 pl Formamide
12.5 pl 20X SSC 12.5 pl 20X SSC
0.5 pl 10% SDS 0.5 pl 10% SDS
5 pl 2 pg/pl BSA 5 pl 5 pg/pl poly dA
5 pl 5 pg/pl yeast tRNA 5 pl 2 pg/pl BSA
2 pl 10 pg/pl salmon testes DNA 2 pl 10 pg/pl salmon testes DNA
v.010612
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background value is then subtracted from each spot intensity to obtain the background- 
corrected value. This algorithm was used in an R script that applied the correction sepa­
rately for the Cy3 and Cy5 channels of each sub-grid on the array.
I then calibrated the data by writing my own R scripts (Appendix A). I used a number 
of standard statistical functions (see section 3.1) and specialized function libraries written 
in R:
1. Non-normalized log-ratios.
2. Total intensity normalization using the log-median as the normalization factor (Equa­
tion 3.5).
3. the statistics for microarray analysis (SMA) package, which includes lowess,print- 
tip normalization and scaling. [Yang et al., 2002b] (stat.berkeley.edu/ 
users/terry/Group).
4. Variance stabilisation [Huber etal., 2002] (dkf z-heidelberg. de/abt0840/ 
whuber).
I first compared the effect o f different algorithms by producing diagnostic MA plots 
(see section 3.1 and Equation 3.6) of differential expression to display the spatial and 
intensity trends [Smyth and Speed, 2003]. I then chose the analysis method that produced 
the least bias in my overall data set and ran the R scripts using the parsed data from each 
slide. I then plotted the difference in expression (Cy3 - Cy5) against the rank of the mean 
expression for both the log transformed and variance stabilised data.
I mined the processed data by inserting it into a relational database using Structured 
Query Language (SQL). The database was implemented using mySQL (www.mysql. 
com) on a Linux (www. linux. org) server. By querying the database I developed a set 
of strict selection criteria for obtaining genes with evidence of differential expression.
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Firstly, I pooled equal volumes of 9 samples of peripheral retinal RNA from separate 
eyes (all but lane twelve in chapter 1 Figure 1.17) into one tube. Secondly, I measured
1.5/xg aliquots o f RNA from the pooled peripheral retina and foveo-macular samples by 
spectrophotometry. I reverse transcribed each aliquot using Ambion’s RETROscript kit 
with random decamers according to the protocol.
Secondly, I designed primers within rhodopsin exons 3 and 4 (see Table 2.1) to am­
plify a product that spanned the 3rd intron (C -  166bp). I optimised these primers to 
amplify the corresponding 405bp genomic fragment of rhodopsin using DNA from a hu­
man control panel. I then amplified a further 1/d sample of genomic DNA, a 1/d sample 
of the peripheral retinal cDNA, and a 1/d sample of the cDNA at a 1:10 dilution, using 
the identical optimised conditions.
I generated primer pairs to amplify cDNAs from 12 genes obtained from microar­
ray analysis chosen to undergo further study (see chapter 3 Table 3.4). Additionally, I 
designed primer pairs to amplify cDNAs from rod and red/green cone opsin, and four 
‘housekeeping’ controls: 18S ribosomal RNA, acidic ribosomal phosphoprotein (ARP), 
/3-actin (ACTB) and ubiquitin C (UBC). I designed primer pairs using the prime program 
in the GCG-Wisconsin package (www. a c c e l r y s  . c o m /p r o d u c t s /g c g _ w is c o n s in  
p a c k a g e  to specifically amplify target cDNA using an annealing temperature of 60°C. 
The resultant amplicons were designed to be 100-300 base pairs long, with the region of 
the cDNA amplified determined by which primer pairs were most specific according to the 
annealing scores produced by prime. The additional primer-repeat and primer-template 
annealing tests were included to increase the specificity of the primers.
I designed the primer pairs to be used for quantitative PCR with SYBR-green PCR 
(Applied Biosystems) as the reporter dye. Two-step SYBR-green PCR (with a joint an­
nealing and extension step) was performed for both primer optimisation and qPCR ac­
cording to the manufacturer’s protocol. I used the peripheral retinal cDNA at a 1:10 
dilution to find optimal primer pairs for each target. I ran 1.5% agarose gels to check for
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presence o f a single clean product, otherwise I designed further primer pairs. I melted the 
products of reactions, that looked optimal by gel electrophoresis, in the ABI 7700 (Ap­
plied Biosystems International) to check for a single product (and to discern its melting 
temperature) by generating a graph o f fluorescence against temperature. To double-check 
the specificity o f the primers, I directly sequenced 6 of the PCR products. Optimal primer 
pairs are shown in Table 2.1.
I ran quantitative PCR reactions for each target to compare amplification from the 
peripheral and foveo-macular samples. I diluted a fresh aliquot of each cDNA sample 
1:10 and used the same diluted aliquot for all reactions, except the 18S rRNA, in which 
both aliquots had to be diluted a further 1:100. Each target was amplified in triplicate 
from foveo-macula, peripheral retina, and a no-template (water) control. An additional 
PCR step was inserted in the ABI 7700 program at an appropriate melting temperature at 
which to measure the fluorescence of the product. This was determined from the melting 
curves. I obtained fluorescence values for each cycle using the ABI software that came 
with the 7700 and exported them as a spreadsheet.
I analysed the data using the Data Analysis for Real-Time PCR (DART-PCR) sys­
tem. DART comprises several stages of data analysis that are contained within an Excel 
(Microsoft) workbook (see Appendix B). DART uses the amplification plot method (see 
section 4.1) to determine the reaction efficiency (E) and threshold values (f(ct)). I used 
the mean efficiency and threshold for the two triplicate reactions (foveo-macula and pe­
ripheral retina) to determine the initial fluorescence values (f(0)) for each primer pair.
On a separate spreadsheet, I calculated normalized f(0) values for each test gene by 
dividing the calculated f(0) by the geometric mean of the the 4 control gene f(0) val­
ues. I calculated normalized f(0) values for foveo-macula and peripheral retina separately 
and then obtained the relative expression ratio in foveo-macula:peripheral retina. I then 
computed the log2expression ratios and plotted these on a graph.
After normalization to the 4 control genes, I determined the expression of each test 
gene as a percentage o f opsin expression. I took only the genes which were two or more
CHAPTER 2. M ETHODS 75
Symbol Accession S tart Prim er pair End Total Amp
RHO NM 000539 662 CGACTACTACACGCTCAAGCCGGAGG
CGTAGGGCACCCAGCAGATCAGGAAAGC 900 2767 239
RHO NM 000539 1394 CCCTCCTCCTCCCAACTCATCTTTCAGGAACAC
GCCCAGGGAGGGAAAAACAACTGCTCCATATC 1643 2767 250
OPN1LW NM 020061 923 CCTACTTTGCCAAAAGTGCCACTATCTACAACCCC
TCATGCAGGCGATACCGAGGACACAGATGAG 1095 1095 173
6q A L133101 1931 AC AG AG AG A ACCTTTT GTGCCTTTTT GCCT GC
C AGGG A AGGCT GGGCTCC A A AG AC ATCTAT C 2155 2715 225
BHM2 NM_017614 1152 GAAAAAGTTGCCCTCAAGCCTGACCTGGAAC
CAAAGGAATGCACCACAGCATGATTGGACAGTAAG 1401 2007 250
CRP NM_016280 137 GGCAAAGTGTTGGGGAAGTTCATCAGCTTAGAAGG
AAATAGCTCTGAGATTAACTGCCCCCCCCGC 352 2270 216
FLJ AK000110 41 CCAGGATAAAAACAGACCGTGTCTCAGTAACTGGC
ACAAAAGAGCACTGTTCCCAACTGATGACACAGG 195 1798 155
GCN2 AB037759 1160 CCCAGCCAAAAATGCCTCTAGTGGAACAAAGTCC
CTGCACCTTGATGACAGCTCCAAAAGCTCC 1362 4994 203
HDAC9 NM_178423 3085 CCACTTGCAGAAGATATTCTCCACCAAAGCCCG
ACACAGGAAATATCAGAGGGGGACTTGGCAC 3383 4659 299
NPIP NM 006985 452 GCATGAAAGAACGTGAGCACGGAGAAAAGGAGAG
TTTTGC AT CT GTAGTAGTCCT CT GCCCGCC 607 1070 156
RP2 NM 006915 845 GGGGTCAGAGACAGAAGAGCAGCGATGAATC
ACCATCCCCATTAAACTCCAAGGCAATAACAGGAC 1090 3813 246
SAG X I2453 816 CAGTTCTTCATGTCTGACAAGCCCCTGCAC
GCACTTTTTCTTGCGCTTCCTCCATAGCCAC 1038 1582 223
SRGAP2 AB032982 879 AACATTGCCAAGAGGAGAGCCAACCAGC
TCCCACCTCGGGCAGCAGATGAAAGAAAAC 1065 5677 187
X AL 110203 80 TCCCAAGGGAATACTGCAACATGCAGGCAC
TCGGCAGTCTTCTGATCCTGTCAAGCAGAAAC 240 2060 161
YAP65 X80507 1056 AAGCATGAGCAGCTACAGTGTCCCTCGAACC
TCTCCTTCCAGTGTTCCAAGGTCCACATTTGTC 1200 5153 145
18S X03205 1233 GCGGCTTAATTTGACTCAACACGGGAAACCTCAC
T CGTTATCGG A ATTA ACC AG AC A A AT CGCT CC ACC 1382 1869 150
ARP Ml 7885 590 AGCCACGCTGCTGAACATGCTCAACATCTC
TCCACAGACAAGGCCAGGACTCGTTTGTACC 838 1097 249
ACTB N M 0 0 1 101 1348 CTGGAACGGTGAAGGTGACA
AAGGGACTTCCTGTAACAATGCA 1487 1793 140
UBC NM 021009 20 ATTTGGGT CGCGGTTCTT G
TGCCTTGACATTCTCGATGGT 152 2192 133
Table 2.1: PCR primer pairs. The first pair was used to amplify exons 3 and 4 of rhodopsin 
to assess the cDNA. The remaining pairs were the final set used for quantitative PCR. Accession 
numbers for the source sequence are given. The start and end co-ordinates of the amplified region, 
as well as the total length of the source sequence and amplicon length {amp) are also shown.
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fold over- or under-expressed. I then divided the f(0) value in the appropriate part of the 
retina by the f(0) value for the corresponding opsin in that part of the retina. For example, 
for s-antigen (rod arrestin) I divided its f(0) value in the peripheral retina (where it was 
over-expressed) by the f(0) value of rhodopsin in the peripheral retina. I multiplied this 
value by 100 to determine that s-antigen was expressed at approximately 31% the level 
of rhodopsin in the peripheral retina. Conversely, for GCN2 I divided its f(0) value in the 
foveo-macula by the f(0) value for cone opsin in the foveo-macula. I then corrected these 
values for amplicon length (Table 2.1) by multiplying the percentage by the amplicon 
length ratio o f test geneiopsin.
For genes of interest, I performed several bioinformatic analyses and looked at pre­
viously published data. I obtained information about gene structures by using tools at 
ncbi .nlm.nih.gov, including the UniGene, Online Mendelian Inheritance in Man 
(OMIM), Gene Expression Omnibus (GEO) databases, and the Basic Local Alignment 
Search Tool (BLAST). I also used the Ensembl genome browser (www. ensembl. org), 
and the GenomeScan (genes . mit. edu/genome sc an), GenScan (genes . mit. edu/ 
GENSCAN) and est2genome (part o f the EMBOSS suite www. emboss . org) gene pre­
diction tools.
2.9 Tissue and antibody resources
Bob Molday’s laboratory very kindly sent me cryo-sections of human retina. I was 
also very grateful to receive a rabbit polyclonal antibody to the C-terminus of HDAC9 
(NP 848512, 1069 amino acids) by Arthur Zelent’s laboratory at The Institute of Cancer 
Research (www. i c r . c a . uk). The antibody was made to the peptide:
DVEQPFAQEDSRTAG
from amino acid 1046-1060 and is specific to the full-length protein. They also sent me a 
human B cell precursor leukemia (REH) cell line, in which full-length HDAC9 is highly 
expressed.
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2.10 Tissue culture
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I maintained the REH cell line as a control for the expression of HDAC9 protein. REH 
is a line of suspension cells although I have also been responsible for maintaining ad­
herent cell lines -  such as COS (simian fibroblast), 293T (human renal epithelial) and 
SK-N-SH (human neuroblastoma) -  at various times during my research. Tissue cul­
ture is a complex discipline. I learned the techniques applicable to my research from 
expert teaching, observation, listening, note-taking and periods of supervision in the early 
stages of my own culture experiments. A large amount of information is also available 
in many books and online, for example from the handbook produced jointly by Sigma 
(w w w .s ig m a a lr ic h .c o m ) and the European Collection of Cell Cultures (ECACC, 
www. e c a c c  . o r g . uk).
I grew the REH cells in a 250ml culture flask at 37°C in 15ml of complete culture 
medium, which consists of: RPMI (Gibco, for REH suspension cells)/DMEM (Gibco, 
for most adherent cell lines), 10% (v/v) fetal bovine serum (FBS), 2mM L-Glutamine, 
1% (w/v) Penicillin and 1% (w/v) Streptomycin. I passaged the cells twice per week 
according to the following protocol:
1. Warm complete medium to 37° C in a water bath.
2. Check cells under microscope for confluence.
3. Mix the cells thoroughly in the medium by pipetting up and down.
4. Draw all of the cells into the pipette.
5. Pipette 4-5ml o f the cells back into the flask.
6. Pipette the remaining suspension into a centrifuge tube.
7. Add fresh medium to the flask up to 15ml.
8. Incubate the flask at 37°C.
9. Centrifuge the remaining suspension at low speed for 5 minutes.
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10. Discard the supernatant.
11. Re-suspend in 15ml PBS (2.7 mM KC1,4.3 mM Sodium Phosphate Dibasic (Na2HP04), 
1.8 mM Potassium Phosphate Monobasic (KH2P 0 4) 137 mM NaCl, pH 7.2).
12. Repeat last 3 steps another two times.
13. Spin down once more.
14. Discard the supernatant.
15. Freeze the cell pellet a t-80°C.
I saved the cell pellet for Western blotting. Procedures for adherent cells are very sim­
ilar except that they must be detached by gentle trypsinisation for 1-2 minutes prior to 
splitting:
1. Draw off all supernatant with a pipette. Take care not to disturb the cell layer.
2. Wash once, gently, with PBS to remove any debris.
3. Pipette off PBS.
4. Add just enough trypsin to cover the cell layer («0.5mL in 25ml flask).
5. Incubate for 2 minutes maximum at room temperature.
6. Shake and tap occasionally to verify that the cells are releasing.
7. Add lOmL of complete medium.
8. Mix the cells thoroughly by pipetting up and down until there are few clumps.
9. Draw all o f the cell suspension into the pipette.
10. Leave l-2ml in the flask.
11. Discard the rest or save for an experiment.
12. Add 25mL of fresh medium.
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13. Incubate flask on its side at 37°C.
To prepare a cell extract from the frozen pellet I re-suspended it in «  5ml of PBS and 
passed it twice through a 26-gauge needle to shear the genomic DNA. To prepare a retinal 
extract, I homogenized retinal tissue in the smallest possible volume of PBS and also 
passed it twice trough a needle - 1 obtained a small amount of donor tissue from Pathology 
at the Institute of Ophthalmology.
2.11 Enzym e linked im muno-sorbent assay (ELISA)
2.11.1 Coating
1. Add lOOul peptide at 5-10/zg/ml in 50mM carbonate buffer ^pH 9.5:
Na2C 03 1.59g
NaHC03 2.93g
NaN3 0.20g
2. Make up to one liter with distilled water.
3. Incubate at room temperature overnight in a humid chamber.
2.11.2 Blocking
1. Remove coating solution, rinse twice with distilled water, and flip dry on paper 
towel.
2. Add 200//1 0.1% BSA-PBS-0.02% thimerosal.
3. Incubate for one to two hours at room temperature in a humid chamber.
2.11.3 Sample
1. Remove blocking solution, rinse twice with distilled water, and flip dry on paper 
towel.
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2. Prepare serum dilutions by diluting in the blocking buffer.
3. Prepare the following dilutions (make 1:5 serial dilutions):
Pre-immune Test bleed
1:1000 1:1000
1:5000 1:5000
1:25000 1:25000
1:125,000
1:625,000
4. Add lOOul of serum samples to the wells. Run in duplicate.
5. Incubate for one to two hours at room temperature in a humid chamber.
2.11.4 Wash
1. Dump out the serum dilutions and wash the wells thoroughly and vigorously five 
times with PBS-0.02-% thimerosal-0.05% tween.
2. Wash five times as above with distilled water.
3. Flip dry.
2.11.5 Conjugate
1. To each well, add 100/zl o f Goat anti rabbit-HRP conjugate (similar to Boehringer 
605 220) 1:10,000 dilution in 0.1% BSA-PBS-0.02% thimerosal.
2. Incubate at room temperature for two hours in humid chamber.
2.11.6 Wash
1. Dump out the conjugate and wash the wells thoroughly and vigorously with PBS-
0.02% thimerosal-0.05% tween, three times.
CHAPTER 2. M ETHODS
2. Wash three times with distilled water. Flip dry.
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2.11.7 Substrate
1. Add lOOul o f 3 ,3 \5 ,5 ’-Tetramethylbenzidine (TMB) soluble substrate and develop 
at room temperature for ten minutes.
2. If the color develops too quickly, dilute the peptide further.
2.11.8 Stop
1. Add 50/d IN HC1 to each well to stop the color development
2. Read immediately at A450.
2.12 Western blotting
I used Western blotting to study HDAC9 protein expression in cell and human retinal 
extracts. Western blotting is a widely used method of in vitro protein detection that entails 
electrophoretic separation and immobilization of protein followed by antibody binding 
and imaging.
I separated protein using sodium dodecyl sulphate polyacrylamide gel electrophore­
sis (SDS-PAGE). I prepared 10% gels, according to a standard recipe [Sambrook et al., 
1989]. To the extracts I added 5x  sample buffer (SB) containing 62.5mM Tris-HCL pH 
6.8, 2% (v/v) SDS, 10% (v/v) glycerol, 0.1% (w/v) bromophenol blue and 5% (v/v) (3- 
mercaptoethanol, to chemically reduce the proteins in the extracts and boiled for 2 minutes 
for denaturation. I ran gels at 200V until the dye front just reached the end.
I then transferred the protein onto a nitrocellulose membrane using a semi-dry electri­
cal transfer unit (BioRad). I pre-soaked the membrane in water and 6 pieces of the same 
size filter paper (Whatmann) in transfer buffer (TB, 25mM Tris, 192mM Glycine, 20% 
MeOH, 0.1% SDS) for 15 minutes. I attached the protein gel to the top of the membrane
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and sandwiched both above and beneath 3 filter papers. I transferred the protein at 20V, 
limited to 0.4A per membrane for 20 minutes.
I then processed the membrane containing immobilised protein according to the fol­
lowing protocol. All incubation steps were carried out at room temperature on a rocker. 
Alternatively, the blocking3 step was allowed to proceed in the refrigerator over-night:
1. Block in PBS-5% milk-0.05% Tween (5% Milk) for 1 hour.
2. Incubate with 1:500 primary antibody in 5% Milk for 1 hour.
3. Wash 5x for 5-10 minutes in PBS-Tween.
4. Incubate in 1:30,000 secondary antibody (goat anti-rabbit horseradish peroxidase) 
in 5% Milk for 1 hour.
5. Wash 4x  for 5-10 minutes in PBS-Tween.
6. Wash for 5-10 minutes in PBS.
7. Perform enhanced chemiluminescence.
Enhanced chemiluminescence (ECL) was performed by placing the membrane on a flat 
surface and adding the mixed ECL reagent from the kit (Amersham) so that it just covered 
the blot for 5 minutes. Excess reagent was allowed to drip from the blot and it was placed 
face down on a fresh piece o f cling-film. The blot was sealed by folding the cling-film 
over the top of it. It was then imaged by exposing it to X-ray film inside a light-tight 
cassette for 10 seconds to several minutes in the dark-room. The film was developed 
immediately to examine the signal and adjust exposure accordingly.
I scanned films in un-compressed tagged image file format (TIFF) at 300-600 dots 
per inch (dpi) using a flat-bed scanner (HP). I adjusted levels, brightness and contrast of 
the whole image in Photoshop (Adobe) before cropping any un-informative parts of the
3Nucleic acid hybridization requires a mobile source of nucleic acid (such as salmon testes DNA or yeast 
tRNA) to prevent non-specific binding of target (microarray) or probe (Northern blotting) to the support. 
Similarly, detection of protein using antibodies requires the use of mobile proteins such as those in milk 
(Western blotting) or bovine serum albumin (immunohistochemistry).
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image. I imported images to Illustrator (Adobe) to add labels and text and saved them as 
(encapsulated) postscript.4
2.13 Im m unofluorescence
2.13.1 Cell culture
I used 8-well chamber glass5 slides (Nunc) for immunofluorescence, which require a 
minimum volume o f 100/d to cover the slide surface within each chamber. I chose to 
use SK-N-SH adherent cells6 for immunofluorescence studies. I used bovine serum albu­
min (BSA) against non-specific binding o f the primary and normal donkey serum (NDS) 
against the secondary antibody. All incubation steps were carried out at room temper­
ature and washes involved carefully pipetting the solution into each chamber and then 
carefully pipetting it out o f each chamber with a pasteur pipette. I used the fluorescent die 
4’,6-Diamidino-2-phenylindole (DAPI), which forms fluorescent complexes with double- 
stranded DNA to stain nuclei:
1. Wash 2 x with PBS.
2. Fix in PBS-3.7% paraformaldehyde 15 minutes.
3. Wash 2 x with PBS.
4. Permeabilize with PBS-0.1% Triton 15 minutes.
5. Wash 2 x with PBS.
6. Block with 100/d PBS-3% BSA-10% NDS per well 1 hour.
4TIFF is a raster (bitmap) file format. Raster files (such as TIFF, JPEG, or BMP) are used to store colour 
(including grey-scale) information about each pixel in an image. Vectors are paths such as lines and arcs, 
and include text fonts. Raster files cannot store vector information in a scalable format. Postscript files can 
contain both raster and vector information. Portable document format (PDF) is Adobe’s distillation of a 
postscript file.
5Plastic slides can be a big problem with confocal microscopy, causing the platform to jump minutely 
because of electrostatic charge build-up.
6I previously used REH cells to try and detect HDAC9 by immunohistochemistry by spinning down 
50-100//1 of cells onto a slide using a Cytospin® (Shandon) centrifuge but cell morphology was poor using 
this technique with suspension cells.
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7. Incubate with 200//1 1:250 primary antibody in 3% PBS-BSA per well 1 hour.
8. Wash 5 x with PBS.
9. Incubate with 100/zl 1:100 Cy5 donkey anti-rabbit secondary antibody in 3% BSA- 
PBS per well.
10. Wash 2 x with PBS.
11. Wash with 1:5,000 DAPI in PBS for 5 minutes.
12. Wash 2x  with PBS.
13. Remove all PBS. Remove chambers from slide.
14. Add 1 drop o f DAKO fluorescent mounting medium.
15. Mount with an appropriately sized coverslip.
2.13.2 Retinal sections
The retinal cryo-sections that Bob Molday’s lab sent me were on standard glass micro­
scope slides; I stored them at -80°C. I processed them under as similar conditions as possi­
ble to those used for immunofluorescence. Incubation and washing times were lengthened 
because o f the increased time for penetration of the tissue sections. A vertical slide holder 
was used for washes and a horizontal moisture chamber for incubations:
1. Allow the cryo-sections to thaw and air-dry for 10-20 minutes.
2. Wash in PBS for 20 minutes.
3. Fix in PBS-3.7% paraformaldehyde for 15 minutes.
4. Wash 2x  with PBS for 20 minutes.
5. Carefully let the excess PBS drain onto a paper towel.
6. Place the slide in a moisture chamber.
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7. Pipette ^200/d o f PBS-3% BSA-10% NDS onto the slide to cover all sections 
whilst still retaining surface tension.
8. Block for 1 hour at room temperature.
9. Let the blocking solution run off the slide onto a paper towel.
10. Pipette «200/d  1:250 primary antibody in 3% PBS-BSA onto the slide.
11. Incubate over-night at 4°C in the moisture chamber.
12. Wash 2x  with PBS for 30 minutes, drain.
13. Pipette ^200^1 1:50 Cy5 donkey anti-rabbit secondary antibody in 3% BSA-PBS 
onto the sections with the slide in a moisture chamber.
14. Incubate for 4 hours at room temperature.
15. Wash 2x  with PBS for 30 minutes.
16. Wash with 1:5,000 DAPI in PBS for 30 minutes.
17. Wash 2x  with PBS for 20 minutes, drain.
18. Add 1 drop of DAKO fluorescent mounting medium.
19. Mount with an appropriately sized coverslip.
2.13.3 Imaging
I initially checked slides on a fluorescence microscope and subsequently acquired images 
on a confocal microscope. The confocal is an Axioplan (Zeiss) laser scanning micro­
scope. I used three different lasers -  an Argon laser to excite Cy5 and for simultaneous 
differential interference contrast (DIC, Nomarski), a Helium-Neon laser to excite Cy3, 
and an ultraviolet laser to excite DAPI. I firstly gained a general overview of the sections 
on the slide at low power and then changed to a higher power to find representative cells or
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illustrative regions of tissue. I then acquired several images using the software provided 
with the integral camera system. I used the same software to export the highest quality 
images (and scale bars) as TIFFs. I adjusted the levels, brightness and contrast of whole 
images in Photoshop (Adobe), assembled multiple images and added labels and text in 
Illustrator (Adobe), and saved as (encapsulated) postscript.
2.14 Antisera production
Firstly I performed bioinformatic analyses, with the help of the GCG-Wisconsin package, 
in order to design a peptide to which an antibody could be raised for detection of NPIP 
protein. I obtained the 70 base pair sequence of the oligonucleotide microarray probe for 
NPIP from Qiagen.
1 CTCCCAAGTG TGTCTGCTCA CTCCCCTTCC
31 ACCCTCAGCG GATGATAATC T CAAGAAACT
61 AAGGAAGAAT
I then aligned both the 70mer and the PCR primer pair used for quantitative PCR 
(see chapter 4 Table 2.1) with the reference sequence for NPIP (AF132984). I also lined 
up possible splice variants from ESTs and gene prediction programs (see chapter 4 sec­
tion 2.8). I designed a peptide that was represented in known and predicted isoforms of 
NPIP and that would likely be antigenic and not within a transmembrane domain.
I sent the 15 C-terminal amino acid sequence:
CSLPFHPQRMIISRN
of NPIP to Sigma (www. s ig m a - g e n o s y s  . e u . com) for synthesis of 10mg peptide
and subsequent production of two rabbit polyclonal antisera. After synthesis it was anal­
ysed by mass spectrometry and high performance liquid chromatography (HPLC). I re­
quested 2-3mg o f the peptide to be thiol cross-linked via the N-terminal cysteine residue, 
using the hetero-biofunctional (NH2,SH) m-Maleimidobenzoyl-N-hydroxysuccinimide
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ester (MBS), to the carrier protein keyhole limpet hemacyanin (KLH)7. The remaining 
unconjugated peptide was sent to me. Although I did not personally carry out the im­
munisation protocol (see Table 2.2) on this occasion, I previously oversaw a very similar 
procedure for a side-project in Canada. Institutional Animal Care and Use Committee 
(IACUC) guidelines were followed.
Day Procedure
1 Pre-bleed (15ml), antigen injection (200/xg)
14 Antigen injection (100/xg)
28 Antigen injection (100/xg)
35 Bleed 1 (15ml)
42 Antigen injection (100/xg)
49 Bleed 2 (15ml)
56 Antigen injection (100ug)
63 Bleed 3 (15ml)
70 Antigen injection (100/xg)
77 Bleed 4 (50ml)
Table 2.2: Immunisation/bleeding timetable. The conjugated peptide was injected subcutaneously 
at multiple sites. The initial immunisation was given in Complete Freund’s Adjuvant with all 
subsequent immunisations given in Incomplete Freund’s Adjuvant.
Two New Zealand White rabbits were immunised with the peptide according to the 
timetable (Table 2.2). The rabbits were around 10 weeks old at the start of the protocol and 
have a normal life expectancy of 5-6 years. The KLH-conjugated peptide was dissolved in 
PBS at a concentration o f 1 mg/ml. For each injection, 100/xg of this antigen was diluted 
in 1ml sterile saline and mixed thoroughly with 1ml of the adjuvant to form an emulsion. 
The injections were given subcutaneously at different sites every 2 weeks. Bleeds were 
taken through the central ear artery with a 19 gauge needle. The blood was allowed to 
clot and retract at 37°C for 12 hours. It was then refrigerated for a further 12 hours before 
the serum was decanted and clarified by centrifugation at 2500 RPM for 20 minutes.
After receiving the final bleed, I checked that both polyclonal antisera bound to the 
NPIP C-terminal peptide by enzyme-linked immunosorbent assay (ELISA) using horseradish 
peroxidase (HRP) in conjunction with antiserum bound to a positively charged micro-well
7KLH is typically preferred over bovine serum albumin (BSA) due to the higher immunogenicity of 
KLH. BSA is often used as a blocking agent in many experimental assays. Because antisera raised against 
peptides conjugated to BSA will also contain antibodies to BSA, false positives may occur.
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Name Sequence Tm
EcoRJ-NPIP-2 GAATTCatgttttgttgcttaggatatgaatg 55
EcoRI-NPIP-3 GAATTCatgttttgttgcttaggatatgaatggc 58
Sail- NPIP-2 GTCGACttatttattcttccttagtttcttgag 55
Sail-NPIP-3 GTCGAC............. cttagtttcttgagattatcatccgc 59
Table 2.3: PCR primers used in cloning of full-length NPIP cDNA. Restriction sites are shown in 
capitals. Dots are inserted to show alignment.
plate to which I had bound the NPIP C-terminal peptide. For details of the protocol see 
2 .3 .2 .1 initially tried to characterize the antisera by Western blotting of extracts from COS 
(simian fibroblast), 293T (human renal epithelial) and SK-N-SH (human neuroblastoma) 
primate cell lines. I also used the antisera for immunofluorescence studies in SK-N-SH 
cells (see chapter 5) and in human foveal cryo-sections kindly provided by Bob Molday’s 
laboratory in Vancouver.
2.15 Cloning
Because no previous work had been done to investigate the expression of NPIP protein, 
I decided to design a construct that contained a full-length NPIP cDNA obtained from 
neural tissue (brain or retina). For an overview of the cloning strategy I adopted, please 
see Figure 2.2.
First, I designed primers (Table 2.3) to add restriction sites to each end of NPIP so 
that it could be sub-cloned into expression vectors. A 5’ EcoRI site and 3’ Sail site were 
chosen as they are compatible with in-frame sub-cloning into a glutathione S-transferase 
(GST) fusion vector pGEX-6P-l (Amersham), a maltose binding protein (MBP) vector 
pMAL-c2X (New England Biolabs), and also a GFP fusion vector pEGFP-C2 (Clontech) 
that fuses the insert to the C-terminus8 of GFP.
Two vectors (pGEX and pMAL) were chosen for prokaryotic expression of soluble 
NPIP as they are suitable for use with a two-vector strategy9 for future monoclonal anti-
8I find Clontech’s nomenclature confusing here as the resultant fusion protein will have GFP at its N- 
terminus.
9Mice can be immunized with one fusion protein and serum and subsequent clones are screened with 
the other so as not to pick antibodies against the fusion protein. This can be more successful than trying to
CHAPTER 2. M ETHODS 89
PCR
GAATTC
CAGCTG
TA-clone
pGEM-T
Easy
Digest with EcoRI + Sail 
sub-clone
pMAL
c2X
pGEX
6P-1
pEGFP
Figure 2.2: Schematic diagram to show the cloning strategy adopted. The inserts were checked 
for size on a gel after digestion of pGEM-T Easy and for integrity by direct sequencing before 
sub-cloning.
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body production (as I have carried out for a side-project in Canada).
Initially, I amplified NPIP from brain and retinal cDNA (from a human brain and my 
foveal library), gel purified the products and cloned them into the vector pGEM-T® Easy 
(Promega). I used the high-fidelity enzyme with proofreading activity Pfu10 from New 
England Biolabs (NEB) to amplify the products and then added 0.5/d of Taq (Bioline) 
polymerase and ran an extra cycle before gel purification as Pfu does not add the A-tail 
necessary for TA-cloning.
I estimated the amount o f insert to ligate into the pGEM-T Easy vector from the in­
tensity of the band on the gel before purification and by following the guidelines in the 
manufacturer’s protocol. I used a ratio of insert:vector between 2:1 and 5:1 by volume. 
I ligated the insert into the vector by mixing a reaction using a concentrated T4 ligase 
(NEB) as follows:
lOx buffer 1/d
pGEM-T Easy 1/d
Insert DNA 2-5/d
T4 ligase 1/d
Pure water 5-8/d
Total 10/d
I ligated at room temperature for only half an hour, due to the high efficiency of the 
NEB ligase, and then immediately transformed competent DH5a E. Coli with the lig­
ated vector according to the following protocol, which I adopted for all transformations I 
performed:
1. Thaw competent cells on ice.
2. Pipette the 10/d ligation reaction into 50-75/d competent cells.
3. Sit on ice for 20 minutes.
cleave the fusion protein from the desired immunogen.
10PCR extension times were doubled when using Pfu as it is a slower enzyme than Taq due to its 3’ 
exonuclease proofreading activity.
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4. Heat-shock at 42°C for 90 seconds.
5. Place on ice for 2 minutes.
6. Plate immediately onto appropriate agar growth medium under sterile conditions.
With pGEM-T Easy I used standard LB-agar-ampicillin with added IPTG and X-Gal for 
blue-white screening o f colonies [Sambrook et al., 1989]. I grew the bacteria at 37°C 
over-night and put them in the fridge the next morning. In the afternoon I picked a 
well isolated white colony to seed 3-5ml of selective growth medium (LB-ampicillin for 
pGEM-T Easy) under sterile conditions. I repeated this for several colonies from each 
successful cloning plate. I grew the seeded media over-night at 37°C. The next morn­
ing I took a small amount o f medium separately from each successful growth to make 
a glycerol stock (25% glycerol final) for storage of successful clones at -80°C. I used 
the remaining medium from each successful growth to extract the plasmid DNA using a 
Miniprep (or Maxiprep if more DNA was required) kit (Qiagen). I eluted the plasmid in 
,50/il pure water to most often yield 50ng//xl DNA. I digested 2/d of this plasmid DNA 
with appropriate restriction enzyme(s) (EcoRI for pGEM-T Easy) and ran a gel to visual­
ize the cut plasmid and insert. I then bi-directionally sequenced plasmid DNA containing 
appropriately sized insert.
I sub-cloned inserts with appropriate sequence into the expression vectors. I prepared 
the vectors by performing a sequential digest first with Sail and then with EcoRIu . Both 
digests were performed in the supplied Sail buffer to avoid loss of DNA during an inter­
mediate purification step. It is hard to cleave DNA ends with little overhang using Sail 
so it was used first while the plasmid was still circular. The insert was cut out of pGEM- 
T Easy using a double-digest as there was plenty of overhang at each restriction site. I 
then cloned the inserts separately into each expression vector as outlined above using the 
appropriate bacterial strain, media and antibiotic selection.
11 EcoRI is a very efficient enzyme that can easily cut DNA at a restriction site with little or no overhang 
and also works under a number of different salt conditions. See the New England Biolabs catalogue for a 
useful reference on restriction digests.
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2.16 Prokaryotic protein expression
I expressed NPIP-GST and -MBP fusion proteins by transforming the appropriate bacte­
rial strain. For expression in pGEX I used BL21 E. Coli. For pMAL and pEGFP I used 
DH5a E. Coli. I picked a single colony from a plate of transformed cells containing the 
expression plasmid with sequenced insert after sub-cloning. I grew the colony in 50ml 
growth medium, with antibiotic selection, at 37°C over-night and added the growth to a 
further 500ml o f the same medium the next morning. I performed a restriction digest to 
check the size of the insert. The medium was grown to a density of 0.5-1.0 by measuring 
the absorbance at 600nm (A60o) using a spectrophotometer (fresh medium was used to 
zero the meter). The E.Coli were then induced to produce protein with 0.2mM IPTG and 
grown at 30°C, to minimise degradation, for four hours. I spun down the cells in 2 250ml 
containers at 6,000 rpm for 20 minutes in a centrifuge, discarded the medium and froze 
the pellets at -80°C over-night. The next day I thawed the pellets and re-suspended the 
cells on ice in a total o f 15ml PBS with ImM AEBSF (Calbiochem), a stable non-toxic 
protease inhibitor. I sonicated the cells to complete the lysis (that started by freezing 
them) with six 10 second bursts o f ultra-high frequency sound with an amplitude of 14- 
\5/im. I used the protein for Western blotting (see chapter 5) to characterize the antisera 
and subsequently to compare the expression of native NPIP in human retinal extract.
I expressed GFP-NPIP fusion proteins by transient transfection of human neuroblas­
toma (SK-N-SH) cells using the Lipofectamine™ kit from Invitrogen. I followed the 
instructions from the kit and used lOOng of plasmid DNA per well o f an 8-chamber mi­
croscope slide to transfect cells cultured at &25% confluence. I also transfected cells 
with empty pEGFP-C2 plasmid as a positive control and cultured un-transfected cells on 
the same slide as a negative control. All experiments were carried out in duplicate. I 
checked the cells for confluence and expression of fluorescent fusion protein after over­
night growth. After 24 hours I fixed the cells in 3.7% paraformaldehyde and imaged them 
by confocal microscopy.
Chapter 3
Microarray analysis
3.1 Introduction
In the 1999 Nature Genetics Supplement, "The Chipping Forecast", Southern et al. begin:
The DNA microarray is the latest in a line o f techniques to exploit a po­
tent feature o f  the DNA duplex— the sequence complementarity o f  the two 
strands. It is remarkable that a molecule o f  such great structural complexity 
can reassemble with perfect fidelity from the separated strands.
The introduction of solid supports has greatly increased the range of applications for 
nucleic acid hybridization.
The starting point, for the use of duplex formation as a tool in molecular biology, was 
the observation that single-stranded DNA binds strongly to a nitrocellulose membrane 
in a way that prevents the strands from re-associating with each other, but does permit 
hybridization to complementary RNA [Gillespie and Spiegelman, 1965]. This was the 
direct precursor of the ‘blotting’ methods, the first of which, Southern blotting [1975], 
combined gel separation of restriction digests with hybridization on filters.
Historically, most applications of blotting have combined a single labelled, purified 
oligonucleotide in the liquid phase with a complex mixture of polynucleotides attached to 
a solid support [Duggan et al., 1999]. For example, transcript abundance is often assessed
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by immobilizing mRNA or total RNA (electrophoretically separated as in ‘Northern blot­
ting’) on membranes and then incubating with a radioactively labelled, gene-specific tar­
get (see 2.3.2). If multiple RNA samples are immobilized on the same membrane, infor­
mation about the quantity o f a particular message in each sample can be obtained.
The method o f ‘dot-blotting’ [Kafatos et al., 1979] was developed for rapidly deter­
mining the relative concentrations o f nucleic acids in a mixture. Subsequent automation 
and miniaturization o f the dot-blot showed how hybridization could be used on a large 
scale to exploit the data emerging from genome programmes [Lennon and Lehrach, 1991].
The main advance from dot-blots to microarrays is the use of an impermeable rigid 
support, such as glass, which has practical advantages over porous membranes [Khrapko 
et al., 1989]. As liquid cannot penetrate the surface of the support, target nucleic acids 
have immediate access to the probes without diffusing into pores. This enhances the rate 
of hybridization. The washing step that follows is also unimpeded by diffusion, speeding 
up the procedure and improving reproducibility. The flatness, rigidity and transparency of 
glass supports improve image acquisition and processing, as the locations of the probes 
are much better defined than on a flexible membrane; high resolution is critical for the 
small feature sizes that can be achieved on microarrays. These practical benefits apply to 
arrays of cDNAs, PCR products and synthetic oligonucleotides.
The two main platforms for high-density microarrays are:
1. Direct synthesis o f oligonucleotides, usually 15-25-mers, on glass substrates using 
photolithography [Fodor et al., 1991].
2. Deposition o f DNA samples on to glass substrates using a spotting robot [Schena 
et al., 1995].
One advantage of spotted microarrays over direct synthesis microarrays is greater 
versatility. Researchers can make and design their own microarrays, selecting the DNA 
sources to spot. These arrays are also lower cost, especially for studies involving a large 
number of experiments. Amplified products of cDNA inserts from expressed sequence 
tags (ESTs) are commonly used as a source of samples for spotted microarrays [Schena
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et al., 1995], although several technical difficulties are often associated with using this 
source [Finkelstein et al., 2002], Firstly, mismatches of cDNA clones and EST sequences 
in the database can be as high as 38% [Knight, 2001] due to tracking errors or contami­
nation. Secondly, the tracking and quality tests of amplified products can be tedious and 
difficult to manage. Thirdly, cDNAs may not distinguish among members o f multigene 
families, related genes, and alternatively spliced genes. Finally, current EST collections 
represent only 25-50% of the predicted genes in a genome.
An alternative source o f DNA samples for spotted microarrays are long synthetic oli- 
gos (50-70mers) designed from ESTs or annotated genome sequences. Synthetic oligos 
have advantages over cDNAs because they avoid the need to track clones and amplicons, 
and they can be designed to have a uniform sequence length (ensuring more uniform 
hybridization) and high specificity for distinguishing related DNA sequences. Sets of 
long oligos have been developed using information from all annotated genes of complete 
genome sequences for several model organisms, including yeast, Drosophila , human, 
mouse, and Arabidopsis www. o p e r o n . com.
Spotted arrays are generally used with two coloured fluorescent probes, whereas ar­
rays produced by direct synthesis, for example GeneChips (Affymetrix), use only a sin­
gle intensity reading meaning that only one probe rather than two can be hybridized in 
a single experiment. In two-colour microarray expression analysis many gene-specific 
polynucleotides derived from the 3' end of RNA transcripts are individually arrayed on a 
single matrix. This matrix is then simultaneously hybridized with fluorescently labelled 
cDNA representations of RNA from two separate pools. This allows the relative amount 
of transcript present in each pool to be determined by measuring fluorescence at two 
wavelengths.
For example, if  we have an array with array  distinct elements and compare fluo­
rescence values (in arbitrary units) for query and reference samples, CyS and Cy5 re­
spectively (for the green and red fluorescent dyes commonly used in two-colour array 
experiments), then for the zth gene (where i is an index running over all the arrayed genes
CHAPTER 3. M IC R O A R R A Y A N A LYSIS
from 1 to array), the expression ratio M  can be written as
96
Mi =  (3.1)Cyhi
Although ratios provide an intuitive measure of expression changes, they have the disad­
vantage of treating over- and under-expressed genes differently. Genes over-expressed by 
a factor o f 2 have an expression ratio of 2, whereas those under-expressed by the same 
factor have an expression ratio of 0.5.
The most widely used alternative to the simple ratio is the logarithm base 2 trans­
formation o f the ratio, which has the advantage of producing a continuous spectrum of 
values, treating over- and under-expressed genes in a similar fashion. Logarithms treat 
numbers and their reciprocals symmetrically: log2(l) =  0, log2(2) =  1, log2( 1/2) =  
— 1, log2(A) =  2, log2(l/4:) =  —2 and so on. The logarithms of the expression ratios are 
also treated symmetrically, so that a gene over-expressed by a factor of 2 has a log2 ratio 
of 1, a gene under-expressed by a factor of 2 has a log2 ratio of -1, and a gene expressed 
at a constant level (with a ratio o f 1) has a log2 ratio equal to zero.
Differential gene expression data from microarray experiments are usually calibrated 
(normalized) to account for variations in sample treatment, RNA quantification, labelling 
and dye efficiency, detection, and other systematic biases in the measured expression 
levels (reviewed in Quackenbush [2002]). Typically, normalization adjusts the individ­
ual fluorescence intensities to balance them appropriately so that meaningful biological 
comparisons can be made. Conceptually, normalization is similar to adjusting expres­
sion levels measured by Northern blotting or quantitative PCR (see chapter 4) relative to 
the expression of one or more reference genes, whose levels are assumed to be constant 
between samples.
There are many approaches to normalizing expression levels. Some, such as total 
intensity normalization, are based on simple assumptions. Given equal amounts (weights) 
of labelled cDNA in each sample, one assumption is that the number of labelled cDNA 
molecules in each sample is also the same. A second assumption is that the arrayed
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elements represent a random sampling of the genes in the organism. If the arrayed genes 
are selected to represent only those we know will change, then we will likely over- or 
under-sample the genes in one o f the biological samples being compared. However, if  the 
array contains a large enough assortment of random genes, we do not expect to see such 
a bias. Consequently, approximately the same number of labelled molecules from each 
sample should hybridize to the arrays and, therefore, the total hybridization intensities 
summed over all elements in the array should be the same for each sample.
Using the above assumptions1 a normalization factor N  is calculated by dividing the 
summed intensities for each channel:
array
E CyZ
N  =  ^ ------ ■ (3-2)
E Cy5
i—1
One or both intensities can then be appropriately scaled, for example
C y 5' =  N  x Cybi and Ct/3' =  Cy3i (3.3)
so that the normalized expression ratio for each element becomes
C ^  = 1 QA  
* Cj/5' N  Cybi ( ' ’
which adjusts each ratio such that the mean ratio is equal to 1. This is equivalent to 
subtracting the normalization factor from the logarithm of the expression ratio,
M' =  log2{Mi) -  log2(N)  (3.5)
which results in a mean log2 ratio of zero.
There are many variations on this type of normalization, including scaling the indi­
vidual intensities so that the mean or median intensity is the same within a single array
1 Different amounts of cDNA in each sample can be taken into account by total intensity normalization. 
Equal amounts are assumed for explanatory purposes.
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or across all arrays, or using a selected subset of genes to normalize against. In addition 
to total intensity normalization there are a number of alternative approaches to normal­
izing expression ratios, including linear regression analysis, log centering, rank invariant 
methods [Tseng et al., 2001] and ratio statistics [Chen et al., 1997]. However, none of 
these approaches takes into account systematic bias that appears in the data [Yang et al., 
2002a,b], most commonly as a deviation from zero for low-intensity spots.
The variability in the log2 ratios also increases as the hybridization intensity de­
creases: relative error increases at lower intensities where the signal approaches back­
ground. Commonly used approaches to address this problem are to use only array ele­
ments with intensities that are statistically significantly different from background, and to 
use absolute lower thresholds for ‘acceptable’ array elements or percentage based cut-offs. 
Conversely, at the high end o f the intensity spectrum -  where the array elements saturate 
the fluorescence detector -  saturated pixels can be eliminated in the image-processing 
step or a maximum ‘acceptable’ value can be set.
However, there are a number o f normalization techniques that take into account sys­
tematic bias without pre-processing the intensity data. One method proposed by Yang 
et al. [2002b] to remove intensity-dependent effects in the log2 ratios is locally weighted 
linear regression analysis (lowess).
Another approach to deal with the problem of systematic intensity bias is to adjust the 
log2 ratios so that the amount o f statistical variance is equal for spots of all intensities 
[Yang et al., 2002b; Huber et al., 2002]. This has the advantage of being able to adjust 
both for differences between regions of an array or between arrays.
Lowess, and other methods of normalizing intensity, can be applied either globally or 
locally. For spotted arrays, local normalization is often applied to each group of array 
elements deposited by a single pen, as in the print-tip normalization methods used in 
Terry Speed’s lab [Yang et al., 2002b; Smyth and Speed, 2003]. Local normalization can 
help correct for systematic spatial variation in the array, including inconsistencies among 
pens used to make the array, variability in the slide surface, and slight local differences in
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hybridization conditions. However, this is not important in all types o f  array.
Microarray experiments have previously been used in the retina to identify both disease- 
causing (autosomal dominant retinitis pigmentosa [Kennan et al., 2002]) and major regu­
latory (homeobox Crx [Livesey et al., 2000]) genes. However, many microarray experi­
ments suffer from too few replicates and lack of statistical analysis.
3.2 Objectives
I planned to make use o f microarray technology to look for differences in gene expres­
sion between central and peripheral retina in a large number of genes. My aim was to 
perform multiple microarray experiments using the human macular resource (chapter 1)
I procured. An important objective was to analyse the data obtained from microarray ex­
periments in a way that discriminated between genes well enough to choose a handful for 
further study. Analysing the data from first principles, rather than relying on proprietary 
software, was part o f this objective. I planned to compare different methods of analysis 
and choose those most appropriate to my particular experiments.
3.3 Results
3.3.1 Resources
I found over 50 retina-related genes amongst the 13,899 unique probes on the Array Cen­
tre microarrays (see Appendix B Table B .l). I used six of these slides in separate hy­
bridization experiments to compare gene expression in the central and peripheral retina. 
Messenger RNA isolated from 24 separate donor eyes (see section 2.3) was used for mi­
croarray and subsequent quantitative PCR analysis. The donor age varied from forty to 
seventy-seven years and the sex distribution was approximately even. No signs of retinal 
disease were observed in any o f the eyes used, nor was any ocular disease mentioned 
on the consent forms. All eyes were placed at four degrees Celsius post-enucleation and
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many were additionally bathed in RNAlater (Ambion, Texas) at this time. Most donors 
had been cooled in the morgue prior to enucleation. The time between death and either 
dissection or RNAlater treatment ranged from four to twelve hours.
Two separate RNA samples from the mid-peripheral retinas of separate donors were 
chosen at random from the best quality RNA samples obtained using RNAlater and the 
column extraction method. The peripheral retina 1 sample originated from a 72 year old 
woman who died from a cardiac arrest secondary to lung cancer (lane 2, autoreffig:peri) 
and whose eyes were enucleated and bathed in RNAlater within 7 hours of death. The 
peripheral retina 2 sample originated from a 57 year old man who died from a stroke sec­
ondary to carotid artery stenosis (lane 2, autoreffig:peri) and whose eyes were enucleated 
and bathed in RNAlater within 6 hours o f death. The two pooled 4mm punches and ten 
pooled 2mm punches (Figure 1.17, left and right panels respectively) used were extracted 
using the modified TRIzol method. Dye-swap experiments were not performed as the 
amount of foveal RNA was a limiting factor.
3.3.2 Experiments
1. peripheral retina 1 vs. peripheral retina 1
2. peripheral retina 1 vs. peripheral retina 2
3. 4mm pooled macula vs. peripheral retina 1
4. 4mm pooled macula vs. peripheral retina 2
5. 2mm pooled foveo-macula vs. peripheral retina 1
6. 2mm pooled foveo-macula vs. peripheral retina 2
Each experiment was carried out on a new microarray slide that had been subject to quality 
control. The scanned slides consisted of two channels of data each -  one for Cy3 and 
one for Cy5 (see Figure 3.1). High resolution TIFF files (^25 Megabytes per channel) 
were used to align grids corresponding with the spots on the arrays and numerical spot
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fluorescence values were successfully extracted using ImaGene. The custom R scripts 
then successfully parsed the data and the map of genes on the array into text files.
3.3.3 Optimisation
Diagnostic M vs. A (see Equation 3.6) plots using data from each of these 6 experiments 
displayed varying amounts o f bias with the different normalization techniques used. This 
analysis was particularly useful for experiment 1 -  a self-self control in which two aliquots 
of the same RNA sample were labelled with different dyes and hybridized competitively 
on the array (see /autoreffigireanalysis). Non-normalized log-ratios produced the most 
bias. Intensity normalization (using the median expression as the normalization factor) 
resulted in a simple shift of the log data in the y-axis towards the origin, but did not oth­
erwise change the distribution o f the data. The lowess and print-tip normalization graphs 
were very similar to the intensity normalized graphs. A substantial reduction in bias was 
seen with the SMA scaling algorithm and variance stabilisation, with the funnel effect of 
low-expressed genes having exaggerated expression ratios most markedly reduced with 
the latter method.
The top twenty most highly differentially expressed genes were calculated using each 
normalization method (see Table 3.1) for experiment five. The list was identical using 
either no normalization (simple log ratios) or the median expression as a normalization 
factor. The other lists were similar, with some positional differences in the top twenty and 
a few omissions and additions. The SMA scale algorithm produced a top twenty list quite 
dissimilar to any other.
The expression ratios for rod and red/green cone opsin were mined from the data 
obtained for experiments 5 and 6 (2mm foveo-macula vs. peripheral retina) using each of 
the normalization methods and means calculated for the four spots (two on each slide) 
to verify the direction and scale o f opsin expression using the different analysis methods. 
All the analysis methods reported red/green cone opsin over-expression in foveo-macula 
2mm and rhodopsin over-expression in peripheral retina except the non-normalized log
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Figure 3.1: Low resolution merged two-channel image of microarray slide 6 -  2mm pooled foveo- 
macula (Cy3, green) vs. peripheral retina 2 (Cy5, red).
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Figure 3.2: Diagnostic microarray M  vs. A plots using data from the self-self (peripheral retina 1 
vs. peripheral retina 1) duplicate microarray experiment.
Log ratio Log ratio (SMA lowess) Log ratio (SMA print tip) Log ratio (SMA scale) Variance stabilised ratio
neurofilam ent 3 neurofilam ent 3 FAT tum or suppressor hom olog 2 H um an clone C3 CHL1 protein C 3H -type zinc finger protein
m ethyl-C pG  binding dom ain  4 ubiquitin  th io lesterase m ethyl-C pG  binding dom ain 4 am iloride-sensitive cation  channel 3 testis neurofilam ent 3
FAT tum or suppressor hom olog 2 ubiquitin  th io lesterase ubiquitin  th iolesterase N ESH  protein m ethyl-C pG  binding dom ain 4
ubiquitin  th io lesterase FAT tum or suppressor hom olog 2 ubiquitin  th iolesterase papillary  renal cell carcinom a ubiquitin  thiolesterase
ubiquitin  th io lesterase m ethyl-C pG  binding dom ain 4 K1AA1001 protein crystallin  beta A l FAT tum or suppressor hom olog 2
K IA A 1001 protein K.IAA1001 protein neurofilam ent 3 hypothetical protein F23149 1 C 3H -type zinc finger protein
hypothetical pro tein  F L Jl 1029 hypothetical pro tein  F L Jl 1029 hypothetical protein F L Jl 1029 tum or necrosis factor receptor 12 ubiquitin  th io lesterase
C 3H -type zinc finger protein H om o sapiens clone 23860 H om o sapiens clone 23860 ribonuclease HI large subunit far-d iphosphate far-transferase 1
H om o sapiens clone 23860 cartilage o ligom eric m atrix  protein H om o sapiens clone 24894 papillary renal cell carcinom a K IA A 1001 protein
far-d iphosphate far-transferase 1 dev d iff  enhancing factor 2 dev d iff  enhancing  factor 2 beta-1 3-glucuronyltransferase 1 hypothetical protein F L Jl 1029
cartilage oligom eric m atrix  protein D m x-like 1 cartilage o ligom eric m atrix protein GS15 dopam ine receptor D5
dev d iff  enhancing  factor 2 H om o sapiens clone 24894 cD N A  D K FZp564D 042 EU R O IM A G E 35907 N F-L
D m x-like 1 Rab gergertransferase beta subunit Rab gergertransferase beta subunit parathyroid horm one recep tor 2 yes-associated  protein 65 kD a
H om o sapiens clone 24894 far-diphosphate far-transferase 1 D m x-like 1 renal cell carcinom a antigen RAGE-4 cartilage o ligom eric m atrix  protein
Rab gergertransferase beta subunit cD NA  D K FZp564D 042 paired box gene 6 ribonuclease HI large subunit H om o sapiens clone 23860
C 3H -type zinc finger protein paired box gene 6 far-diphosphate far-transferase 1 tubulin  gam m a 1 hom eo box C6
cD N A  D K FZp564D 042 hom eo box C6 hom eo box C6 tum or necrosis factor receptor 12 R ab gergertransferase beta subunit
paired  box gene 6 m annose-6-phosphate receptor m annose-6-phosphate receptor sodium  channel type IX alpha polypeptide cD NA  D K FZp564D 042
m annose-6-phosphate  receptor zinc finger protein 237 tubulin  alpha 2 high-m obility  group protein 2 D m x-like 1
hom eo box C6 tubulin alpha 2 proline and g lutam ic acid rich nuclear protein hypothetical protein F L J l0734 P E G 8/IG F2A S im printing gene
Rod -4.2 -3.3 -2.7 -1.5 -0.9
Cone -1.4 +0.9 +0.7 +0.7 +  1.2
Var 1.4 0.8 1.0 1.2 0.5
Table 3.1: Diagnostic microarray data. Upper section: Top 20 foveo-macula:peripheral retina expression ratios from (duplicate) microarray experiment 5 
-  2mm pooled foveo-macula vs. peripheral retina 1 -  for each of the data calibration methods, except log median ratio intensity normalization which has 
the same top 20 as the log ratio method. SMA = Statistics for MicroArrays package. Note that duplicate genes for a single method represent duplicate 
spots within the microarray. Lower section: Mean expression ratios for rod (Rod) and red/green cone opsin (Cone) in experiments 5 and 6 -  2mm pooled 
foveo-macula vs. peripheral retina 1 and 2 respectively -  for each o f the data calibration methods above. The mean co-efficient of variance (Var) for rod and 
cone opsin using the different methods o f calibration is also shown.
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ratio, which also reported red/green cone opsin over-expression in the peripheral retina. 
This result was also seen in an initial analysis of the data using GeneSpring at the time. 
Rhodopsin over-expression in peripheral retina was reported to be substantially more than 
red/green cone opsin over-expression in 2mm fovea using all but the variance stabilisation 
algorithm. Variance stabilisation reported red/green cone opsin over-expression in 2mm 
fovea to be a third greater than rhodopsin over-expression in the peripheral retina.
3.3.4 Data analysis
All the processed microarray data were subsequently re-analysed using both non-normalized 
log-ratios (as a comparison) and variance stabilization. I applied these two transforma­
tions separately to each slide and plotted the data as the expression ratio between channels 
M  vs. the rank of the mean expression A defined by
where h(x) is defined by equation 3.7 or 3.10. The ranks rather than the absolute values of 
mean expression were plotted as it makes it easier to visualise differential expression (by 
reducing the central bulge in the data due to most genes being of mid-level expression).
Figure 3.3 shows M  vs. rank A  plots for duplicate data from experiments 1-6. In the 
upper graph of each panel, the function:
was applied to the data. Thus, M was the log (base two) expression ratio o f Cy3:Cy5 for 
each non-control spot on the array:
(3.6)
h{x) =  log2 {x) (3.7)
Mi =  log2(Cf/5j) -  log2(C'i/3,) =  log2(Cy5i/Cy3i) (3.8)
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Therefore, +1 represents two-fold over and -1 two-fold under-expression 
Similarly
A, = t ° g ^ )  s  l o g W — — ~ ~
which is the arithmetic mean of the log expression (or the log geometric mean of expres­
sion).
In the lower graph o f each panel, h(x) is the variance stabilized data [Huber et al., 
2002]. The values for the expression ratio M  calculated using the variance stabilization 
function are equivalent to log-ratios for high intensity microarray spots. However, vari­
ance stabilization is designed to reduce the noise in genes with lower mean expression A 
-  a small change in intensity results in a relatively large change in differential expression 
for these genes when log-ratios are used. Variance stabilization is achieved by applying 
the function
h(x) =  sinh_1(a +  bx) (3.10)
where a and b are constants calculated from the expression data according to the variance 
stabilisation algorithm [Huber et al., 2002].
The difference in the log-transformed (upper graph) and variance stabilised (lower 
graph) data in figure 3.3 can be clearly seen. The log-transformation resulted in many 
low-expressed genes with large differences in expression. These funnel-shaped plots are 
typical for logarithmic transformations of microarray data [Chen et al., 1997].
The variance stabilized data produced much flatter graphs that were more centred 
around the origin, especially for the control experiments (1&2). A characteristic cen­
tral bulge of differentially expressed genes at mid-level expression appears in the central 
vs. peripheral experiments, except for experiment 3. There are also a number of highly 
expressed genes which also appear highly differentially expressed in experiments 4-6.
106
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“I peril (Cy3) cf. peril (Cy5) 0  macula(Cy3) cf. peril (Cy5) 0 foveo-macula(Cy3) cf. peril (Cy5)
peril (Cy3) cf. peri2(Cy5) 0  foveo-macula(Cy3) cf. peri2(Cy5)macula(Cy3) cf. peri2(Cy5)
Figure 3.3: Relative vs. rank mean expression ratios in six microarray experiments. The upper 
graphs show log-ratios whilst the lower graphs show variance stabilised ratios.
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3.3.5 Data mining
After I analysed each slide, I placed the results in an SQL database and mined the data by 
querying for genes that showed evidence of differential expression. Genes that met each 
of several criteria were considered to show robust differential expression. I designed the 
criteria to filter out low-expressed genes or those for which the probe was sub-optimal -  
resulting in relatively low expression values. These criteria were also designed to select 
a handful of consistently differentially expressed genes for further study by quantitative 
PCR.
Selection criteria
• For genes expressed more highly in central retina:
-  Variance stabilised expression ratio > 3 (~  eight-fold increase) across foveo- 
macular experiments 5 and 6.
-  Variance stabilised ratio greater in macular experiments (3,4) than in control 
experiments (1,2).
-  Variance stabilised ratio greater in foveo-macular experiments (5,6) than in 
macular experiments (3,4).
• For genes more highly expressed in peripheral retina:
-  Variance stabilised expression ratio < — 2 (^  four-fold decrease) across ex­
periments 5 and 6.
-  Variation in ratios of < 1 across control experiments 1 and 2.
•  For all genes:
-  Absolute fluorescence of probes > 600 above background in at least 2 chan­
nels.
Table 3.2 shows background-corrected fluorescence and variance stabilised data for 
two control genes, rod and red/green cone opsin. The red/green cone opsin probe was
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designed to long wave (red) cone opsin. However, red and green opsin are too similar to 
be distinguished by hybridization (or even RT-PCR).
Table 3.3 shows fluorescence and variance stabilised data for two genes, S-antigen 
and nuclear pore complex interacting protein, that met all of my criteria for differentially 
expressed genes.
Table 3.4 shows a summary o f data from probes that met all o f the above criteria, as 
well as from the rod and long wave cone opsin probes.
3.4 Discussion
The microarray slides were designed from a set of 13,899 cDNAs, each corresponding to 
a unique human UniGene cluster. Of these, over 50 genes were related to the retina (see 
Appendix B Table B .l). This allowed me to look at the expression of a large number of 
genes of potential importance to both precise vision and macular degeneration.
Intensity normalization, using the median expression as the normalization factor, did 
centre the expression data around the origin, although exactly the same intensity biases 
were still evident as in the non-normalized data (see Figure 3.2. These biases include the 
non-linear trends seen especially in experiments 4 and 6 (see 3.3) and most notably the 
large amount o f variation in ratios for genes with low measured hybridization intensity.
Intensity normalization was as far as most commercially available software went to­
wards normalization o f array data. In fact, it is possible that the version o f GeneSpring 
used at the time did not employ any normalization at all, given that both GeneSpring and 
the non-normalized log-ratios both reported under-Qxpression of red/green cone opsin in 
the foveo-macula. The normalization algorithm used in GeneSpring, the only commer­
cially available software accessible to me at the time, was not publicly available. This 
was a factor in deciding to analyse the microarray data using non-propietary but well- 
researched algorithms.
Print-tip normalization, using the SMA package, did not appear to improve the overall 
shape and hence bias o f the data significantly. Perhaps the high degree of quality control
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Rhodopsin Cy3 Cy5 Vsn3 Vsn5 Vsnr AVsnr
Self-self (peri2B) 661 11504 5.75 5.63 0.12
410 8737 5.27 5.35 -0.08
Intra 536 10120 5.51 5.49 0.02 0.10
Peril-peri2B 337 1844 3.19 2.41 -0.78
175 1787 3.16 1.73 -1.43
Inter 256 1816 3.17 2.07 -1.10 1.10
Control 396 5968 4.34 3.78 -0.54 0.60
Fovea4mm-peri2B 6 385 1.21 2.06 -0.84
-3 297 1.00 1.91 -0.91
Fovea4mm-periL 1 120 916 4.68 3.81 0.87
88 780 4.36 3.64 0.73
Fovea4mm 53 594 2.82 2.85 -0.04 0.84
Fovea2mm-periL 1 372 2807 3.00 4.21 -1.22
456 2989 3.20 4.28 -1.07
Fovea2mm-peri2B 12 603 2.94 3.74 -0.80
15 635 3.18 3.79 -0.61
Fovea2mm 213 1758 3.08 4.01 -0.92 0.22
R/g cone opsin Cy3 Cy5 Vsn3 Vsn5 Vsnr AVsnr
Self-self (peri2B) 26 218 2.60 1.77 0.84
4 266 1.21 1.94 -0.73
Intra 15 242 1.91 1.85 0.05 0.78
Peril-peri2B 121 120 0.64 1.36 0.71
38 407 1.68 0.39 -1.29
Inter 80 264 1.16 0.88 -0.29 1.00
Control 47 253 1.54 1.37 -0.12 0.89
Fovea4mm-peri2B 65 432 2.15 2.13 0.02
32 699 1.73 2.46 -0.73
Fovea4mm-periL 1 4 88 1.15 0.61 0.54
3 58 0.86 -0.15 1.01
Fovea4mm 26 320 1.47 1.26 0.21 0.57
Fovea2mm-periL 1 374 194 3.01 1.42 1.58
316 79 2.84 0.53 2.31
Fovea2mm-peri2B 11 165 2.89 2.16 0.73
5 130 2.03 1.80 0.23
Fovea2mm 177 142 2.69 1.48 1.21 0.73
Table 3.2: Background-corrected fluorescence (Cy3 and Cy5) and variance stabilized {VsnS and 
Vsn5) data for rod and red/green cone opsin. Vsnr is the ratio of Vsn3:Vsn5. The samples used 
for each experiment are listed in the leftmost column. Data for duplicate probe spots are shown 
in consecutive rows. Means for each group of experiments are shown in the rows entitled Intra 
(for the self-self control), Inter (for the peril-peri2B control), Control (for the combined controls), 
Fovea4mm (for both 4mm fovea experiments) and Fovea2mm. A Vsnr is the average deviation of 
Vsnr from zero in the control experiments and from the mean Vsnr in the non-control experiments.
CHAPTER 3. M IC R O A R R A Y A N A LYSIS 111
S-antigen Cy3 Cy5 Vsn3 Vsn5 Vsnr AVsnr
Self-self (peri2B) 557 8678 5.57 5.34 0.23
494 7321 5.45 5.18 0.28
Intra 525 7999 5.51 5.26 0.25 0.25
Peril-peri2B 1323 4967 4.19 3.80 -0.38
2056 8439 4.72 4.24 -0.47
Inter 1690 6703 4.45 4.02 -0.43 0.43
Control 1107 7351 4.98 4.64 -0.09 0.34
Fovea4mm-peri2B 65 494 2.15 2.22 -0.07
30 90 1.69 1.43 0.26
Fovea4mm-periL 1 12 340 2.28 2.69 -0.41
38 204 3.50 2.02 1.48
Fovea4mm 36 282 2.41 2.09 0.32 0.58
Fovea2mm-periL 1 142 769 2.04 2.89 -0.85
87 904 1.57 3.06 -1.49
Fovea2mm-peri2B 0 207 -0.61 2.47 -3.08
1 268 0.23 2.80 -2.57
Fovea2mm 57 537 0.81 2.80 -2.00 0.83
NPIP Cy3 Cy5 Vsn3 Vsn5 Vsnr AVsnr
Self-self (peri2B) 116 1810 4.02 3.79 0.24
183 2256 4.47 4.00 0.47
Intra 150 2033 4.25 3.89 0.35 0.35
Peril-peri2B 871 1972 3.26 3.38 0.12
768 1436 2.94 3.25 0.31
Inter 819 1704 3.10 3.31 0.21 0.21
Control 484 1868 3.67 3.60 0.28 0.28
Fovea4mm-peri2B 397 4167 3.65 4.02 -0.37
563 5494 3.98 4.28 -0.30
Fovea4mm-periL 1 968 1584 6.78 4.39 2.39
1072 1400 6.88 4.26 2.62
Fovea4mm 750 3161 5.32 4.24 1.08 1.42
Fovea2mm-periL 1 4004 1675 5.38 3.69 1.69
3700 1392 5.30 3.50 1.80
F ovea2mm-peri2B 728 223 7.15 2.57 4.58
624 224 6.99 2.58 4.42
Fovea2mm 2264 879 6.20 3.08 3.12 1.38
Table 3.3: Background-corrected fluorescence (Cy3 and Cy5) and variance stabilized (Vsn3 and 
Vsn5) data for S-antigen and nuclear pore complex interacting protein (NPIP).
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Name Symbol Accession Exp Cy3 Cy5 Vsn3 Vsn5 Vsn3/Vsn5
Rhodopsin RHO NM 000539 1,2 396 5968 4.34 3.78 -0.54±0.60
3,4 53 594 2.82 2.85 -0.04±0.60
5,6 213 1758 3.08 4.01 -0.92±0.60
Long-wave cone opsin OPN1LW Ml 3305 1,2 47 253 1.54 1.37 -0.12±0.89
3,4 26 320 1.47 1.26 0.21 ±0.89
5,6 177 142 2.69 1.48 1.21 ±0.89
Yes-associated 65 YAP65 X80507 1,2 32 189 1.01 1.06 -0.36±0.5
3,4 349 968 4.60 3.30 1.31 ±0.5
5,6 745 327 5.33 1.81 3.52±0.5
Histone deacetylase 9 HDAC9 AC004744 1,2 90 595 2.66 2.01 -0.07±0.65
3,4 288 915 4.46 1.75 2.70±0.65
5,6 681 199 5.27 1.90 3.37±0.65
SLT-ROBO GTPase act’ing SRGAP2 AB032982 1,2 672 2222 4.03 3.87 0.88±0.88
3,4 1750 6301 6.10 4.49 1.60±0.88
5,6 1234 496 5.64 2.46 3.18±0.88
Hypothetical protein FLJ AK000110 1,2 750 3192 4.29 4.12 0.48±0.48
3,4 705 4257 5.29 4.08 1.20±0.48
5,6 1238 418 5.79 2.61 3.18±0.48
Nuc. pore comp, int’ing NPIP NM 006985 1,2 484 1868 3.67 3.6 0.28±0.28
3,4 750 3161 5.32 4.24 1.08±0.28
5,6 2264 879 6.20 3.08 3.12±0.28
cDNA from 6q22.1 6q AL133101 1,2 896 2939 4.51 4.04 0.62±0.62
3,4 1121 5100 5.70 4.33 1.37±0.62
5,6 1212 494 5.82 2.73 3.09±0.62
cDNA from Xql3.1 X AL 110203 1,2 692 3595 4.25 4.09 0.56±0.56
3,4 456 1839 4.89 3.63 1.26±0.56
5,6 1014 389 5.66 2.57 3.09±0.56
/3-homoCys CH3-t’ase BHMT2 AK000008 1,2 3485 16485 5.9 5.67 0.59±0.59
3,4 6946 27782 7.57 6.15 1.42±0.59
5,6 13332 4995 8.22 5.16 3.06±0.59
GCN2 eIF2alpha kinase GCN2 AB037759 1,2 1670 6990 5.03 4.91 0.71±0.71
3,4 2306 9914 6.45 5.08 1.37±0.71
5,6 4277 1636 6.95 3.92 3.03±0.71
Carboxylesterase-related CRP NM 016280 1,2 1221 5159 4.7 4.57 0.79±0.79
3,4 2342 10425 6.47 5.10 1.37±0.79
5,6 3432 1310 6.88 3.87 3.01±0.79
Retinitis pigmentosa 2 RP2 AJ007590 1,2 2015 9052 5.27 5.15 0.32±0.32
3,4 3318 13635 6.86 5.60 1.26±0.32
5,6 6912 2554 7.62 4.62 3.01±0.32
S-antigen (rod-arrestin) SAG XI2453 1,2 1107 7351 4.98 4.64 -0.09±0.34
3,4 36 282 2.41 2.09 0.32±0.34
5,6 57 537 0.81 2.80 -2.00±0.34
Table 3.4: Summary of microarray data. Experiments 1&2 are controls, 3&4 are macular (4mm) 
vs. peripheral and 5&6 are fgveo-macular (2mm) vs. peripheral retina. Cy3 and Cy5 are the mean 
signal values, for each background-corrected channel, from the two grouped duplicate experi­
ments. The Vsn3 and Vsn5 columns are the variance stabilised expression values for each channel. 
Vsn3: Vsn5 is the variance stabilized expression ratio; a positive value enumerates over-expression 
in the Cy3-labelled sample. The Cy3 channel represents macula or foveo-macula compared with 
peripheral retina in the non-control experiments.
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in array manufacture prevented this from being an issue. Also, the SMA lowess algorithm 
did not seem to make a significant difference. Both the SMA scale algorithm (for scaling 
the array data so that each channel has the same median absolute deviation) and variance 
stabilization -  applied globally to all the intensity values within an array -  produced a 
marked reduction in the non-linearity of the control data.
Variance stabilization reduced the variability in low-expressed genes (see Figure 3.2 
and Figure 3.3, lower graphs). It also produced more consistent results for several control 
genes, including the rod and red/green cone opsin (see Table 3.1 and Table 3.2) in which 
it showed the lowest co-efficient o f variance for expression over these eight spots in slides 
5 and 6. Variance stabilization was therefore chosen as the most appropriate algorithm 
with which to perform calibration before mining the data. Variance stabilization is a 
recent normalization algorithm that is freely available for research use and is designed to 
produce a constant signal-to-noise ratio over the entire data-set [Huber et al., 2002].
All non-control experiments except experiment 3 (4mm pooled macula vs. peripheral 
retina 1) showed a greater central bulge o f mid-intensity differentially expressed genes 
than the control experiments (see Figure 3.3). The reason for this not being observed 
in experiment 3 could be that this particular peripheral retinal section was taken fairly 
close to the macular region, thus diminishing differences in expression. This underlines 
the need to perform more than one comparison. A handful of genes with high measured 
expression also appeared highly over-expressed in central retina, appearing as ‘flares’, 
especially in plots o f experiments 4 and 6. Whilst some of the points in these ‘flares’ 
represent genes that were consistently over-expressed in central retina, others represent 
probes with variable expression data. These appear at a high mean expression level A as 
the mean is skewed by the higher expression value in the Cy3 channel. By calculating 
overall mean expression ratios using duplicate spots, by using data from two equivalent 
experiments, and by applying strict inclusion criteria for differentially expressed genes, it 
was possible to eliminate such artifacts from the analysis.
Like in all microarrays, expression data for individual probes showed some variation
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both between slides (inter-array) and between duplicate spots on the same slide (intra- 
array). I defined the intra-array variation, for a particular gene, as the average deviation of 
the self-self duplicate (experiment 1) expression ratios from zero (see Tables 3.2 and 3 .4 .1 
defined the inter-array variation as the average deviation between two different samples of 
peripheral retina (experiment 2) from zero. I took the mean of these two variation figures 
to be a combined measure o f variation for a particular gene. This gene-specific ‘error 
value’ was used to help interpret the mean of the four (duplicate) non-control experiments: 
foveo-macula (experiments 3&4) and fovea (experiments 5&6) vs. peripheral retina. I also 
calculated the average deviation o f the expression ratios from the mean for these two sets 
of experiments.
Intra- was generally lower than inter-array variation, as expected, although both were 
less than 1 unit for most genes analysed. Whilst intra-array variation was likely due to 
differences in the spotted probe concentration, inter-array variation can be explained by 
differences in biological sample preparation and labelling. The combined variation was 
generally around ±0.5, which on the log2 scale is <1.5 fold. This is significantly less 
than the cut-off ratios o f -2.0 (4-fold under-expression) and 3.0 (8-fold over-expression) 
used to choose genes for further study. Only one gene that was under-expressed in central 
retina (S-antigen) met the strict criteria for further study.
The average deviation of expression ratios from the mean in both groups of 2 non­
control experiments was generally larger for genes with higher measured hybridization 
intensity. This may be due to differences in the two samples of peripheral retina being 
exaggerated in comparing them with central retina. This could perhaps have been min­
imized by applying variance stabilization simultaneously to all of the microarray slides 
instead of separately to each slide. As means were used, it is unlikely that this affected 
the final analysis. If definitive expression profiles of a large number o f genes were sought 
in the foveo-macula, it is likely that a much larger amount of tissue would be needed to 
perform many more array experiments.
Variations in microarray data demonstrate the necessity to combine a number of ex­
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periments to look for consistent differential expression. Similar principles are likely to 
apply to other methods o f looking at differential gene expression, including SAGE. When 
this technique was used to look at differential expression in the macula by Sharon et al. 
[2002], 36 SAGE tags were reported to be significantly differentially expressed between 
two peripheral retinas (HPR1/2 SAGE). Only 24 SAGE tags were reported to be signif­
icantly over-represented in ‘macula’2 (HMAC2 SAGE) compared with peripheral retina 
(HPR2SAGE).
I am often asked whether someone’s ‘favourite’ gene is expressed more in central or 
peripheral retina, according to my microarray data. For many genes it is difficult to give 
a definitive answer as the variability in expression is too high relative to the expression 
ratio. This is explained by either the gene being expressed at a low level or that the probe 
did not work well enough. If more RNA is used then more probes will light up, although 
probes corresponding to higher-expressed genes will saturate and be non-informative in 
differential expression studies. The construction of arrays with non-optimal probe se­
quences could be overcome by designing slides with more than one probe for each gene. 
For example, in the case o f both long-wave cone opsin and rhodopsin, it is likely that the 
probes were not optimal as their absolute fluorescence values were lower than those of 
many other genes (see Table 3.4), whereas we know that opsins represent a substantial 
portion o f the retinal transcriptome.
Another factor in array design is the length of the probes. Whilst very short probes 
(25-mers or less) do not suffer from secondary structure formation they may be less spe­
cific than mid-length probes as a 25-mer can match more than one gene transcript at the 
lower hybridization temperatures that are necessary. Longer probes suffer from an in­
creasing amount of secondary structure competing with the targets for binding and also 
an increasing amount o f non-specificity. For example if whole cDNAs are arrayed, longer 
motifs may be similar enough to match more than one related gene. These limitations can 
often be overcome if  enough experiments are performed, but it is necessary to weigh them 
up when choosing an array to use. The arrays I used were of 70-mers, which is near to
2One 6mm region of central retina was used, whereas the macula is defined as the central 4mm.
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the optimal theoretical probe length. Cost is a major factor and the common Affymetrix 
25-mer array platform was not available to me cheaply in Vancouver, where I procured the 
human macular resource. The Affymetrix platform is a one-colour non-fluorescent array. 
It would therefore also have been necessary to perform twice the number of experiments. 
More recent Affymetrix arrays have the advantage of using 5 different 25-mers for each 
gene, which goes a long way towards creating optimal probes.
3.5 Conclusions
I used microarray analysis to select a manageable number of candidate genes for further 
study. I performed multiple microarray experiments and compared several techniques of 
data analysis. I chose the most suitable method of normalization and mined the data by 
using a custom-built database. I chose candidate genes for further study using a set of 
strict selection criteria.
Chapter 4
Quantitative PCR
4.1 Introduction
The main alternatives to microarray analysis in the study of gene expression are reverse 
transcriptase PCR (RT-PCR) and Northern blotting. Northern blotting is a laborious pro­
cedure with low sensitivity [Bustin, 2000] that therefore requires a large amount of RNA 
for each gene studied. It also suffers similar limitations to microarrays because of its 
basis on hybridization: it is difficult to accurately compare expression between genes be­
cause of varying probe efficiencies. Quantitative PCR has now become widely used to 
validate expression data obtained from microarray experiments [Nadon and Shoemaker, 
2002] because o f its exquisite sensitivity and large dynamic range of up to 8 log units.
Quantification o f PCR by measuring the amount of product at an end-point in the 
reaction is problematic because of the plateau that occurs as reaction components become 
limiting and PCR products compete for polymerase binding.
Competitive PCR [Becker-Andre and Hahlbrock, 1989] requires many extra reactions 
and optimisations. First, a mutated template (competimer) must be constructed that is 
amplifiable by the same primer pair as the query template, but can be distinguished from 
it by a unique restriction site or a size difference of tens of nucleotides. This competimer 
is then added at a known quantity to the test sample. PCR is performed until a measurable 
amount of product is obtained from both template and competimer in the exponential
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phase o f amplification.
The advent o f ‘real-time’ PCR has brought quantitative PCR into the mainstream 
[Ginzinger, 2002; Walker, 2002]. Real-time PCR combines improvements in fluores­
cence chemistry with thermal cycler technology. A precise light source such as a laser is 
used to stimulate fluorescence, which is detected -  via preferably high-fidelity optics -  by 
a detector system such as a charge coupled device (CCD) or photomultiplier tube (PMT).
This enables fluorescence measurement o f PCR reactions on a cycle-by-cycle basis. A 
simple real-time PCR platform may consist of a UV lamp as the source, a CCD camera 
as the detector, and the inclusion o f ethidium bromide (EtBr) in the PCR reactions.
The basis of quantitative PCR lies in the observation that accumulation o f  fluores­
cence is proportional to accumulation o f  amplification products [Higuchi et al., 1993]. 
Therefore, the amount o f  fluorescence at cycle zero is proportional to the amount o f tem­
plate. This initial fluorescence, and hence the amount of starting material, is too small 
to measure directly but can be calculated from the accumulation of fluorescence during 
subsequent PCR cycles.
Once blunt-ended copies o f the template are produced in the second cycle of PCR1, 
these products undergo doubling for each perfectly efficient additional cycle. The fluorescence- 
cycle amplification plot (Figure 4.1) is sigmoidal for real PCR data because the initial ex­
ponential increase in fluorescence reaches a plateau as the reaction efficiency decreases.
The exponential part o f the amplification plot takes the form
f ( C)  =  m  x (1 +  E f  (4.1)
where /(C )  is the fluorescence at cycle C and E  is the reaction efficiency. E  is a fraction 
between zero and perfect efficiency at a value of one. In quantitative PCR, the threshold 
is an arbitrary level o f fluorescence within the exponential phase of amplification. The 
threshold cycle Ct is the PCR cycle during which the fluorescence reaches this threshold.
11 will not count these first 2 cycles as they complicate the analysis and can be ignored for purposes of 
relative quantification.
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Figure 4.1: Graph to show qPCR data and an exponential model (orange line) of amplification. 
Fluorescence is shown using arbritrary units.
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Figure 4.2: Amplification plot with log-transformed fluorescence values. The orange line is the 
gradient of the linear part o f the the plot.
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So to calculate the initial fluorescence /(0 )  and thus the amount of template, Equation 4.1 
can be re-written:
The reaction efficiency E  can be quantified from a standard concentration series, by 
assumption, or by using the fluorescence data.
A standard curve may be drawn by plotting the Ct values against the log-concentration 
of a serial dilution o f cDNA [Pfaffl, 2001]. The efficiency can then be calculated as
where slope is the gradient o f the plot. However, this introduces potentially contaminating 
DNA and any pipetting or spectrophotometer errors will be amplified along with the DNA.
Commonly, the reaction efficiencies in quantitative PCR are assumed to be perfect 
(E =  1). This is referred to throughout the literature as the 2_AACt method [Livak and 
Schmittgen, 2001]. Whilst this is a good approximation, it tends to exaggerate differential 
expression.
A more accurate measure o f the reaction efficiency, and thus the amount of template, 
can be calculated for each primer pair from their fluorescence data [Peirson et al., 2003]. 
If amplification is plotted as log(fluorescence) against cycle then the exponential phase 
is transformed into a straight line (Figure 4.2). The noise due to fluorescence detection 
is particularly apparent during the 1 st 10 cycles of PCR. A mid-point of the linear part 
of the plot can be determined by defining a noise value. This can be estimated as the 
minimum log(fluorescence) plus the variance over the 1st 10 cycles. The mid-point is 
halfway between the noise and the max. fluorescence. The gradient of the plot can then 
be calculated by linear regression of several data-points above and below the mid value.
The gradient o f the linear part of the log(fluorescence) against cycle plot (Figure 4.2,
/(O) =  f ( C t) X ( I +  E)~C‘. (4.2)
E  -- 10si°pe — 1 (4.3)
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orange line) can be written as:
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gradien t =
lo g /(C ) -  lo g /(0 )  
C
(4.4)
The efficiency E  o f amplification can then calculated by re-arranging Equation 4.1 as:
which is equal to the gradient. Finally, by exponentiating and then subtracting 1,
Data from qPCR, although much more accurate than Northern blotting, are often nor­
malized using RNA quantification and/or a single ‘housekeeping gene’ as an internal 
control. Using RNA quantification alone is inappropriate because of the propagation of 
measuring errors and because rRNA, the major contributor to quantification, does not de­
grade at the same rate as all transcripts. The expression of so-called housekeeping genes is 
also variable. This is especially relevant when using post-mortem tissue [Tricarico et al., 
2002]. Vandesompele et al. [2002] describe an approach, in which they recommend using 
at least three separate genes as a robust internal control for quantitative PCR. They found 
single control normalization error values that point to inherent noisy oscillations in ex­
pression levels of the control genes. This is corroborated by other large-scale expression 
studies including microarray data. [Warrington et al., 2000; Ross et al., 2000]
(4.5)
Taking logs,
C  x  log(l +  E ) =  log f ( C)  -  log /(0 ) . (4.6)
Dividing by C,
l ° g / ( C ) - k > g /( 0 )
(4.7)
  Y^gradient   -j^ (4.8)
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After selecting twelve candidate genes that were differentially expressed in the foveo- 
macula by microarray analyses, my aim was to investigate these results further by using 
a complementary technique. My main objective was to confirm marked differential ex­
pression in a subset o f these genes that would be suitable for further characterization. I 
planned to perform quantitative PCR using RNA from the human macular resource. I also 
planned to use the best possible technique for studying relative expression and normaliza­
tion o f the data, given that I had a limited supply of foveo-macular RNA. Finally I planned 
to investigate genes, using bioinformatics, that showed robust differential expression to 
gain useful information for protein work.
4.3 Results
Figure 4.3 shows that an intron-spanning fragment (see section 2.8) of rhodopsin was 
amplifiable as 405 and 239 base pair products from genomic DNA and peripheral retinal 
cDNA respectively. The smaller fragment, lacking the intron, was also amplifiable from a 
1:10 dilution o f the cDNA. There was no visible genomic fragment amplified from either 
cDNA sample.
Six out of six PCR products that I sequenced using the optimised qPCR primers (see 
Table 2.1) revealed amplification o f the correct product.
I analysed the fluorescence data for each of the 12 test genes, red/green cone and rod 
opsin, and the 4 control genes using the DART system. An example of the analysis for 
red/green cone opsin is shown in Appendix B. A summary of the normalized expression 
for each non-control gene is shown in Table 4.1. A graph of the log-base-two expression 
ratios is also shown in Figure 4.4 where +1 is a two-fold increase and -1 a two-fold 
decrease in expression in foveo-macula:peripheral retina.
The amount of fluorescence due to SYBR-green is proportional to length of the DNA 
fragment amplified. Therefore by correcting for amplicon length, I calculated percent-
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Figure 4.3: Agarose gel to show amplification o f part of rhodopsin, using intron-spanning primers, 
from both genomic DNA and peripheral retinal cDNA subsequently used for qPCR. Lane 1 shows 
the 405bp product with genomic DNA. Lane 2 shows the 239bp product with peripheral retinal 
cDNA. Lane 3 contains the same product obtained from a 1:10 dilution of retinal cDNA.
age expression o f selected genes relative to either rod or cone opsin (Table 4.1. NPIP, 
GCN2, and to a lesser extent X showed expression in the central retina approaching that 
of cone opsin, whilst SAG showed expression in the peripheral retina approaching that of 
rhodopsin.
4.4 Discussion
I used quantitative PCR as an experimental technique to analyse expression of twelve 
genes that were differentially expressed in the foveo-macula compared with peripheral 
retina according to microarray experiments (see chapter 3). I used a computational method 
[Peirson et al., 2003] to analyse the data and normalized it to four control genes.
The data show that the highest transcript levels were obtained for rod and cone opsin 
out of all the genes tested2. Red/green cone opsin was more abundant in the foveo-macula 
than rhodopsin, which was more abundant in the peripheral retina. The cone opsin mes­
sage was also slightly more abundant in the foveo-macula than rhodopsin was in the 
peripheral retina. This may reflect the higher turnover of cones and their larger size.
2This excludes 18S rRNA, which represents over 10% of total RNA.
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Symbol Peri (P) Fovea (F) F/P log2(F/P) % opsin
X 4.42E-02 1.95E-01 4.40 2.14 7
OPN1LW 8.12E-01 2.72E+00 3.35 1.75 100
HDAC9 1.37E-03 4.30E-03 3.15 1.65 <1
NPIP 9.01E-01 1.97E+00 2.19 1.13 76
GCN2 5.37E-01 1.15E+00 2.14 1.10 34
SRGAP2 1.18E-02 2.31E-02 1.95 0.96 1
FLJ 3.19E-01 5.76E-01 1.81 0.85 *
6q 1.80E-03 2.65E-03 1.47 0.56 *
CRP 2.67E-04 3.63E-04 1.36 0.44 *
BHM2 8.39E-05 1.14E-04 1.35 0.44 *
RP2 3.16E-03 2.36E-03 0.75 -0.42 *
YAP 3.80E-03 2.49E-03 0.65 -0.61 *
RHO 1.90E+00 4.16E-01 0.22 -2.20 100
SAG 5.70E-01 1.06E-01 0.19 -2.43 34
Table 4.1: Summary o f qPCR data. The first two columns show initial fluorescence /(0 )  values 
for peripheral and central retina, normalized to the four internal control genes (18S, ARP, ACTB, 
UBC), which are proportional to mRNA copy numbers. The third column is the ratio of /(0 )  
values, the expression ratio, in central:peripheral retina. The fourth column is the base-two loga­
rithm of this ratio. The final column is expression level as a percentage o f the appropriate opsin 
expression.
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Figure 4.4: Graph to show quantitative PCR data comparing gene expression in pooled
foveo-macular with pooled peripheral retinal RNA. Log-base-two expression ratios are shown. 
OPN=OPN 1, HDA=HDAC9, NPI=NPIP, GCN=GCN2, SRG=SRGAP2.
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Results for all but two out of the twelve test genes were in the same direction as the 
microarray expression data, with fold changes ranging from over four (for over-expressed 
genes) to less than one fifth (for under-expressed genes) in foveo-macula cf. peripheral 
retina. Because I used the amplification plot method to determine reaction efficiencies, 
the fold-changes are less likely to be exaggerated than with the commonly used 2~AACi 
method. For example, there was only about a two-fold difference in expression of both 
opsins between foveo-macula and peripheral retina, whereas the true ratio is likely to be 
higher than this because central cones are large.
Because pooled samples were used, no statistical measure of variation could be calcu­
lated for the comparison of foveo-macula with peripheral retina. The peripheral samples 
were pooled because the small size of the foveo-macula necessitated pooling for RNA ex­
traction (see chapter 1). Pooling 11 foveo-macular and 9 peripheral retina samples does 
means that the results are subject to less sample-sample variation than if single retinal 
samples had been compared, resulting in an increased level of statistical certainty. It was 
not possible to quantify the inter-sample level of significance due to the limited amount 
of tissue available. However, the co-efficient of variance for each triplicate was typically 
less than 10% (see Appendix B).
I also calculated the relative expression levels, compared to rod or cone opsin, for 
genes that were two-or-more fold over or under-expressed in foveo-macula (Table 4.1). 
This suggests that NPIP, GCN2, SAG, and to a lesser extent X, represent a relatively large 
proportion of the retinal transcriptome.
It is well recognized that protein expression is not always proportional to mRNA ex­
pression. A recent study by Tian et al. [2004] even suggests that less than half the variation 
in protein expression can be explained by variation in mRNA levels. It would be interest­
ing to perform proteomic analyses for a large number of genes in order to choose previ­
ously un-investigated proteins that are differentially expressed in the macula. However, 
genes that are highly over-expressed at the mRNA level may be of importance despite 
modest differences in protein expression due to higher turnover.
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The gene products o f NPIP, GCN2, X, SRGAP2 and HDAC9 are as yet uncharacter­
ized in the retina. My data provides evidence that they are over-expressed in the foveo- 
macula. Additionally, the messages for NPIP, GCN2 and X are expressed at levels that 
are likely to represent a significant proportion of the foveo-macular transcriptome (Ta­
ble 4.1). O f these five genes, only SRGAP2 is as yet associated with a monogenic disease 
phenotype. However, NPIP, GCN2 and SRGAP2 are all located within possible regions of 
linkage suggested by a recent whole-genome screen of age-related maculopathy [Schick 
et al., 2003].
4.4.1 Differentially expressed genes
For discussion o f HDAC9 and NPIP, please see chapter 5 and chapter 6 respectively.
GCN2 - Eukaryotic translation initiation factor two-alpha kinase 4 (Hs.261587)
GCN2 was highly expressed in human retina, its expression level being 36% of the red/- 
green cone opsin expression level in the foveo-macula. Homo sapiens eukaryotic trans­
lation initiation factor two-alpha kinase 4 is located at 15ql3.3. It is a protein kinase 
that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2a). 
Such protein kinases are activated in response to environmental stresses resulting in down- 
regulation of protein synthesis [Harding et al., 2000].
Human GCN2 is 88% identical to Mus musculus eIF2a kinase. It is also highly similar 
to GCN2 or similar genes in pig, rat, frog, drosophila, mosquito and Arabidopsis. EN- 
SEMBL predicts 3 alternate proteins for human GCN2 (ENSG00000128829), the largest 
of which has 35 exons over 86kB coding for a 1473aa protein.
Human GCN2 contains many functional domains with similar catalytic elements to 
yeast GCN2. However, eukaryotic GCN2 proteins have distinct regulatory domains from 
yeast, allowing different signals to regulate translation. No diseases are associated with 
human GCN2 at this time.
Three SAGE tags were found that map uniquely to this reliable UniGene cluster and
CHAPTER 4. Q UANTITATIVE PCR 128
were contained in a human retinal pigment epithelium SAGE library (HRPE1SAGE); of 
these three tags, one was also found in the human macular SAGE library (HMAC2 SAGE) 
[Sharon et al., 2002] (ENSEMBL, NCBI: UniGene, OMIM, LocusLink, GEO).
X - predicted gene (Hs.138411)
This predicted gene was relatively highly expressed in human retina, its expression level 
being about 1% o f the red/green cone opsin expression level in the foveo-macula. X is 
part of UniGene cluster Hs.138411 at Xq 13.1. This cluster contains more than 20 ESTs 
or mRNAs. Gene prediction programs (GenScan, GenomeScan, EST2GENOME) predict 
a single exon gene from the mRNA and a peptide (X P098999) of 126aa.
A unique SAGE tag for this UniGene cluster was found in a normal cerebellum 
(SAGE-normal-cerebellum) library. Also, a non-unique tag was highly represented in 
the human macular (HMAC2-SAGE), two peripheral retinal (HPR1/2-SAGE) and retinal 
pigment epithelium (HRPE1-SAGE) libraries (NCBI:UniGene, GEO, BLAST).
SRGAP2 - slit-robo Rho GTPase activating protein 2 (Hs.7977)
This gene is located cytogenetically at 3p25.3. SRGAP2 is also known as SRGAP3 or 
MEGAP and is part of the slit-robo Rho GTPase activating protein (SRGAP) gene family. 
The SRGAPs contain an FCH domain, a RHOGAP domain and an SH3 domain. SRGAP2 
is highly expressed in brain and plays a critical role in the slit-robo signal transduction 
pathway [Endris et al., 2002].
Several SRGAP2 transcript isoforms have been described, at least 2 of which have 
been shown to represent functional GTPase-activating proteins (GAPs) by an in vitro 
GAP assay. Molecular analysis in a patient with a balanced de novo translocation t(X;3) 
(pll.2;p25), hypotonia, and severe mental retardation -  features characteristic of 3p- 
syndrome -  showed a translocation breakpoint on chromosome 3 interrupted the pre­
viously unknown gene termed MEGAP (mental disorder-associated GAP protein). The 
phenotype was suggested to be caused by mis-regulation of neuronal signal-transduction
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machinery controlling the correct migration of neurons and their axonal connectivity. 
Haplo-insufficiency o f MEGAP is proposed to lead to abnormal development of neuronal 
structures important for normal cognitive function [Endris et al., 2002] (NCBI: UniGene, 
OMIM, LocusLink).
SAG - S-antigen (Hs.32721)
S-antigen is located cytogenetically at 2q37.1. A soluble protein of 405 amino acids with 
a molecular weight of 45kD, SAG is implicated in the inactivation of the phototransduc­
tion cascade. The active form of rhodopsin (R*, meta-rhodopsin-II) is bound by S-antigen, 
especially after phosphorylation by rhodopsin kinase. The binding of SAG blocks inter­
action of the G-protein transducin thus inactivating the visual cascade [Fain et al., 2001].
Oguchi disease (MIM:258100) is a recessively inherited form of stationary night 
blindness. Patients with this disease show a distinctive golden-brown colour of the fun­
dus that occurs as the retina adapts to light, called the Mizuo phenomenon. In many cases 
Oguchi disease is due to mutation in the SAG gene [Fuchs et al., 1995]. Adaptation of 
rod photoreceptors to light is extremely retarded in Oguchi disease, while that of cones 
appears to proceed normally.
Whilst some studies report the expression of the SAG protein only in rod photorecep­
tors [Reid et al., 1987; McKechnie et al., 1986], there is evidence that human rods and 
cones contain antigenically distinct S-antigens [Nork et al., 1993], and that mouse and rat 
also express S-antigen in both rods and cones [Mirshahi et al., 1994].
No unique SAGE tags were found for this gene. However, a non-unique tag was 
found to be well represented in only human peripheral retina (HPR1/2-SAGE) and macu­
lar (HMAC2-SAGE), with the representation being about two-fold greater in the periph­
eral retinal libraries (NCBI: UniGene, OMIM, GEO).
Although s-antigen is often referred to as rod-arrestin, there is evidence that it is also 
expressed in cones [Nork et al., 1993; Mirshahi et al., 1994]. My microarray and quan­
titative PCR data together provide strong evidence for over-expression of the s-antigen
CHAPTER 4. QUANTITATIVE PCR 130
message in the peripheral retina, perhaps by around five-fold. This is corroborated by the 
clinical picture of Oguchi disease, in which central vision is normal.
4.4.2 Proteins
I went on to study HDAC9 and NPIP in some detail, as outlined in the next two chapters. 
I initially chose to study HDAC9, NPIP and GCN2 as the three genes most highly over­
expressed in central retina (excluding X) according to quantitative PCR. X was excluded 
as it is a one exon predicted gene so despite plenty of hits in dbEST, the possibility that 
X did not represent a ‘real’ gene could not be excluded. The number of proteins studied 
was limited by the resources available to obtain good antibodies.
4.5 Conclusions
The main aim of the qPCR experiments was to confirm the expression data obtained from 
microarray analysis. It is encouraging that both opsins and ten out of the twelve test genes 
showed expression values that agreed with those obtained from microarray analysis. I 
used effective methods o f analysis and normalization given the limited amount of foveo- 
macular RNA available and also determined the expression levels of the genes studied 
relative to opsin. The protein products of all the genes with confirmed over-expression in 
the macula (except cone opsin) are as yet uncharacterized in the retina. They are suitable 
targets for the investigation of protein expression in the macula. These genes are likely 
to play a role in the mechanism of precise vision and also represent good candidates for 
macular disease.
Chapter 5
Histone deacetylase 9
5.1 Introduction
Chromatin is a highly specialized structure composed of tightly compacted chromosomal 
DNA. Transcription is controlled by a host of protein complexes that continuously pack 
and unpack chromosomal DNA. The nucleosome is the basic structural unit of eukaryotic 
nuclear chromosomes. A nucleosome consists of 1.75 superhelical turns of chromosomal 
DNA wrapped around a histone octamer (two molecules each of the four core histones 
H2A, H2B, H3 and H4) via a single molecule of the linker histone HI. Histones are 
simple, basic proteins that are soluble in water.
One of the mechanisms that unwinds nucleosomes from inaccessible, tightly packed 
units into accessible particles involves the acetylation and deacetylation of the histone 
proteins comprising its core. Acetylation of histones confers accessibility of the DNA 
template. It is a major factor in regulating chromatin structural dynamics during tran­
scription [Lee et al., 1993; Bauer et al., 1994].
Histone deacetylases (HDACs) are essentially chromatin remodelling factors that de- 
acetylate histones and thus act as transcriptional repressors. HDACs are classified by 
their sequence homology to the yeast HDACs. Class I HDACs are related to Rpd3 while 
members of class II are larger molecules (100+ kDa) that resemble Hdalp.
HDAC9 is part of the class II histone deacetylase gene family and is orthologous
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Figure 5.1: Schematic diagram of HDAC9. Exon (box) numbers are shown underneath in black. 
Where introns (lines) are not shown to scale, the intronic size appears in red above.
to the corresponding Xenopus and mouse genes. It was originally identified by Nagase 
et al. [1998] while looking for cDNAs that encoded large proteins expressed in the human 
brain. Their RT-PCR analysis detected highest expression in brain, lower expression in 
heart and smooth muscle, and little or no expression in other tissues. Zhou et al. [2001] 
found 6 isoforms of HDAC9 and detected preferential expression of the longer isoform, 
by RT-PCR, in brain, heart, and pancreas. They also determined that the full-length hu­
man gene contains 23 (out of 26) coding exons spanning 458 kb and explained the variable 
exon usage of different HDAC9 isoforms. Petrie et al. [2003] showed that HDAC9 en­
codes multiple, functionally distinct, and differentially expressed protein isoforms. For 
example, full-length HDAC9 was localized to the nucleus whereas the isoform lacking 
exon 7 was expressed in the cytoplasm.
Full-length HDAC9 (see Figure 5.1) consists of an N-terminal region that is conserved 
in HDAC 4, 5 and 7, an HDAC catalytic domain in the C-half, and a C-terminal non- 
catalytic domain. Histone deacetylase 9 (HDAC9) is located cytogenetically at 7p21.1. 
HDAC9’s huge genomic size ( ^  500 kb) and the degree to which it is regulated is un­
precedented among other HDACs. This may indicate a wider role for HDAC9 than just 
histone modification [Petrie et al., 2003].
It has recently been suggested that HDAC9 may be jointly (with TGF/?2) responsible 
for possible digenic inheritance of Peter’s Anomaly. This is a disease of the anterior seg­
ment of the eye thought to be the result of abnormal migration or function of neural crest 
cells [David et al.. 2003]. Also, mice lacking HDAC9 are known to be super-sensitive to 
stress signals [Antos et al., 2003; Zhang et al., 2002]. This is consistent with the hypoth­
esis that histone deacetylases are involved in the cellular response to stress.
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5.2 Objectives
The data I obtained from microarray (chapter 3) and qPCR (chapter 4) analyses showed 
that HDAC9 is highly differentially expressed in the human macula. My aim was to study 
the expression of HDAC9 protein. I planned to obtain an antibody to HDAC9 that was 
useful and specific in both Western blotting and immunohistochemistry. I aimed to use the 
antibody for Western blotting to detect HDAC9 in cultured cell lines and in retinal extract. 
I planned to test the specificity o f the antibody for immunohistochemistry in cultured cells 
and then go on to use it in human retinal sections to elucidate the localization and possible 
function for HDAC9 in the macula. By studying HDAC9 protein in the retina, I also set 
out to assess it as a possible candidate for macular disease.
5.3 Results
I detected a single band by Western blotting of REH cells, Chinese hamster ovary (CHO) 
cells, and 293T cells with a 1:500 dilution of rabbit polyclonal anti-HDAC9c - te rm  anti­
body (Figure 5.2). The REH cell band was very dark, thick and slightly smeared, even 
after a short exposure of 15 seconds. I was not able to detect full-length HDAC9 in human 
retina.
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Figure 5.2: Western blot showing expression of full-length HDAC9 in mammalian cell lines using 
a rabbit polyclonal anti-HDAC9c - te r m  antibody.
I was able to localize full-length HDAC9 in adherent cells (SK-N-SH) using the anti- 
HDAC9c - te rm  polyclonal antibody (Figure 5.3). Using confocal microscopy I was able 
to focus on several cells in more than one plane. I found that anti-HDAC9c-term was
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Figure 5.3: Confocal microscope images of cultured human neuroblastoma (SK-N-SH) cells. Un­
transfected cells were immunostained with 1:250 rabbit anti-hdac9 serum and a Cy3 secondary 
antibody and counter-stained with DAPI. A - red fluorescence showing HDAC9 expression in 
the nucleus. B - merged image showing DIC, DAPI staining of the nucleus and red HDAC9 
fluorescence. C - the same cell in a different plane shows a filamentous staining pattern with 
anti-HDAC9c-term- D - merged DIC, DAPI and anti-HDAC9 image.
not only localized to the nucleus, as evident by its co-localization with DAPI, but also to 
filamentous structures in a different plane of the cell.
I was also able to localize full-length HDAC9 in the human fovea using cryo-sections 
and the same titre of anti-HDAC9c-ierm (Figure 5.4). I saw fluorescence in many cell 
nuclei in the outer and inner nuclear layers, and in several nuclei of the ganglion cell layer. 
This was re-enforced by co-localization of the DAPI fluorescence. I also saw marked mtl- 
HD AC9 c - te r m  fluorescence in the photoreceptor layer, which consisted mostly of cones 
in the cryo-sections that were available. This was strongest in the photoreceptor outer 
segments. There was also fluorescence of the inner limiting membrane but very little 
anti-HDAC9c - te rm  signal in the plexiform layers.
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Figure 5.4: Full-length HDAC9 expression in human fovea (A). Anti-HDAC9c-term (green) flu­
orescence is also shown against DAPI (blue) nuclear staining (B).
5.4 Discussion
I was able to show expression of full-length HDAC9 protein («160 kDa) in both non­
primate (CHO) and primate (293T, REH) cell lines (Figure 5.2). It was highly expressed 
in the REH cells that I received from Arthur Zelent’s lab (which I successfully cultured) 
as previously reported [Petrie et al., 2003]. I was not able to detect the full-length HDAC9 
by Western blotting in the human retina sample I used. This may have been partly because 
1 received the particular retina I used more than 48 hours after enucleation. The retina is 
also very difficult to homogenize so this may have contributed to a low level of protein. 
My quantitative PCR data (chapter 4 Table 4.1) suggested that the HDAC9 gene was only 
expressed at a low level in the retina. However, gene expression does not necessarily 
correlate with protein expression [Tian et al., 2004]. HDAC9 may be important in retinal 
function or turnover even if the protein is not expressed at a high level. For example, 
the X-linked retinitis pigmentosa protein RP2 is ubiquitously expressed at relatively low 
levels (0.01% of total protein) [Chappie et al., 2000].
I localized full-length HDAC9 to the nucleus of human neuroblastoma (SK-N-SH) 
cells (Figure 5.3). Full-length HDAC9 has been previously localized to the nucleus by 
transiently transfecting simian fibroblast (COS-7) cells with an HDAC9-FLAG construct 
followed by immunofluorescence with an anti-FLAG antibody [Petrie et al., 2003]. It
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is logical that a histone deacetylase protein is expressed in the nucleus, although there 
are many members of the gene family, some of which may have alternative functional 
specializations. I also detected full-length HDAC9 in filamentous structures that looked 
very much like part o f the cytoskeleton. Interestingly, histone deacetylase 6 (HDAC6) has 
been recently found to act as a molecular motor in the cytoskeleton [Kopito, 2003].
I was also able to localize full-length HDAC9 in human fovea. That I was able to 
detect HDAC9 by immunofluorescence of the fovea but not by Western blotting of whole 
retina may reflect a higher level o f protein preservation in the cryo-sections I received 
from Canada and also higher expression of HDAC9 in the fovea. Full-length HDAC9 is 
expressed in the outer and inner nuclear layers, the ganglion cell nuclei and the inner lim­
iting membrane (Figure 5.4). However, the expression is greatest in the photoreceptors, 
especially in the outer segments.
Histone deacetylation is correlated with the transcriptional repression and silencing of 
genes. Genetic repression may have a protective role in neuronal aging and degeneration; 
histone acetylation induces a stress response that leads to apoptosis of neuronal cells 
[Salminen et al., 1998]. This may be especially important in the macula, which is likely 
to have a higher turnover of proteins than the peripheral retina.1
The presence of full-length HDAC9 in outer segments suggests that it may have a 
function related to the photo-transduction cascade or its maintenance. Mutations in many 
of the proteins expressed in photoreceptor outer segments are responsible for retinal de­
generative disease. Interestingly, there is also a retina-specific promoter of HDAC9 in 
mice [K Petrie, personal communication]. Histone is known to activate photoreceptor 
outer segment cyclic nucleotide phosphodiesterase (PDE) [Hurwitz et al., 1984a,b]. It is 
possible that HDAC9 has a modulatory effect on phototransduction via the deacetylation 
of histone. HDAC9 could also be involved in the transport of molecular cargo to the outer 
segment along microtubules.
The more than three-fold over-expression of HDAC9 in the foveo-macula compared
'The macula comprises <1.5% of the retina yet it contains ^8.5% of the cone photoreceptors, ^3.5% 
of the rod photoreceptors, and ^60%  of the ganglion cells of the retina [Sharon et al., 2002],
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with peripheral retina (see chapter 3 and chapter 4) also suggests that it is enriched in 
cone photoreceptors. Mutations in HDAC9 may therefore be responsible for macular, 
cone, or cone-rod dystrophy. HDAC9 may also play an important part in age-related 
macular degeneration. Autosomal dominant cystoid macular dystrophy has been mapped 
to the same chromosomal location as HDAC9 (7p21-15), although it is thought to be due 
leaking peri-macular capillaries [Kremer et al., 1994].
5.S C onclusions
I was able to obtain an antibody to HDAC9 that was useful and specific in both Western 
blotting and immunohistochemistry. As well as nuclear localization, I showed a novel 
cytoskeletal localization o f endogenous HDAC9 in human neuroblastoma cells, similar to 
HDAC6. Although I was not able to detect HDAC9 in retinal extract by Western blotting, 
I did show that HDAC9 is expressed in the human macula by immunofluorescence. These 
observations suggest a novel role for HDAC9 in the macula. This is the first implication, 
to my knowledge, o f a histone deacetylase playing a part in retina-specific biology. In 
summary, I have made some headway towards eliciting the function of HDAC9 in the 
macula and demonstrated that it is an interesting candidate for macular disease.
Chapter 6
Morpheus
The morpheus gene family found within a 20kb duplicated segment -  low-copy repeat 
sequence ‘a’ (LCR16a) -  throughout 15Mb of human chromosome 16p [Johnson et al., 
2001]. It is the result o f adaptive evolution during the emergence of humans and African 
apes.
Adaptive evolution was originally defined by Darwin [1859] when he made the ob­
servation that island finches had a diversity of mouth parts that was inexplicable by usual 
trends in variation. The original population of birds had not inhabited the island for long 
yet they had developed a huge diversity of bill morphologies. Darwin concluded that 
there was selective pressure on the birds to adapt very quickly to many small niches on 
the island. This facilitated the rapid adaptive evolution of their mouth parts -  some for 
digging in the sand, some for nut-cracking, some for scavenging under the bark and so 
on.
The concept o f adaptation is strongly linked to function. A trait is considered to be 
adaptive if it confers a function that is beneficial to the organism. However, this does not 
imply any theory about how the adaptive trait originated.
Darwin’s notion o f natural selection is that evolution of a new adaptive trait can be 
explained if there is:
•  A process by which a new trait can appear in a population.
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•  A biological mechanism for heredity.
•  A “struggle for existence” arising from larger reproductive capacity than the envi­
ronment can support.
•  A benefit in terms o f survival1 o f the trait in question.
So in the Darwinian sense, the term adaptation does imply how the trait originated. In 
Mendelian terms, adaptation benefits an individual by representation of its genes in the 
next generation. As Dobzhansky [1956] put it:
Selection favors genotypes the carriers o f which transmit their genes to suc­
ceeding generations more efficiently than do the carriers o f other genotypes.
However, it is important to note that not all traits that are adaptive in the Darwinian 
sense are the result o f natural selection. Although a trait is adaptive, it has not necessarily 
been ‘selected for’. For example, a trait can arise in a species that is the result of random 
fixation o f a selectively neutral allele {genetic drift). Later, environmental changes lead to 
the trait becoming adaptive}  An adaptive trait can also result from changes within the life 
of an individual in response to the environment, such as acclimatisation to altitude, that 
does not result in a change in gene frequency. In humans, a dramatic form of adaptation 
is illustrated by cultural differences. Cultural traits often yield Darwinian fitness that is 
not due to genetic differences.
Negative selection decreases the prevalence of traits that diminish an individual’s fit­
ness. Conversely, positive selection is a phenomenon whereby there is selective pres­
sure favouring adaptation. Negative selection can be seen as a process of editing genetic 
change so that only a small number o f mutations are retained in a population. With posi­
tive selection, the retention o f mutations is much closer to the rate of mutation. Since the 
advent of molecular techniques, a common test for positive selection is to compare the
1 Sexual selection can be defined by the same criteria as natural selection except that the trait is beneficial 
in terms of reproduction rather than survival.
2The Dykhuizen-Hartl effect [Dykhuizen and Hartl, 1980].
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rates of synonymous to non-synonymous nucleotide change K a/ K s [Lee, 1997]. A ratio 
significantly greater than 1 is taken as evidence for positive selection.
The evolutionary significance o f gene duplication was first recognized by Haldane 
[1932] and Muller et al. [1935], who suggested that a redundant duplicate may acquire 
divergent mutations and eventually emerge as a new gene. Gene duplication was first 
observed by Bridges [1936] at the Drosophila Bar locus. Gene duplication, followed 
by functional divergence, is considered to be one of the most important mechanisms for 
the evolution o f novel gene function [Ohno, 1970]. However, it has been controversial 
whether functional divergence (and hence adaptive evolution) occurs by positive selec­
tion [Goodman et al., 1975], or by random fixation of neutral mutations3 that later become 
adaptive due to environmental changes [Dykhuizen and Hard, 1980; Kimura, 1983]. A 
recent model for the evolution o f new proteins is that a period of gene sharing [Piatig- 
orsky et al., 1988] usually precedes the evolution of functionally distinct proteins. Gene 
duplication then allows each daughter gene to specialize for one of the functions of the 
ancestral gene [Hughes, 1994].
The principal molecular mechanism responsible for gene duplication is unequal cross­
ing over [Grauer and Li, 2000]. This results in mis-aligned sequences giving rise to a 
tandemly duplicated region on one chromosome and a complementary deletion on the 
other. Unequal crossing over is facilitated by the presence of repeated sequences. Once 
a duplication event has occurred, the process of gene duplication can accelerate because 
the chance o f unequal crossing over increases with the number of duplicated copies.
Many other mechanisms also play important roles in molecular evolution. For exam­
ple, regional duplications such as gene elongation and domain duplication [Grauer and 
Li, 2000]. Gene conversion is an important mechanism that does not involve a duplica­
tion event. It is a type o f nonreciprocal recombination in which the recipient strand of 
DNA receives information from another strand. The transfer occurs by DNA repair of 
a damaged allele using the donor strand as the template. The donor can be either the
3The neutral theory of evolution [Kimura, 1968, 1983] and subsequent molecular-clock hypothesis 
[Zuckerland and Pauling, 1965] are now thought to be too simple to entirely explain adaptation, although 
they provide a stable background against which to test positive selection at a molecular level.
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sister chromatid or homologous chromosome during meiosis or a duplicate gene during 
mitosis. Both gene duplication [Dulai et al., 1999] and gene conversion have been shown 
to be important mechanisms in the evolution of red and green cone opsin in Old World 
monkeys [Ibbotson et al., 1992] and humans [Winderickx et al., 1993].
The dispersal o f LCR16a was accompanied by considerable chromosome map and 
copy number variation among hominoids, as revealed by fluorescence in situ hybridiza­
tion (FISH) [Johnson et al., 2001]. The estimated copy number in orangutans, gorillas, 
humans and chimpanzees is 9, 17, 15 and 25-30 respectively. By calculating the K a/ K s 
ratios of putative protein encoding exons, Johnson et al. revealed the most extreme case 
of positive selection. Between Old World Monkeys and humans the ratio in exon 2 was 
13.0. The major episode o f enhanced amino acid replacement was calculated to occur 
after the separation o f human and great ape from the orangutan lineage. Positive selection 
also continued after separation o f the human and chimpanzee lineages. Johnson et al. did 
not find any significant sequence similarity to the morpheus gene family in non-primate 
species, which is likely because o f the rapidity of its evolution. Interestingly, it is only 
primates that have a macula.
Johnson et al. found transcripts in dbEST (n c b i . n lm . n i h . gov) for 6 out of 15 
genes in the morpheus family. Amino acid sequence comparison of two full-length tran­
scripts showed 81 % identity. In sharp contrast, the corresponding introns were 98% iden­
tical. This is a hallmark o f genes undergoing adaptive evolution [Vacquier et al., 1997]. 
One of these transcripts, nuclear pore complex interacting protein (NPIP), had been inde­
pendently isolated by a two-hybrid assay in an effort to identify components that interact 
with the human SWI/SNF transcriptional activator complex. Johnson et al. predicted the 
presence o f one transmembrane domain flanked by a-helical secondary structure. Ex­
pression of a green fluorescent protein (GFP) fusion construct showed localization to the 
nuclear envelope and co-localization with nucleoporin (p62). Whilst RT-PCR showed a 
broad distribution of the morpheus gene family in human tissues, no specific localization 
or function of one o f its members, such as NPIP, has been found in vivo.
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As well as being consistently over-expressed in macula compared with peripheral retina, 
I found NPIP (and/or other very similar members of the morpheus gene family) to be 
very highly expressed in human retina at the mRNA level (see chapter 3 and chapter 4). 
My aim was to study the expression of proteins in the morpheus family. I planned to 
obtain an antibody to NPIP that was useful and specific in both Western blotting and 
immunohistochemistry. I aimed to use Western blotting to detect morpheus in the retina, 
in cultured cells to test the specificity o f the antibody for immunohistochemistry, and in 
human retinal sections to elucidate the localization and possible function for morpheus in 
the macula. By studying proteins in the morpheus family in the retina, I also set out to 
assess them as possible candidates for macular disease.
6.2 Results
The NPIP protein AAD34394, a translation of the reference cDNA A F132984 aligned 
with a number o f NPIP-like sequences from the database as well as predicted proteins 
obtained using the Genomescan program (see Appendix B). The translation of the ampli- 
con used in qPCR lined up very well with these sequences. All but one of these putative 
proteins terminated at the same place as the reference NPIP sequence. However, the pro­
teins seemed to begin in various places. The C-terminus of NPIP was chosen to raise an 
antibody against.
ELISA revealed that both of the two antisera produced bound to the NPIP peptide 
with increasing affinity as the titre o f antibody was increased. Control serum did not bind 
to the NPIP peptide, nor did either anti-NPIP antibody bind to a control peptide.
I detected a number o f different bands by Western blotting of primate cell lines using 
each antiserum, antia-NPIP and anti6-NPIP, with anti6-NPIP yielding less bands although 
the blots were not 100% specific with either antiserum under the conditions used.
I successfully cloned several NPIP cDNAs into pGEM-T Easy from both brain and
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retina. All clones were correctly sized on a gel after digestion and sequenced before 
sub-cloning (see Appendix B for examples of sequence data.
I found two novel cDNA sequences in brain and one in retina. One brain sequence 
(NPlP-brainl, see Appendix B Figure B.6) was very similar to AF132984, except that 
there are an extra 47 bases within exon 8. Despite changing the reading frame it results in 
an almost identical protein to the 350aa AAD34394 with an additional 19 amino acids in 
the C-half (the only 2 changes are in the N-half, see Appendix B Figure B.5).
The second cDNA sequence (NPIP-brain2) I found was identical in more than one 
clone. Alignment with several genomic sequences from the morpheus gene family re­
vealed a longer exon 1 using an alternative splice donor site that followed the GT-rule 
(Figure B.6). This would result in a very premature STOP codon within the novel exon 
1 A. However, the longest open reading frame of this cDNA codes for a very similar pro­
tein that is missing 123aa of the N-terminus (see Figure B.7).
I also cloned several cDNAs o f the same length as NPIP-brainl and NPIP-brain2 from 
foveo-macula and peripheral retina but did not obtain novel sequence that was the same 
in two or more clones.
I attempted to align and orientate the above transcripts with genomic DNA from the 
database, in order to find out from which part o f chromosome 16p they originate, by 
exhaustive BLAST and BLAT (genom e . u c s c . ed u ) searching and manual analysis of 
the hits to check the exons order and adherence to the AT-GT splice site rule. Each of 
the transcripts produced thousands o f incomplete alignments in at least fifteen different 
genomic locations. However, none of these alignments produced an exact match for any 
of the transcripts when they were analysed by hand for exon order and the conservative 
splicing rule.
I was able to detect expressed NPIP-GST fusion protein by Western blotting using 
antib-NPIP primary, goat anti-rabbit secondary antibody, and ECL. I was subsequently 
to identify NPIP in both peripheral and whole retinal extract (Figure 6.1) with a primary 
antibody titre of 1:250. The two bands of ^25  and ^4 0  kDa correspond to size of the
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Figure 6.1: Western blot to show NPIP in human retina using 1:250 antife-NPIP rabbit polyclonal 
antibody. The first two lanes contain NPIP-GST and the last two contain peripheral and whole 
retinal extracts respectively.
putative NPIP isoforms found in brain and retinal cDNA.
I detected specific fluorescence with 1:200 anti6-NPIP and a Cy5 donkey anti-rabbit 
secondary antibody in un-transfected SK-N-SH cells by using fixation in methanol for 15 
minutes at -20°C (Figure 6.2). Staining was seen in the region of the nuclear envelope. I 
also expressed separate GFP constructs containing NPIP-brainl and NPIP-brain2 in SK- 
N-SH cells (see Figure 6.3). NPIP-brain2 definitely did not localize to the nuclear pore 
-  it was within the nucleus and in nuclear inclusion bodies. NPIP-brainl localized to the 
nuclear pore (I also co-localized it with antib-NPIP) although imaging was difficult as the 
SK-N-SH cells became very rounded after transfection.
I was able to stain human macular cryo-sections under the same conditions. Confocal 
microscopy revealed staining of a sub-population of photoreceptors that looked more like 
cones than rods. However, the secondary antibody appeared speckled at high magnifi­
cation. I changed the secondary antibody to Cy3 and used 1:150 Cy5-streptavidin with 
1:100 biotinylated peanut agglutinin (PNA) for a co-localization study in human fovea 
Figure 6.4. I examined three sections of fovea and acquired many images at low and 
high power. I was also able to acquire several stacks of images where I focused the laser 
scanning microscope in several parallel planes to gain a 3-dimensional impression of lo­
calization. This revealed very specific staining in cone outer segments. There was also 
very close co-localization of PNA, which stains cone sheaths. In animations of the image 
stacks, it looked like the antife-NPIP staining was just inside the cone sheaths.
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Figure 6.2: Confocal microscope images of cultured human neuroblastoma (SK-N-SH) cells. Un­
transfected cells were immuno-stained with 1:200 rabbit anti-NPIP serum and a Cy5 secondary 
antibody and counter-stained with DAPI. A - red NPIP fluorescence at medium magnification 
showing expression in the vicinity o f the nuclear envelope. B - merged DIC (grey), DAPI (blue) 
and NPIP (red) image at medium magnification. C - Red NPIP fluorescence at high magnification. 
D - Merged DIC (grey), DAPI (blue) and NPIP (red) image at high magnification.
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Figure 6.3: Confocal microscope images of cultured human neuroblastoma cells transfected with 
two different NPIP GFP constructs. Each row shows the same cells imaged under the same con­
ditions for GFP (1st column) and DAPI (2nd column) and a merged image (3rd column). The 
first row shows cells transfected with vector containing a GFP construct. The 2nd and 3rd rows 
show cells transfected with vector containing GFP-NPIP-brainl (NPIP1) and GFP-NPIP-brain2 
(NPIP2) respectively. The white bars in each sub-figure represent a distance of ten microns.
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Figure 6.4: Confocal microscopy showing anti{,-NPIP and PNA staining in human fovea. At 
low magnification (red) peanut agglutinin (PNA) readily stains cone outer segments (A). Many 
outer segments also stain with (green) antifc-NPIP (B,C). At high magnification the very close 
correspondence between PNA and anti^-NPIP can be seen (D-F).
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As well as being consistently over-expressed in macula compared with peripheral retina, 
NPIP was found by quantitative PCR to be highly expressed in human retina (see chap­
ter 4). Its expression level is 80% of the red/green cone opsin expression level in the 
foveo-macula. This PCR was very specific to members of the morpheus gene family as 
two long primers were used at a highly stringent temperature. However, it is not certain 
exactly which member o f the morpheus gene family was picked up by the gene expression 
studies. There is a high degree o f similarity between most exons amongst the gene fam­
ily members [Johnson et al., 2001]. More than one member could have been detected by 
qPCR only if the primers yielded a product of identical size from more than one transcript, 
which is possible given 15 or more copies of LCR16a in the human genome.
LCR16a is thought to have been duplicated very recently in evolution and evolved 
rapidly, suggesting there may not be orthologues in other species. I corroborated this 
by a BLAST search o f the most recent dbEST (July 2004) using A F132984. No signif­
icant hits (E<0.1) were found in non-primate species. Morpheus is highly represented 
in several libraries with more than seven hundred ESTs. NPIP shows over 90% iden­
tity with regions o f chimpanzee, 60% or more identity with regions of Kloss’s gibbon, 
orangutan and vervet monkey NPIP-like proteins and similarity with a number of other 
Old World monkey NPIP-like proteins (HomoloGene, BLAST). Apart from about 25% 
similarity with chicken caldesmon, a drosophila predicted protein and a portion of an 
archeal coiled-coil domain, no significant similarities with any other known protein were 
revealed by BLAST, PROSITE or motif-based domain searching software. Johnson et al. 
determined eight exons for NPIP by genomic sequence analysis. They also reported a sin­
gle putative trans-membrane domain surrounded by alpha-coil in AAD34394. I detected 
a putative transmembrane domain from amino acid 54-72 and also a putative coiled-coil 
domain from amino acid 139-172 using several prediction programs.
I raised two anti-sera to the C-terminus of NPIP. It is likely that antibodies raised this 
way (even if they were monoclonal) will cross-react with other members of the morpheus
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family due to sequence similarity. However, this will be desirable until the members that 
are expressed in retina are found. It is also possible that only one member is not a pseudo­
gene. Initial characterization was difficult as there are no reference cells or tissues known 
to express morpheus proteins in large quantities.
I cloned and sequenced several cDNAs from both brain and retina amplified using 
primers (Table 2.3) to yield full-length NPIP. Note that the forward primers both begin at 
the START codon as this was the most 5’ high-quality sequence found. My sequence data 
(Appendix B Figure B.6, Figure B.5) provide evidence for at least two novel isoforms of 
NPIP.
The first novel iso form (NPIP-brainl) I had high-quality bi-directional sequence for 
differs from the reference A F132988 by an extra 47 nucleotides. This extra sequence is 
within exon 8 if the genomic structure determined by Johnson et al. within AC002045 
is used. However, it is not known exactly where in chromosome 16 real transcripts are 
derived from. Although a 47 nucleotide insertion would be expected to produce a frame- 
shift, the resulting translation is a protein that has an identical C-half but is 19 amino 
acids longer. This illustrates the repetitive nature o f exon 8. I found both NPIP-brainl 
and AF 132988 match the human genome sequence in several locations in chromosome 
16p using BLAST, BLAT and by manually aligning resultant sequence. Neither appear 
to match 100% o f bases at any location in their entirety as well as fitting into orthodox 
AT-GT splice sites for each putative exon. However, I also found a large number of ESTs 
containing the ‘extra’ sequence.
The second novel isoform (NPIP-brain2), that I obtained high-quality bi-directional 
sequence for contains a longer exon 1 that I refer to as exon 1 A. It fits in with the exon 
structure of NPIP derived from AC002045 by using an orthodox alternative splice site. 
However, there are several differences in exon 6. A translation of reading frame 2 (relative 
to AF132984 and N PIP-brainl) results in the same protein as NPIP-brainl minus the first 
123 amino acids and with 4 amino acid changes due to exon 6. I obtained high-quality 
sequence from another clone that also contained exon 1A as well as several corresponding
CHAPTER 6. MORPHEUS  150
EST hits. However, I did not find any other evidence for the expression of the 4 amino 
acid changes.
It is clear that AF 132984 and my novel transcripts may potentially have originated 
from one or more members o f the morpheus gene family in chromosome 16. Difficulty in 
pinning down transcripts to genomic locations may well reflect problems with the genome 
sequence due to micro and macro repeats, problems with cloning and sequencing tran­
scripts from human tissue, and genuine polymorphism. However, even if a large number 
of morpheus clones were sequenced it may still be difficult to determine their genomic 
origin by this method or by rapid sequencing of cDNA ends (RACE). A single species of 
morpheus transcript may also be derived from more than one genomic location. Studying 
the promoter regions may help in exclusion of pseudo-genes and in determining tissue 
specific expression. Linkage studies and mutational analyses may reveal which morpheus 
gene is expressed in human macula.
Sub-cloning o f NPIP-brainl into pGEX as a GST fusion protein for prokaryotic ex­
pression allowed me to optimize conditions for Western blotting. Subsequently, I showed 
expression of morpheus in both peripheral and whole retina Figure 6.1). I detected bands 
suggestive that both a long ^ 4 0  kDa and short ^2 5  kDa isoform are expressed in human 
retina. The larger band corresponds to the predicted size for NPIP-brainl and the smaller 
band for NPIP-brain2. However, the smaller band could have been due to degradation and 
this could also explain why the signal in retina was not overwhelming. The antibody was 
not perfect for Western blotting as it was difficult to detect a specific signal in cultured 
cells, although they had been boiled and freeze-thawed several times so degradation could 
be a factor, especially if the protein was susceptible to protease. Interestingly, I found sig­
nificant PEST sequences (PEST score >5) in AAD34394, NPIP-brainl and NPIP-brain2. 
PEST polypeptides -  proteins rich in proline (P), acidic residues glutamic acid (E) or 
aspartic acid, and hydrophilic residues serine (S) and threonine (T) are degraded rapidly 
inside eukaryotic cells [Rogers et al., 1986] 4. This could be one reason that there is such
4Duplicated PEST domains have been found in some proteins [Chevaillier, 1993] and are an example of 
regional rather than gene duplication.
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a large amount o f morpheus mRNA in the retina, especially in the macula which has the 
highest turnover.
I showed that the anti^-NPIP antibody was useful for immunofluorescence studies by 
staining endogenous protein in un-transfected human neuroblastoma cells (Figure 6.2). It 
showed a very similar pattern o f staining around the nuclear pore to that of a GFP con­
struct containing AF 132984 [Johnson et al., 2001, supplementary data]. It was a little less 
specific, although that is partly expected from a polyclonal antibody. It is also possible 
that members o f the morpheus family not localized to the nuclear pore are detected by the 
antibody.
I found different localization o f my 2 novel morpheus isoforms using GFP expression 
constructs. NPIP-brain2 definitely did not localize to the nuclear pore, while NPIP-brainl 
was present in the region o f the nuclear envelope. However, SK-N-SH cells tend to round 
up when transfected with some constructs, which squashes the cytoplasm towards the 
nucleus making it very difficult to definitively distinguish the nuclear envelope, hence the 
images are not shown. It is likely that expression in another cell line, such as the COS 
cells used by Johnson et al. would yield clearer nuclear pore localization of NPIP-brainl. 
NPIP-brain2 is missing a large part of the N-terminus compared with AAD34394 and 
NPIP-brainl, in which there is a single putative transmembrane domain. This provides 
further evidence that AAD34394 and NPIP-brainl are membrane-bound proteins. There 
may also be a nuclear pore localization signal in the N-terminus.
There was very specific localization o f morpheus in the human retina. In initial studies 
of macular sections a sub-population of photoreceptors were labelled by my antibody 
that looked more like cones than rods. Use of a superior secondary antibody and co­
localization with PNA in the human fovea revealed that morpheus is expressed in cone 
outer segments (Figure 6.4). My imaging studies and evidence that at least one member 
of the gene family is a membrane-bound protein infer specific localization of morpheus 
to the cone outer segment membrane. This suggests that it may have a function related to 
the photo-transduction cascade or its maintenance.
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Mutations in the morpheus gene family may cause monogenic macular, cone, or cone- 
rod dystrophy. Alterations in the sequence or expressed ‘dose’ of one or more family 
members may also contribute to the pathogenesis of age-related macular degeneration. 
Autosomal dominant retinitis pigmentosa (adRP) has been linked to a chromosomal re­
gion that overlaps with morpheus (16pl2.3-pl2.1) [Finckh et al., 1998]. However, one 
of the two families showed "physical signs frequently seen in patients with (Bardet-Biedl 
syndrome) BBS". The other family reported night-blindness from the second decade, 
which is characteristic o f rod-cone dystrophy, although no retinal electrophysiology was 
published. At least two members of the morpheus gene family are located within a re­
gion of suggested linkage (16pl2) obtained from three separate genome-wide scans of 
age-related maculopathy [Schick et al., 2003; Iyengar et al., 2004; Schmidt et al., 2004].
This is the first report, to my knowledge, o f tissue-specific localization of the mor­
pheus gene family. It is interesting that it seems to be limited to cone photoreceptors. 
Although longer isoforms o f NPIP appear to be expressed close to the nuclear pore, it is 
possible that this member o f the morpheus family has an alternative expression pattern in 
photoreceptors. Morpheus certainly appears to be highly expressed at an mRNA level in 
the retina (chapter 4), especially in the macula. There is evidence that RanBP2 -  a large 
protein that binds the nuclear pore associated GTPase Ran -  is highly expressed in cone 
photoreceptors o f the vertebrate retina [Ferreira et al., 1996]. Indeed, it is thought to be a 
chaperone for red/green cone opsin.
6.4 Conclusions
I was able to produce an antibody to NPIP that was useful and specific in both Western 
blotting and immunohistochemistry. By cloning NPIP from retinal cDNA I found two 
novel transcripts that are isoforms or different members of the morpheus gene family. 
Additionally, I expressed these novel transcripts and found that they localize to different 
parts of the cell. I detected both proteins in human retina by Western blotting. I also 
showed very specific expression o f morpheus in cone outer segments by immunofluores-
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cence. These observations suggest a novel role for morpheus in the macula. It may be 
important in relation to phototransduction due to its location. This is the first implication 
of morpheus playing a part in retina-specific biology. In summary, I have made progress 
towards eliciting the function o f morpheus in the macula and demonstrated that it is a very 
interesting candidate for macular disease.
6.5 O verall conclusions
I procured a human macular resource that was suitable for gene expression studies and 
went on to rigorously combine multiple microarray experiments with quantitative PCR 
analysis. I identified several genes enriched in the macula and made progress in char­
acterizing the proteins encoded by histone deacetylase 9 and the morpheus gene family, 
both of which are expressed in cone photoreceptors. Several other genes also provided 
insight into the mechanisms o f precise vision and its maintenance.
I met the overall objectives to find genes that are differentially expressed in the macula 
and to characterize one or more o f the proteins encoded by these genes. Several genes I 
identified by this approach are novel in the context of macular expression and are excellent 
candidates for macular disease.
6.6 Future work
There is a great deal o f future work that could stem from this thesis. There are many 
potential candidate genes for macular disease to study and many genes that could lead to 
insight into the function o f the human macula. One difficulty is knowing which o f the 
many genes implicated are worthy o f further study.
6.6.1 Gene expression
In an ideal world with exhaustive amounts of fresh human retinal tissue and other re­
sources, it would be very useful to repeat both the microarray and quantitative PCR ex­
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periments on a much larger scale. A detailed expression map of the retina, with accurate 
expression levels in average individuals of specific age groups would be an excellent 
foundation for studying the molecular physiology and pathology of the retina.
Another logical step is to study both maculas of different age and the differences 
between gene expression in AMD and non-AMD eyes. Perhaps more genes could also be 
found for study amongst the many that were found to be differentially expressed according 
to my microarray data, by applying less stringent exclusion criteria. However as others 
have also shown, microarray data is inherently noisy and there is a relatively large amount 
of variation across different samples. [Ross et al., 2000] It would be best to combine my 
microarray data with independent data from another group or further set of experiments.
6.6.2 Mutation screening
It would be very useful to look for mutations in genes I have identified as candidates for 
macular disease in panels o f DNA from patients who suffer from these diseases. Work 
is currently underway by Mark Lathrop’s group at the Centre Nationale Genotypage in 
France to study polymorphism in HDAC9, GCN2 and X in a panel of over 1500 AMD 
patients and many controls. The morpheus gene family is too large to study in its entirety 
so further work is needed to accurately determine which members are of most importance 
in the macula.
To the best o f my knowledge, there are currently no loci for monogenic macular dis­
ease which correspond to any o f the genes I confirmed to be differentially expressed in 
central retina for which a panel is available. One locus at 16p 12.3-1 RP22 [Finckh et al., 
1998] does correspond with the morpheus locus but the panel was not available anymore. 
Also, the phenotype was more peripheral than central retinal and it is likely that one of 
the two families carried a Bardet-Biedl mutation at 16q21 (OMIM #209900).
One further approach would be to screen panels of unrelated patients with cone, cone- 
rod, or macular dystrophies, in which a Mendelian inheritance pattern is likely, by associ­
ation studies -  for example by sequencing exons. The chance of finding a polymorphism
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that is associated with an unknown dystrophy is small for any one gene and would require 
many panel members and controls to be studied. This approach may be more effective 
if many genes could be screened for at once -  for example by using an array based re­
sequencing approach. Panels of patients with cone, cone-rod and macular dystrophies are 
being assembled at Moorfields and The Institute of Ophthalmology.
6.6.3 Functional models
One direction of study that would be extremely useful in determining the physiology 
and pathology of the macula is to dissect the function of the macular genes I identified. 
Although there is no primate cell culture model of cone photoreceptors that I know about, 
some macular genes I identified may be applicable to study in avian photoreceptor cultures 
(chickens do not have a macula although some other bird species have either single or dual 
maculas).
Animal models may also be useful in vitro. For example, an HDAC9 knockout mouse 
may exhibit retinal pathology -  although mice do not have maculas. Knockout mice 
would also not be applicable to the morpheus gene as it is primate specific. Other animal 
models may also be useful for some genes, such as the tetraploid knock-in Xenopus.
A particular function may be elicited at the cellular level for one or more macular 
genes, either by animal models, disease mutations or by direct assays that may be appli­
cable to genes further down the list on which I have not completed protein work. If a 
particular function is suspected, RNA inhibition may be a useful tool to show evidence 
for such a role.
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Appendix A
Scripts
A .l M icroarray data calibration
#  s o u r c e  (" a n a l y s i s  . r ") 
l i b r a r y  ( sma)
l i b r a r y  ( v s n )
s o u r c e ( " b a c k g r o u n d _ c o r r e c t i o n . r " )  
ba rcode  <— " 0 1 6 . t x t / 1 6 "
# c y  3 :
# r e a d  in d a t a
i n p u t ,  f i l e  < -  p a s t e ( ba rcode  1 . t x t " , sep = " ")
cy3 <— b a c k g r o u n d . c o r r e c t ( i n p u t . fi  1 e )
#  cy 5  :
#  r e a d  in d a t a :
i n p u t ,  f i l e  <— p a s t e ( ba rcode  , " _ 2 . t x t " , s e p = " ") 
cy5 < -  b a c k g r o u n d . c o r r e c t ( i n p u t . fi 1 e )
l a y o u t  <— NULL 
l a y o u t $ n g r i d  . r <— 12 
l a y o u t $ n g r i d . c  <— 4
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l a y o u t $ n s p o t . r <— 23 
l a y o u t $ n s p o t . c  <— 26
s l i d e  < -  NULL
s l i d e  $G < -  c b i n d ( c y 3 $ S i g n a l . M e d i  an—cy3$Ba c kg r ound . Ad j us t me n t )  
s l i d e  $Gb < -  NULL
s l i d e  $R < -  c b i n d ( c y 5 $ S i g n a l . M e d i  an—cy5$Bac kground.  Adj us tment )  
s l i de SRb  < -  NULL
s l i d e . v s n  < -  c b i n d (  s l i d e  $R, s l i d e  $G)
#  S p o t s  b e l o w  b a c k g r o u n d  w i l l  n o t  be c o u n t e d  in t he  a n a l y s i s
#  I n c l u d e  t h e s e  2 l i n e s  i f  y o u  want  t o s e t  t hem to 1 
U s I i d  e $G[  s l i d e  $ G< 1 ]  < -  1
# s l i d e $ R [  s l i d e  $ R < I ]  < —  1
l og .  r a t i o s  <— s t a t . m a  ( s l i d e ,  l a y o u t ,  norm=" n " )
l og .  r a t i o s  .median <— s t a t . ma( s l i d e ,  l a y o u t ,  norm="m" )
log . r a t i o s  . l owess  <— s t a t  .ma( s l i d e ,  l a y o u t ,  norm=" 1 " )
l og .  r a t i o s  . t i p  <— s t a t .  ma ( s l i d e ,  l a y o u t )
log . r a t i  os . s c a l e  <— s t a t  ,ma( s l i de  , l a y o u t ,  norm="s")
res <— vsn ( s 1 i de  . vsn )
pa r  ( mfrow=c ( 2 , 1 ) )
p l o t ( l o g .  r a t i o s $ A , l o g .  r a t i o s  $M)
p l o t  ( log . r a t i o s  . median$A,  log . r a t i o s  . median$M)
p l o t (  log . r a t i o s  . l owess  $ A , log . r a t i o s  . lowess  $M)
p l o t ( l o g .  r a t i o s  . t i p  $ A , l og .  r a t i o s  . t ip  $M)
p l o t ( l o g .  r a t i o s  . s c a l e  $A, log . r a t i o s  . s c a l e  $M)
pl o t  (( res $ h y [ ,1 ] + r e s $hy  [ , 2 ] )  / 2 , r e s $ h y [ , l ]  — r e s $hy [  , 2] )
columns <— c ( 1 ,2)
col s  < -  c ( " r e d " ,  " b 1 ue " ) [  as . numer ic  ( res $ s e 1 ) +1 ] 
cnam < -  c ( ”Cy5" , "Cy3" )
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r t x t y  < -  r a n k ( r e s S h a v g )
d t x t y  < -  r e s $ h y [ , 2 ] -  r e s $ h y [ , l ]
p l o t ( rtx ty , d t x t y ,  pch = " ." , c o l =c o l s  ,
yl im = q u a n t i l e  ( d t x t y  , p r obs=c  (1 e - 3 ,  l - l e - 3 ) ) ,
xlab = " r a n k ^ o f ^ m e a n ^ e x p r e s s i o n  " , ylab = p a s t e  (" d i f f e r e n c e  " , cnam[ 2] ,  , 
cnam [ 1 ]) )
l i n e s ( 1 e6*c(  -  1 ,1) , c ( 0 , 0 ) ,  col  = " b l a c k " ,  1ty = " d a s h e d ") 
l ogrank  < -  r ank  ( log . r a t i o s . median$A)
p l o t ( l ogrank , — log . r a t i o s  . medianSM, pch = " ."  , col = " b l u e " ,  
xlab = " r a n k ^ o f ^ m e a n ^ e x p r e s s i o n  " , yl ab = p a s t e  (" d i f f e r e n c e  " , c nam[ 2] ,  " —" , 
cnam [ 1 ]) )
l i n e s ( 1 e6*c(  — 1 ,1) , c ( 0 , 0 ) ,  col  = " b l a c k " ,  1 t y = " d a s h e d ")
a r r ay  1 <— da t a  . f r a m e ( c y 3 $ l n d e x  , cy3$Access i on  , cy3$Text  , c y 3 $ S i g n a l  .Median 
, cy3$Bac kg round .  Adj us tment  , cy 5$ Si gna l  . Median , cy5 $ Background . 
Adjus tment  , log . r a t i o s  $A, log . r a t i o s  $M, log . r a t i o s  . median $M, log . r a t i o s  
. lowess$M , log . r a t i o s  . t i p  $M, log . r a t i o s  . scale$M,  r e s $hy [  ,2] , r es$hy 
[ ,1] , r e s $ h y [ , 2 ] - r e s $ h y [  , 1 ] )
names ( a r r a y l )  < -  c ( " i d a c c e s s i o n " , "name" , " c y 3 " , " c y 3 . b g " , " c y 5 " , " c y 5 . bg 
" / ' e x p r e s s i o n "  ," log . r a t i o  " ," l r  . median"  , " lr . lowess"  lr . t i p "  l r  . 
s c a l e " , " c y 3 . v s n "  , " c y 5 . v s n "  , " v s n . r a t i o " )
s ave(  I i s t = Is () , f i l e = p a s t e ( b a r c o d e  , " . r d a t a "  , sep = " " ))
#  w r i t e  f o r  s p r e a d s h e e t
w r i t e . t a b l e ( a r r a y l  , " 0 1 2 . t x t / s l i d e l 2  . csv " , col  . names=TRUE, quote=FALSE, sep 
= " \ t " , row . names=FALSE)
a r r ay  1 S e x p r e s s i o n  [! i s . fi  n i t e ( a r r ay  1 S e x p r e s s i o n  ) ] < -  "NULL" 
a r r a y l S l o g  . r a t i o  [!  is . f i n i t e ( a r r a y l S l o g . r a t i o )]  < -  "NULL"
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ar r ay  1 $ 1 r . m e d i a n  [! i s . fi  n i t e ( a r r a y  1 $ 1 r . m e d i a n  ) ] < -  "NULL" 
ar r ay  1 S i r  . l o w e s s  [! i s  . f i n i t e  ( a r r a y  1 $ l r  . l o w e s s ) ]  < -  "NULL" 
a r r ay  1$ l r  . t i p  [! i s  . f i n i t e ( a r r a y  1$ l r  . t i p )] < -  "NULL" 
a r r ay  1 $ l r  . s c a l e [ !  i s  . f i n i t e ( a r r a y  1$ l r . s c a l e ) ]  < -  "NULL"
#  u  r i t e  f o  r SQL
wr i t e  . t a b l e  ( a r r a y l  , " 0 1 2 .  t x t / s l i d e l 2 "  , co l  . names=FALSE, quote=FALSE, sep = " \ 
t " , row . names=FALSE)
A.2 M icroarray data m ining  
A.2.1 Final table design
DROP DATABASE a r r a y  
CREATE DATABASE a r r a y  ;
USE a r r a y ;
DROP TABLE s l i de  n ;
CREATE TABLE s 1 i d e n (
id INT UNSIGNED NOT NULL PRIMARY KEY,
a c c e s s i o n  VARCHAR(15) NOT NULL,
name VARCHAR( 2 5 5 ) ,
cy3 FLOAT NOT NULL,
cy3 bg FLOAT NOT NULL,
cy5 FLOAT NOT NULL,
cy5 bg FLOAT NOT NULL,
e x p r e s s i o n  FLOAT NOT NULL,
log r a t i o  FLOAT NOT NULL,
lr medi an  FLOAT NOT NULL,
lr l owe s s  FLOAT NOT NULL,
1 r t i p FLOAT NOT NULL, 
lr s c a l e  FLOAT NOT NULL, 
cy3 vsn FLOAT NOT NULL, 
cy5 vsn FLOAT NOT NULL,
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vsn r a t i o  FLOAT NOT NULL,
INDEX (name,  a c c e s s i o n )
) ;
A.2.2 Example queries for robust over- and under-expression
# i n c r e a s e d  e x p r e s s i o n  in f ovea  
s e l e c t  combined_ 1 5 . name , 
combined 1 5 . a c c e s s i o n  ,
( combined_ 15 . cy3—combined_ 15 . cy3 _b g + combined_ 1 6 . cy3—combine d_ 16. cy3_bg)  
/2 as cy3 ,
( combine d_ 15 . cy5—combined_ 15 . cy5_bg + combined_16 . cy 5—combine d_ 16 . cy5_bg)  
/2 as cy5 ,
( combined_ 15 . v s n _ r a t i o  + combined_15 . v s n_ r a t i o _ 2 + c o mb i n e d _ 1 6 .  v s n _ r a t i o  + 
combined_l  6 . v s n _ r a t i o _ 2  ) /4 as mean vsnr l 5 1  6 
from combined 1 5 , combined_ 1 6 
where combined_ 15.  name=combined_ 1 6 . name 
and combined l 5 . a c c e s s i o n = c o mb i n e d _ 1 6  . a c c e s s i o n  
and ( combined_15 . v s n _ r a t i o  + combined_15 . v s n_r a t i o_2+c ombi ne d_16  .
vsn  r a t i o  + combined l 6 . v s n _ r a t i o _ 2  ) /4 >= 3 
and ( combined_15 . cy5—c o m b i n e d l  5 . cy5_bg + combined_l  6 . cy5—c o m b i n e d l  6 .
c y 5 _ b g ) / 2  >= 200 
o r d e r  by mean v s n r _ 15 _ 16 ;
# i n c r e a s e d  e x p r e s s i o n  in pe r i  
s e l e c t  combined_ 1 5 . name , 
combined_15 . a c c e s s i o n  ,
( combined_15 . c y3 - c o mb i n e d _  15 . cy3_bg + combined_l  6 . cy3-combined_l  6 . cy3_bg ) 
12 as cy3 ,
( combined_ 1 5 . c y 5 - c o m b i n e d _ l  5 . cy5_bg + combined_l  6 . cy5-combined_l  6 . cy5_bg ) 
/2 as cy5 ,
( combined_15 . v s n _ r a t i o  + combined_15 . v s n_ r a t i o_2+c ombi ne d_ l  6.  v s n _ r a t i o  + 
combined l 6 . v s n _ r a t i o _ 2  ) /4 as vsnr  
from combined_ 1 5 , combi ned  l 6 
where combined 1 5 . name=combined_ 16 . name
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and combined_15 . a c c e s s i o n = c o m b i n e d _ 1 6  . a c c e s s i o n
and ( combined l 5 . v s n _ r a t i o + c o m b i n e d _ 1 5  . v s n _ r a t i o _ 2 + c o mb i n e d _ 1 6 .
vs n r a t  i o +c ombi ned_ l  6 . v s n _ r a t i o _ 2  ) /4 <= -1 
and ( combined l 5 . cy5—combined l 5 . cy5_bg + combined_16 . cy5— combined_ 16 .
c y 5 _ b g ) / 2  >= 200 
o r d e r  by v s n r ;
A.2.3 Im porting data into a spreadsheet
#  /  /  bi n /  bas h
# r e t r i e v e  a l l  d a t a  f o r  a c c e s s i o n  n u mb e r = $ l  ( 1 s t  command—l i n e  p a r a m e t e r )  
t o a s e p a r a t e  f i l e  f o r  e a c h  s l i d e  
mysql  — e x e c u t e  = " s e 1 e c t name , a c c e s s i o n  , cy3—cy3_bg as cy3 , cy5—cy5_bg as
cy5 , cy5_vsn as cy_3 , cy3_vsn  as cy_5 , v s n _ r a t i o  from s l i d e  1 1 where
a c c e s s i o n  = ’S l ,M a r r a y  > s l i d e l l  
mysql  —N — e x e c u t e = " s e 1e c t  name , a c c e s s i o n  , c y 3 —cy3_bg as c y 3 , cy5—cy5_bg 
as cy5 , cy5_vsn as cy_3 , cy3_vsn as cy_5 , v s n _ r a t i o  from s l i de _12
where a c c e s s i o n  = ’$ 1 ’ " a r r a y  > s 1 ide 1 2 
mysql  —N — e x e c u t e ^ "  s e 1 e c t name , a c c e s s i o n  , c y3—cy3_bg as cy3 , cy5—cy5_bg 
as cy5 , cy5_vsn as cy_3 , cy3_vsn as cy_5 , v s n _ r a t i o  from s l i de_13
where a c c e s s i o n  = ’$l ’ " a r r a y  > s l i d e  1 3 
mysql  -N  — e x e c u t e  = " se 1 ec t name , a c c e s s i o n  , cy3—cy3_bg as cy3 , cy5—cy5_bg
as cy5 , cy5_vsn as cy_3 , cy3_vsn as cy_5 , v s n _ r a t i o  from s l i de _14
where a c c e s s i o n  = ’Sl ’ " a r r a y  > s 1 ide  1 4 
mysql  -N — e x e c u t e ^ "  s e 1 e c t name , a c c e s s i o n  , cy3-cy3_bg  as cy3 , cy5-cy5_bg
as cy5 , cy5_vsn as cy_3 , cy3_vsn as cy_5 , v s n _ r a t i o  from s l i de _15
where a c c e s s i o n  = ’Sl a r r a y  > s 1 ide 1 5 
mysql  -N  — e x e c u t e ^ "  s e l e c t  name , a c c e s s i o n  , cy3-cy3_bg  as cy3 , cy5-cy5_bg  
as cy5 , cy5 vsn as cy_3 , cy3_vsn as cy_5 , vsn r a t i o  from s l i d e _ 1 6  
where a c c e s s i o n  = ’SI ’ " a r r a y  > s 1 ide 1 6
# c o n c a t e n a t e  f i  I e s
ca t  s l i d e l l  s 1 i d e 12 s l i d e  13 s 1 i d e 14 s 1 i d e 15 s 1 i d e 16 > S l . c s v
He lean up
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rm s l i d e l l  
rm s 1i d e 1 2 
rm s 1i d e 1 3 
rm s 1i d e 1 4 
rm s 1i d e 1 5 
rm s 1i d e 1 6
A.3 G raph to sim ulate ideal and real PCR
U o u t p u t  t o e n c a p s u l a t e d  p o s t s c r i p t  f i l e
p os t sc r i p t ( " / home / Dan / ps /qPCR . eps " , h o r i z o n t a l  = FALSE, o n e f i l e  = FALSE 
)
cyc l e  <— 1:40
U r e a l  d a t a  i s  s i g m o i d a l
f l u o r e s c e n c e  <— 1 / (1 +2.7 1 8 3 A( —0.5 *( cycle —30)))
p l o t  ( cycle  , f l u o r e s c e n c e  , c e x . a x i s  = 1 . 2 , c o l = ’ g r e e n ’ ,pch = 16)
s < -  seq ( l e n g t h  ( c yc l e  ) —1)
s e gme n t s (  cyc l e  [ s ]  , f l u o r e s c e n c e  [ s ]  , cyc l e  [s + 1] , f l u o r e s c e n c e  [s + 1] , c o l = ’ 
green ’ )
l i n e s  ( c ( 2 5  ,25 ,0) , c ( 0  , f l u o r e s c e n c e  [25]  , f l u o r e s c e n c e  [25] )  , coI = ’ red ’ , l ty 
=2)
l i n e s  ( c ( 2 9  ,29 ,0) , c ( 0  , f l u o r e s c e n c e  [29]  , f l u o r e s c e n c e  [29] )  , c o l = ’ red ’ , l ty 
= 2)
t ex t (2 7 , 0 .05 , e x p r e s s i o n ( D e l t a * c )  , c o l = ’ blue ’ , cex = 1.75) 
t e x t ( 1 0 , 0 .225  , e x p r e s s i o n ( D e l t a * f )  , c o ! = ’ blue ’ , cex = 1.75) 
a r r o w s ( 1 0 , 0 . 2  ,10 , 0 . 085  , c o I = ’ blue  ’ , l e n g t h = 0 . 1 )  
a r rows  ( 1 0 , 0 .25 ,1 0 , 0 . 37  , c o I = ’ blue  ’ , l e n g t h = 0 . 1 )
# t h e o r e t i c a l  a m p l i f i c a t i o n  i s  e x p o n e n t i a l  
f < -  100000A- 1 . 1  18* 1 . 50 9 As
segment s  ( cyc l e  [ s ] , f [ s ] , c y c l e [ s  + l ] , f [ s  + l ] , c o l = ’ orange ’ , l ty =2) 
l e g e n d ( 3 3 . 5  , 0 . 7  , c (  ’ da t a  ’ , ’ model  ’ ) , col=c ( ’ green ’ , ’ orange ’ ) , lwd = l , l ty  =c 
(1 ,2) ,pch = c ( 1 6 , 2 5 6 ) )
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# t ur n  o f f  o u t p u t  
dev . o f f ()
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Gene Symbol Description Accession UniGeneID Tm
A B C A 4 A T P -b ind ing  casse tte  sub -fam ily  A (A B C 1) m em ber 4 A F000148 198396 79.4
A O C2 am in e  o x id a se  co p p er con ta in ing  2 (retina-specific) A B 012943 143102 77.1
AR R3 arres tin  3 re tina l (X -a rres tin ) S66793 308 78.8
ARRB1 arres tin  be ta  1 A F084040 112278 76.5
A R R B 2 arres tin  b e ta  2 A F 106941 18142 80.0
BCP blue  co n e  p igm en t M l 3299 102119 78.3
CA LB1 calb in d in  1 (2 8 k D ) A F068862 65425 73.6
C A L B 2 calb in d in  2 (2 9 k D  c a lre tin in ) NM  001740 106857 81.2
C A LB 3 calb in d in  3 (v itam in  D -dependen t calc ium -b ind ing  pro te in) LI 3220 639 75.3
C D H 4 cad h erin  4 R -cad h erin  (re tinal) L34059 89484 73.6
C K C R I cat eye sy n d ro m e  c ritica l reg ion  gene 1 NM  017424 170.0310 76.5
C L U L I c lu ste r in -lik e  1 (re tin a l) D63813 26886 74.2
C N G A 1 cyclic  n u c leo tid e  ga ted  channel a lpha  1 S42457 1323 74.7
C N G A 3 cyclic  nu c leo tid e  gated  channel a lpha  3 A F 0 6 5 3 14 234785 78.3
C N GB1 cyclic  n u c leo tid e  ga ted  channel beta  1 A F042498 93909 80.0
C RX co n e-ro d  hom eobox A F 0 2 4 7 1 1 249186 80.0
FSCN 2 fascin  h o m o lo g  2 (ac tin  bund ling  p ro te in  retinal) A F030165 118555 80.0
G C P green  cone  p ig m en t (co lo r b lindness deutan) M l 3305 247787 80.0
G U C A 1A g u an y la te  cy c lase  ac tivato r 1A (retina) L36861 92858 77.7
G U C A 1B guany la te  cyclase  activato r IB  (retina) M 97496 778 81.2
G U C Y 2D g u an y la te  cy c lase  2D  m em brane  (retina-specific) M 92432 1974 82.4
G U C Y 2F g u an y la te  cyclase  2F re tinal L37378 123074 77.7
HCR H C R  (a-he lix  co iled -co il rod  hom ologue) A K 000204 110746 78.8
IM PG1 in te rp h o to recep to r m a trix  p ro teog lycan  1 NM  001563 129882 73.6
L O C 5 1 170.0 re tina l sh o rt-ch a in  deh y d ro g en ase /red u ctase  retSD R 2 NM  016245 12150 74.2
L O C 5 1 171 retinal sho rt-ch a in  dehyd ro g en ase /red u ctase  retSD R 3 NM  016246 18788 78.8
LRAT lec ith in  re tino l acyl transferase A F 0 7 1 5 10 19470.08 73.6
N one H om o sap iens  re tina l m R N A L23852 73838 70.0
N one X -linked  re tin o p a th y  p ro te in S58722 207812 70.0
N R L neura l re tina  leuc ine  z ip p er M 95925 89606 80.6
N T N 2L re tin a ld eh y d e-b in d in g  p ro te in  1 U 86758 158336 81.2
O C A 2 o cu lo c u tan eo u s  a lb in ism  11 NM  000275 82027 76.5
P D E 2A ph o sp h o d ies te ra se  2A  cG M P -stim u la ted U 67733 154437 75.9
PD E 5A p h o sp h o d ies te ra se  5A  cG M P -spec ific D 89094 139271 75.3
PD E 6A p h o sp h o d ies te rase  6A  cG M P -spec ific  rod alpha M 26061 182240 75.9
PD E 6B p h o sp h o d ies te ra se  6B  cG M P -spec ific  rod  beta (adC S N B 3) S41458 2593 76.5
PD E 6C p h o sp h o d ies te rase  6C  cG M P -specific  cone alpha prim e U31973 93173 75.9
P D E 6D p h o sp h o d ies te rase  6D  cG M P -spec ific  rod  delta A F022912 48291 75.9
PD E 6G p h o sp h o d ies te ra se  6G  cG M P -spec ific  rod gam m a X62025 1857 81.2
P D E 6H p h o sp h o d ies te rase  6H  cG M P -spec ific  cone gam m a D 45399 54471 75.9
PR R D H p h o to recep to r o u te r segm en t a ll-trans re tinol dehydrogenase A F229845 272405 78.3
R A L D H 2 re tin a ld eh y d e  d eh y d ro g en ase  2 A L 110274 95197 75.3
RBP1 re tin o l-b in d in g  p ro te in  1 ce llu la r NM  002899 101850 78.3
RB P2 re tin o l-b in d in g  p ro te in  2 ce llu la r NM  004164 182313 80.0
RBP3 re tin o l-b in d in g  p ro te in  3 in te rstitia l M 33875 857 82.4
R BP4 re tin o l-b in d in g  p ro te in  4 in te rstitia l NM  006744 76461 74.2
RCV1 recoverin S43855 80.0539 79.4
R D G B B retinal d eg en era tio n  B beta NM  012417 109219 76.5
RD H5 re tino l d eh y d ro g en ase  5 ( 1 1-cis and 9-cis) A F0370.062 172914 74.2
R D H L retino l d eh y d ro g en ase  hom olog NM  005771 179608 77.7
RD S retinal d eg en era tio n  slow  (re tin itis  p igm entosa  7) M 73531 1937 79.4
RGR retinal G  pro te in  co u p led  recep to r U 14910 1544 75.9
RH O rhod o p sin  (re tin itis  p ig m en to sa  4 au tosom al dom inant) NM  000539 247565 76.5
R H OK rhodopsin  k inase U 63973 103501 81.8
RLBP1 re tin a ld eh y d e-b in d in g  p ro te in  1 L34219 1933 76.5
R ODH retino l d e h y d ro g en ase U89281 11958 75.9
R O D H -4 m icrosom al N A D + -d ep en d en t retinol dehydrogenase  4 A F0570.034 134958 79.4
ROM  1 retinal o u te r seg m en t m em b ran e  p ro te in  1 M 96759 189852 78.8
RP1 retin itis  p ig m en to sa  1 (au to som al dom inan t) NM  006269 251687 73.6
RP2 retin itis  p ig m en to sa  2 (X -linked  recessive) A J007590 44766 75.3
RPF.65 retinal p ig m e n t ep ith e liu m -sp ec ific  p ro te in  (65kD ) U 18991 2133 73.1
RPF-1 R etina-derived  P O U -d o m ain  fa c to r-1 U91935 233321 78.3
RPG R retin itis  p ig m en to sa  G T P ase  regu lato r A J238395 153614 74.2
R SI re tin o sch isis  (X -lin k ed  ju v en ile ) 1 A F014459 113250 80.0
RX retinal h o m eo b o x  p ro te in NM  013435 278957 75.3
SAG S -an tigen ; re tina  and  p inea l g land (arrestin) X I 2453 32721 77.1
SC A 7 sp in o ce reb e lla r a tax ia  7 A J0 0 0 5 17 108447 75.9
SPA C R C A N in te rp h o to recep to r m a trix  p ro teog lycan  200 N M  016247 272380.0 78.3
Table B. 1: A search for retina-related genes amongst the 13,899 probes in the microarray revealed 
over 50.
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File: D H 11 08.abl Run Ended: M ar 27, 2004. 4:32:50 Signal G:61 A:58 T:59 C:58 Comment:
Sample: D H 11________Lane: 8 Base spacing 13.65_________ 850 bases in 10003 scans______ Page 1 o f 1
10 1 0 0  1 1 0
t 'O G O C G  "  rOOOCCTTCC 'I 'O t ' ■ '■S' ' ' C O O C C O C C - TOOC :l C C G C G G G •• 7-TTCOATTOTCG ACCTT N O TTTCTTQAOf n  t T O l  c c g c t g - - g g g t g g  a g g g g g t  g a g c a g
r e  ■' ' C'GGG too iflt C ' O ' G ' ' : ! r  • CCG C 1 G 'G G G T G G .' * GGGG r G7 G \G C  A G C ' C l  CGGG fGG7 G'F C  1 G r GGCTC: GGG A G TT’ T C ; G T 1 r  1 r.G W  r GT 7 GT 7 G AG T TGG M
3G -4SO TGOC7GG TOGCCC ICC T O ’ ’ " r n . V G ' t  C '-GC - G IG  AGG I -G GGCC G T GGGC-' ' ICC TO /-AG A ■' 7 0 A C 0  ATGC T CCGC TGCCGCC A 7 T C I G ACCCA.G TTGCA./ --OAOCC
4 0 0  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0  4 6 0  4 7 0
Gs‘ G " G G G G 'G  ' 1 ' ’ ’ GC C 1G T G 1 'G  IC C 1 C T G C C C G C C G C C G C " ,C G C  : IG CG C C G - TG ' ' r C ’ M  ICC G 1 - GG IG G C C
• T , T TCCTCTGCCTCTG-'CACCTGCCTCTCCTTTTCTCCGTGCTCACGTTCI rrCATQC’T r.-G T f rcCTCAGATGTTCTTTGGCGGTC7TCCTCTTTCCATTGATTTTGTCATGACGGTTOA
; OTTCTC CC TC < 'GG P H  G C  CO C G G  " X C r  i S ' C ' C C  ' ; : 1 tTAAATT GCTTTOCT G T  C TACG®I AMTTHG»fAC
- , , ,  - XiGt' G ; ATCCt'GGGG CC I*C G '.H ' I ' G l  GGG TCTTTCC GG 1 CCC ' GGG" AC G COB GGG
Figure B. 1: Direct sequencing of npip-brainl cDNA (forward strand).
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f Q v  C O O A O O C ro t/- .-  'C i G G '. ' . '  r  ' GC : rGGG I 4 rO A G G ! 'C  CC G C C A 'C C rG C C A 'C A i I !G T I r ! ! A I G r i  rorCGCCAAA AGTO .* C  r  IGBGG A.ACCC TOGO tOC IC /GO MB
File DHI2_IO.abl 
Sample: P H I2
Run Ended: Mar 27. 2004, 4:32:50 
Lane: 10 Base spacing 13.30
Signal G :16A :I9T :I6C :16  
905 bases in 10669 scans
Comment: 
Page 1 o f 1
30 4 0  5 0  6 0  7 0  8 0  9 0  1 0 0  1 1 0  120
■ G C B -’GG ' C -CGCG 1 IGGGAGC ICICCCA I A : G G ’-CGACC TGCAGGCGGCCGCGAA ITCACTAG I G n  I G. I I'CA I’G T T I1 W3TTGC rTAOGA I'ATGAA 7 GGC
2 6 0  2 7  0 ' 3 10  3 2 0  3 3 0  3 4 0  3 5 0  3 6 0  3 7 0  3 8 0
3  3 10GAGCACCCAG AGC AQGG ACM3GG34GC 1GG I GGGGAGGACCAG a ;  C .G G  I'TATCAA I AC 1C IGGC TGACCA ICG TC A ICG I GGG ACTG ACT riG G  IGGAAG1CCT IGG I I AC fTA FCAT
i - a c i g i o  i v r c  rGAG t  -g  i - i r  i g c c ~  r e  r c c c  r e  i g c a c a a g  • r e  i t g t g i G ' c  r r c c  t o *  a g a c t a  t e n  c o c g  i c t c w a a  i g g  a c a i g  a  i g g a t o c a c g g a i g  i a c a g c
5 1 0  5 2 0  5 3 0  5 4 0  5 5 0  5 6 0  5 7 0  5 8 0  5 9 0  6 0 0  6 1 0  6 2 0  6 3 0
,G-G  ..GC ’ G G  ■'0G ICC--.. C IGCCG T AGaCAGG •-.•G G -; r-w- - IMG 1C C l GGAAGACA I C n  T4C i n  ATGG AG ACAGGTG G AAAtEAAAG riCGAGC TTAAA T C ' GTMtGATG AA GGTOACAACW
£ 4 0  6 5 0  6 6 0  6 7 0  6 8 0  6 9 0  7 0 0  7 1 0  7 2 0  7 3 0  7 4 0  7 5 0  7 6 0  7 7 0
lArGTOCACGGrCAf-GAC A A A T X A A ta-A  G GG G 3 ’ G 3 G G G  GGAAAC I G G !’! G  - - .C  .1 , C- CH3  ............... GG ■ • GCC AG i ' I CA A A' GCA1AA QGAAA’-A
- n  ■ ■ aga i' iic a a a a  r ro cccE C i 'i rc i  i' ig gaa .A';  X C C C C C T- C 1 G G . IG p n  ' CCr G C C G C iA A 'C "  T1CCGGGGGG'GGGCA'
Figure B.2: Direct sequencing of npip-brainl cDNA (reverse strand).
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Experiment 
Sam ple Setup
Red/green cone opsin in foveo-macula and peripheral retina
EXPERIMENTAL GROUPS
G ro u p  1 
G ro u p  2 
G ro u p  3 
G ro u p  4 
G ro u p  5 
G ro u p  6
fovea
peri
Ct Sum m ary
A
B
C
D
E
F
G
H
19.85 21.02
A m p lif ica tio n  P lot
Cycle
Linear Phase D eterm ination  
ESSENT1AI PARAMETERS 
Efficiency 
Threshold
ADDITIONAL OPTIONS 
M idpoint 
Minimum points 
Range 
N oise factor 
Calibrate to
0.782
0.182
10
To
M EA N SD
Mean Efficiency 0.782 0 .0 6 1
Mean Midpoint 0.182
Mean points in LP 7
Between groups:
p-value
Figure B.3: DART-PCR for red/green cone opsin
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R esu lts
Efficiency Results Experimental Group Efficiency
1 4 7 10
A Sample E SD p-value
B 1 0.739
C 2 0.826
D 3
E 4
F 5
G 0.739 0.826 6
H
(pression (Rq) Fold Change
A Group Fold SD
B 1 1.000
C 2 0.505
D 3
E 4
F 5
G 1.91 E-06 9.68E-07 6
H
G ene Expression Summary
f o v e a
Expression CV Efficiency CV
1 4 7 10 1 4 7 10
A A
B B
C C
D D
E E
F F
G 11 4". 7.7% G 13,3% 10.4%
H H
M ean  CV 9.6° M ean CV 11.8%
Figure B.4: DART-PCR for red/green cone opsin
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PRETTYBOX o f :  n p i p / p i l e u p . m s f { * }  J u l y  2 9 ,  2 0 0 4  2 1 : 4 8 : 0 1 . 2 7
n p i p _ p r o t e i n  
n p i p _ a m p l i  c o n _ l  
a a h 4 6 1 4 5  
b a c 8 5 1 3 5  
x p _ 2  9 0 6 7 1  
g e n o m e s c a n A A S H A A L L R F |r
BHTHB
- ......................................
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Figure B.5: Multiple alignment of NPIP protein (AAD34394) with the amplicon used for qPCR, 
various NPIP-like proteins, and a predicted protein from a BAC clone covering 16p 13.1.
APPENDIX B. SUPPLEM ENTARY DATA
PRETTYBOX o f :  n p i p - c D N A . m s f { * }  J u l y  3 0 ,  2 0 0 4  1 2 : 4 2 : 5 1 . 6 1
174
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
yera□Ef tm npiran*
40
40
40
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
G T A A A A C C T G
G T A A A A C C T G
G T A A A A C C T G
□ QQ
□ m
T G G G T A T G A G H G T T C T T C C T G
63
63
80
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
63
63
120
63
63
1 6 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2 1 E
63
63
2 0 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2 G A A A T C A G G T
T A T C A A T A C T
T A T C A A T A C T
T A T C A A T A C T
□E - □ am§f t E
a □y - R
B Emft f t n [t
95
95
2 4 0
a f 1 3 2 9 8 4 □ y
n p i p - b r a i n l E□n p i p - b r a i n 2 □ EH
y y u -B□ H M En 9 f t Hn ti
Eu a a . . -c|□u FjEQlag 9□EBEf t Hn a ft Ej
jFj □ • ; a3 □ □3 0f t ■ ;
1 3 5
1 3 5
2 8 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
M3 y y
EBE Q$ft H n f t f t
Fj
□
u
F 1 .T 1 9 D
T A A A T T T G C C
T A A A T T T G C C
T A A A T T T G C C
a y a a y ra
EBEEEBraBft f t ft ft ft 9 H
1 7 5
1 7 5
3 2 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
C C T T T G T G T G
C C T T T G T G T G
C C T T T G T G T G
u N E jy y L iL□ f t □E 9 aB9 ra9 n 9
y by EjI □BEf t Ed3ft f t0 9 ft □f j
2 1 5
2 1 5
3 6 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
• >b y!EE Bv;‘ raSft -H 9 w.w.l
p 13r a n Ej□□o0 R □ Q i0n Rj 0 nr
Byi j0 B ft0 f t ft
i E ra AaE ABI y Fj ra - ftft ft IS9 ft n ra ft
2 5 5
2 5 5
4 0 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
r F ra
g FXlB•Br raa riel0 r (eH
y raa
E EBraE■ f tg
C A G G A A G G A A
C A G G A A G G A A
C A G G A A G G A A
2 9 5
2 9 5
4 4 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
T T A A A A T T G T
T T A A A A T T G T
T T A A A A T T G T
ray Bjy ra .•....
EraBEE ra Eh ra9 BB ra p
y y canray ii•y ra9 □■vBraB uISn 9 f t0 ran If
By P y je Nf t□ oa R 3R ••R raj1?3R IS
3 3 5
3 3 5
4 8 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
mm□ a
"KM ©Bmn B
y M a &BB sE9 ElEF 3F
ray y raijraB 9 ft r a Era 9 B r a
yn n ny 1a
BraraEraBE s* AEf trara raaE ISp
3 7 5
3 7 5
5 2 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
ey p j
CTel LriU Je n m
y rsC T i B m
f t r j i 1
a m E B E
T C A T G A C A A A
T C A T G A C A A A
T C A T G A C A A A
a ABy m rE '■A□ QE P* 5 nF p
4 1 5
4 1 5
5 6 0
APPENDIX B. SUPPLEM ENTARY DATA 175
PRETTYBOX o f :  n p i p - c D N A . m s f { * }  J u l y  2 9 ,  2 0 0 4  2 3 : 2 7 : 5 1 . 0 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
E23Q ft BS3 BEHn PP
4 5 5
4 5 5
6 0 0
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
G A A A G A A C G T
G A A A G A A C G T
G A A A G A A C G T
GAGGCAGAGG
G A G G C A G A G G
G A G G C A G A G G
G A G C A C G G A G
G A G C A C G G A G
G A G C A C G G A G
F I•
□ % B 3
0 ' B 0 0
y a u □E jHE J
□ DE$ □ 1 □ E00 PP 0 P 0 r
□ B □ □ □ ..B E J
□ Qn EEQP n P0□u u P0 P Qp
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
Lj
£- ■
A A G C G T T G C G
A A G C G T T G C G
A A G C G T T G C G
5 7 5
5 7 5
7 2 0
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2 0
G A G G A C T A C T
G A G G A C T A C T
G A G G A C T A C T
A C A G A T G C A A
A C A G A T G C A A
A C A G A T G C A A
rj m[ijaQE £ En P 31PR|P n
6 1 5
6 1 5
7 6 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
y □EJ□Q3 3 • 0 3 3 3nr m
A G C C T C T T T G
A G C C T C T T T G
A G C C T C T T T G
C A A C C G G G T C
C A A C C G G G T C
C A A C C G G G T C
r ? r a mE J
E R r a v Ef l i t p r a
6 5 5
6 5 5
8 0 0
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
a MWy u□r?H□ • ira3
T C G T C A T T C T
T C G T C A T T C T
T C G T C A T T C T
a L J□y L iy Eo 0 E□□M □Ey p r¥flP0 B 0
C C T A C T G G C C
C C T A C T G G C C
C C T A C T G G C C
6 9 5
6 9 5
8 4 0
a f  1 3 2 9 8 4
n p i p - b r a i n l
n p i p - b r a i n 2
□B 3E0 - En - Age
B□□□BBB 0EEMil*□ PP
7 3 5
7 3 5
8 8 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
C A G C C A C C T C
C A G C C A C C T C
raa CjjB□raBB□FJjEn -i3raB 0 m Pn
A C A A C A T T C T
A C A A C A T T C T
A C A A C A T T C T
□EH□ran□%EEHB 0 EH
7 7 5
7 7 5
9 2 0
a f  1 3 2 9 8 4 □ BBBB aBB□ BBBBn p i p - b r a i n l 0 > □ E a 0 E
n p i p - b r a i n 2 0PBPP 3BP0 p PHP
d y ra u
E 3 3 □ E r raP -1H rar m m ra
S 3 8 0 7
0 r a n r a n S 3 8 1 50 E H B H 9 6 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2 By u□ 0 BBMy|BP
piran
0 m r»n[fjBiel0 □0 □ E J□3 3 f t rl0
8 0 7
8 5 5
1 0 0 0
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
C C C G A G T G T C
C C C G A G T G T C
T G C T C A C T C C
T G C T C A C T C C B
ray R m
- raQB mn M i l gjB B m
838
8 9 5
1 0 4 0
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
T G A T A A T C T C
T G A T A A T C T C
T G A T A A T C T C
y E Jrajm□ 0 B □EfriBH0 0 BMBP
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2 lW«iH
ray ramrararan
□ w ia rara□ g
By - U• 1□EP □ ■jHPNr anp
y By * QF3mQEBEEHPIB■mr FTVl
9 1 8
9 7 5
1120
APPENDIX B. SUPPLEM 176
PRETTYBOX o f :  n p i p - c D N A . m s f { * }  J u l y  2 9 ,  2 0 0 4  2 3 : 2 7 : 5 1 . 0 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
A C A C C T C C C G
A C A C C T C C C G
A C A C C T C C C G
H r a n
0 r a n
Idaa ididEa□ t* 0□E n nH
9 5 8
1 0 1 5
1 1 6 0
a f 1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
□H QU f i
□E EHE Es c
LJ y
y r-iEl
Q 1 2 0 0
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
a f  1 3 2 9 8 4  
n p i p - b r a i n l  
n p i p - b r a i n 2
A T C T C A A G A A
A T C T C A A G A A
A T C T C A A G A A
T C A C T C C C C T  
T C A C T C C C C T  
T  C
a •ft □ Ma U
□ SF □p EE□□Ea •F n EM n P
□ u y □ L3E ma ;3 0 hE
B E  070
. 1 1 2 4  
. . 1 2 6 9
1 0 3 8
1 0 9 5
1 2 4 0
Figure B.6: Multiple alignment o f NPIP reference cDNA AF 132984 with 2 cDNAs found in brain.
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Figure B.7: Multiple alignment o f NPIP reference protein AAD34394 with longest open reading 
frame translations o f 2 cDNAs found in brain.
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